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Tissue homeostasis is necessary for optimal organ functioning. The onset of tissue 
trauma compromises the homeostatic environment resulting in widespread cell death 
with the likelihood of exposure to invading micro-organisms. Early stage elimination 
of microbes and immunomodulation is co-ordinated by leukocytes of the innate 
immune system of which neutrophils and macrophages play a pivotal role. 
Leukocyte-released pro-inflammatory factors are vital in the containment of infection 
but bring with it a degree of collateral tissue destruction. Thus cascading stages 
during inflammation must be tightly regulated to bring about timely tissue 
regeneration and regained homeostasis. However, chronic inflammatory diseases e.g. 
rheumatoid arthritis highlights the existence of defective regulation at numerous 
stages during this transition, often leading to debilitating disease progression.  
Recently published findings by our research group identified the anti-inflammatory 
properties of α-defensin - an anti-microbial peptide released from dying human 
neutrophils - on stimulated macrophages. Thus the main objective of my research 
was to gain an understanding into the molecular actions of α-defensins which inhibit 
the macrophage inflammatory potential. Strong evidence supported the propensity of 
α-defensins to inhibit both intracellular and secreted protein synthesis, as assessed by 
de novo 
35
S-radiolabeled Methionine incorporation. Inhibition was not attributed to 
endoplasmic reticulum stress events, a common diagnosis in the regulation of global 
translation. Supporting evidence using cell-free systems identified a fundamental 
block in translation with the inclusion of α-defensin. Biochemical studies linked the 
ability of α-defensin to bind non-specifically to oligonucleotide sequences. This 
binding potential was also demonstrated on ribosomal RNA (rRNA), impeding its 
migration through electrophoretic gels. Immunocytochemical assays proposed an 
emerging suggestion of α-defensins in macrophages concentrated in close proximity 
to ribosomes around the perinuclear region. Evidence of suggested 
defensin/ribosome accumulation after 24hrs after treatment were attempted but to 
date remained unconfirmed. Attempts to determine the fate of these proposed 





This thesis describes for the first time an enhanced understanding into the 
intracellular inhibitory mechanisms of α-defensins on macrophages and possibly 
other cell types. Understanding the molecular impact of α-defensins provide key 
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Inflammation regulation is critical to tissue homeostasis within an organism. 
Functioning as a defensive mechanism to combat the invasion of various pathogens 
that bridge the epithelial barrier upon tissue trauma, inflammation is the host’s first 
line of defence in eliminating potentially fatal infections. The complex inflammatory 
cascade is a series of stages, triggers, stop signals, go signals, all being orchestrated 
in very tight time constraints. Premature inflammation termination might leave the 
host susceptible to lingering infection with the risk of sepsis. The prolonging of 
inflammation brings with it the risk of extensive tissue damage with possible organ 
failure. It is imperative to the host that this delicate balance remains tightly regulated.  
 
The many examples of chronic inflammatory disorders in humans are testament to 
the need for tight regulation as persistent inflammatory events can indeed cause 
greater harm than the initial triggering event itself
1
. Current trends in inflammation 
research aim to gain a better understanding of the intricacies surrounding the 
inflammatory pathway to identify key regulators, which could serve as potential new 
therapies. This need is particularly applicable to autoimmune disease research. In 
many instances the cause for disease onset is poorly understood while costs to 
governmental health services continue to escalate. For example, estimates show costs 
to the UK’s NHS in alleviating symptoms of rheumatoid arthritis amount to £560 




While scientific research continues to further understand disease onset and 
progression, new therapeutics are continuously being researched and developed to 
replace ineffective or costly treatments, or those with long term side effects. 
Identifying new modulators of inflammation that can supersede current treatment is 





 Inflammation during injury  1.1
Innate immunity forms the first line of defence 
The role of the innate immune system is crucial to host survival. This is evident in 
the fact that even simpler life forms possess an innate immune system in one form or 
another. Innate immunity is a system designed to discriminate species self from 
infectious nonself
3
, and serves as an initial pathogen recognition, response and 
elimination system comprised of modulatory cells and proteins. In evolutionary 
terms, it can thus be appreciated that the inclusion or adaptation to elicit some form 
of host response to invading microbes was essential to species survival. As a result, it 




In mammals, initial detection of foreign invaders is by localised tissue-resident 
sentinel cells, mainly mast cells and macrophages. Recognition of characteristic 
pathogen components known as Pathogen Associated Molecular Patterns (PAMPs) 
include bacterial products such as the cell membrane endotoxin lipopolysaccharide 
(LPS), flagellin, lipoteichoic acid, and peptidoglycan. Viral products such double 
stranded RNA (dsRNA) or unmethylated CpG motifs are also recognized within the 
infected cell through intracellular PAMPs
5
. In addition, sites of tissue trauma will 
result in the unregulated dying of cells (necrosis), releasing Danger Associated 
Molecular Patterns (DAMPS) into the extracellular matrix. These include heat shock 
proteins, DNA, RNA, HMGB1 (high mobility group box 1) and purine 
metabolites
6,7
. Sentinel cells detect these various stimuli through a variety of outer 
membrane and intracellular Pattern Recognition Receptors (PRRs), including the 
family of Toll-Like Receptors (TLRs)
3
. These recognition patterns will activate a 
complex network of cell transduction pathways, activating transcription factors 
resulting in the synthesis and secretion of a multitude of defence molecules and 
cytokines which act as cell activators and chemoattractants (chemokines)
8
. The main 
function of released chemoattractants is in orchestration of the inflammatory 
response cascade, which will result in enhanced infiltration of activated leukocytes as 
further reinforcement. Neutrophils are regarded as the foot soldiers of the immune 







Neutrophils are essential inflammatory cells 
Mature neutrophils are developed over 10-14 days in the bone marrow from 
multipotent progenitor cells by the process of granulopoiesis
10
. These 
polymorphonuclear leukocytes (PMNs) are released into the bloodstream where they 
circulate under a resting phase in the absence of extracellular stimuli for 1-5 days 
before undergoing programmed cell death known as apoptosis
11
. Early pathogen 
detection by mast cells releases neutrophil activating and recruiting factors histamine 
and eicosanoids (e.g. leukotrienes and prostaglandin D2)
1
. Activated macrophages 
meanwhile secrete neutrophil activating and recruitment factors such as tumour 
necrosis factor (TNF), GM-CSF (granulocyte macrophage colony-stimulating factor) 
and interleukin (IL)-8. Subsequently, increased amounts of neutrophils are released 
from the bone marrow while the endothelium near sites of local inflammation 
become leaky to fluid as well as sticky for leukocytes, facilitated by increased 
expression of leukocyte-endothelial cell adhesion molecules
12,13
. As a result, rolling 
neutrophils (and other leukocytes) are tethered to the endothelial barrier, then tightly 
adhere and subsequently enter the tissues through the process of diapedesis. 
 
Activated neutrophils undergo degranulation and massive respiratory burst and begin 
to actively phagocytose microorgansims, the rate of which is enhanced by 
opsonisation of particles by immunoglobulins or complement fragments
14-16
. Foreign 
particles sequestered in phagosomes are eliminated by activated products of 
neutrophil respiratory burst. This includes killing by oxidants (e.g. hydrogen 
peroxide, hypohalites and chloramines), mediated through the opening of 
intracellular ion channels as well as the activation NADPH oxidase to generate the 





In addition to oxidative killing mechanisms, neutrophils release an arsenal of 
antimicrobial proteins that are harboured with four types of storage granules. These 
granules develop during maturation within the bone marrow with each granule 
protein facilitating a specific antimicrobial function
16
. The first of these granules are 




antimicrobial peptides) and the serine proteases Cathepsin G, Elastase and Proteinase 
3. These agents have a direct impact in the killing and digestion of pathogens when 
the azurophil granules fuse with phagosomes
12
. In addition, specific granules contain 
the Cathelicidin LL37/hCAP18 cationic peptide, which in addition to having direct 
microbicidal activity against a broad spectrum of pathogens, serves to activate both 
neutrophils and monocytes
17,18
. They also act as chemoattractants to neutrophils, 




Furthermore specific (secondary) granules contain Pentraxin 3 (PTX3) which possess 
opsonin-like activity
20
, and Lactoferrin, which when released upon cell apoptosis, 
selectively inhibits granulocyte migration through interaction with cell adhesion and 
motility signalling pathways
21
. Lastly, gelatinase granules contain Arginase I which 
undergo exocytosis when activated by azurophil contents and act to suppress the 
immune response by inhibiting T cell proliferation
22
. As powerful as neutrophil 
respiratory burst is at eliminating pathogens, these released products contribute 
extensively to the destruction of surrounding tissue. This is deemed a necessary 
collateral damage for overall host survival but does require very tight regulation. 
 
In addition to this function, neutrophils play an integral part in shaping the 
extracellular matrix by acting as paracrine modulators. Before the 1990s the 
paradigm existed that neutrophils were terminally differentiated cells with minimal 
protein synthesis, having synthesized a complete set of required proteins during 
maturation within the bone marrow. Subsequently, studies now show that activated 
neutrophils are indeed effectors cells, releasing a plethora of active compounds as 







Table 1.1: Immunomodulatory factors released from neutrophils 
Pro-inflammatory cytokines  











, IL-18, MIF 
Anti-inflammatory cytokines  
 IL-1RA, IL-4, TGF-β1, TGF-β2 
Immunoregulatory cytokines   
 IFN-γ
ǂ
, IL-12, IL-23 








Other cytokines  
 Amphiregulin, midkine, oncostatin M, PBEF 
CXC-chemokines  
 CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, 
CXCL8, CXCL9, CXCL10, CXCL11 
CC-chemokines  
 CCL2 CCL3 CCL4 CCL17 CCL19 CCL20 CCL22 
Angiogenic and fibrogenic factors  
 HB-EGF, HGF, FGF2, TGF-α, VEGF, prokineticin 2 
  
TNF superfamily members  
 
 
Antimicrobial peptides  
(in humans) 
APRIL, BAFF, CD30L, CD95L, RANKL, TNF, 
TRAIL 
 
Azurocidin, α-defensins (Human Neutrophil Peptide 
1 - 4, Cathelicidin (hCAP-18/LL-37) 
ǂ Denotes controversial data for human neutrophils at present 
 
The synthesis and release of these modulators are regulated at the intracellular level 
depending on the current physiological state of the inflammatory environment. These 
levels of regulation are largely at the stage of mRNA transcription, governed by cell 
surface receptors and signal transduction pathways in response to external stimuli, 
and also at the levels of post transcriptional regulation
25,26
. In addition regulation at 
the stage of protein secretion has been published in the case of TNF superfamily 
proteins BAFF and APRIL, where they are stored in pools and secreted in response 





The functions of neutrophils have been extended further. Over the past decade 
interest has been heightened in the ability of neutrophils to exhibit extracellular 
microbicidal properties by way of ‘casting’ NETs (Neutrophil Extracellular Traps)
28
. 




laced with proteins originating from azurophilic, secondary and tertiary granules. 
These proteins are involved in direct microbial recognition (e.g. PTX3), possess 
antimicrobial activity (e.g. LL-37, myeloperoxidase) and tissue remodelling (e.g. 
elastase and MMP9) capabilities. NETs have been demonstrated to trap a multitude 
of pathogens for killing by granule protein-mediated killing, such as Staphylococcus 
aureus, Shigella flexneri, Salmonella typhimurium
28
. Simon et al. (2013)
29
 references 
a number of observations that suggest NETs are the product of viable, motile 
neutrophils, requiring energy once activated to rapidly (within 5-10min) eject DNA. 
Up until very recently it was widely regarded that dying neutrophils undergo a 
specialised form of death that differed from necrosis and apoptosis, termed NETosis. 
However, as highlighted in Simon et al. (2009), this release of DNA from dying 
neutrophils has only been observed in PMA (phorbyl-12-myristate-13-acetate) 
treated neutrophils thus far and remains a controversial subject. 
As effective as NETs are considered in the elimination of microorganisms, studies 
have identified the contribution of NETs to enhanced inflammation in chronic 
autoimmune disorders. Patients with systemic lupus erythematosus (SLE) 
demonstrate B cell generation of autoantibodies to released ribonucleoproteins 





One other notable mention of recent interest is the discovery of a cell’s ability to 
produce extracellular vesicles (EVs) as a means of intercellular communication. EVs 
are commonly between 30nm to 1μm in diameter with the vesicles >100nm in size 
referred to as exosomes while larger vesicles are known as ectosomes, microvesicles 
or microparticles. Apoptotic bodies are also classified under the general terminology 
of EVs. They are formed by way of shedding or budding from the plasma 
membrane
31
, although they are considered difficult to confidently identify using 
current techniques (flow cytometry, light scattering and electron microscopy)
32
.It is 
considered that most cells produce EVs comprised of varying amount of membrane 
and cytoplasmic rich constituents. EVs are reportedly to have number of functions 
depending on the type of cell that they originate from
16
. PMN-derived EVs have 




endothelial cell expression of IL-6, IL-8 and ICAM-1 in vitro 
33
. Neutrophil-derived 
EVs have been suggested to possess antibacterial properties as published recently by 
Timar et al. (2013)
16
. EVs generated after exposure to opsonised zymosan or whole 
bacteria were able to inhibit S. aureus growth and form aggregates with the bacteria. 
This was compared to EVs generated from neutrophils in complement-depleted 
serum and in the presence of TNF-α. This study suggests the possibility that the 
antimicrobial effect of neutrophils may be far-reaching.  
 
It is clearly evident how essential neutrophils are to the host’s innate immune 
response. This is highlighted by defective neutrophil disorders such as chronic 





Antimicrobial actions of α-defensins within neutrophils 
As briefly mentioned, essential to the elimination of invading pathogens by 
neutrophils are the actions of antimicrobial peptides harboured within storage 
granules. Antimicrobial peptides form part of the host’s innate defence system 
against a broad range of bacterial, fungal and viral pathogens. These peptides, fewer 
than 100 amino acids in length, are widely expressed in organisms ranging from 




A key constituent of the neutrophil-containing antimicrobial peptide arsenal is a 
family of small peptides known as α-defensins, approximately 3-5kDa in size (Figure 
1.1). This subfamily form part of a structurally similar family divided into α-, β- and 
θ-defensins, with θ-defensins present in certain non-human primates
38
. α- and β-
defensins are similar in that they are largely comprised of a core, triple-stranded β-
sheet structure stabilized by three intramolecular disulphide bonds between six 
conserved cysteines. They differ in the length of peptide segments between these six 
cysteine amino acids
39
. Within humans, α-defensin isoforms consist of Human 
Neutrophil Peptide (HNP) 1-4 contained within neutrophils azurophil granules, and 
HD-5 and -6 abundantly expressed in intestinal Paneth cells. β-defensins are located 
mostly on epithelial surfaces and secretory glands
40




encoded by five DEFA genes, with the proteolytic removal of amino acids on HNP1 
(DEFA1) or HNP3 (DEFA3) forming HNP2
41
. It is widely thought that α-defensin 
genes ascended from the genes of β-defensins, given the abundance of β-defensin 
genes present throughout the evolutionary tree compared to α-defensin genes found 
exclusively in mammals
42
. Defensins are cationic antimicrobial peptides due to 
excess arginine and lysine expression but do vary in charge number. In addition to 





Figure 1.1: Quaternary structure of wild type HNP1 
The crystal structure of the dimeric (A) and tetrameric (B) assembly of Human 
Neutrophil Peptide-1 (HNP1). Disulphide bonds as well as residues involved in 
oligomerization are shown as balls and sticks and reciprocal main chain hydrogen 





The antimicrobial mechanisms of α-defensins have been extensively studied
44
. 
Within human neutrophils, azurophil granules fuse with phagosomes containing 
captured microbes. It is thought that released antimicrobial peptides initially make 
contact by binding to the outer microbial membrane through electrostatic 
interactions
45
. Through their amphipathic and lectin-like properties they are then able 
to insert themselves within the outer membrane lipid bilayer, with their hydrophilic 
portions associating with the hydrophilic outer heads while utilizing its hydrophobic 




membrane association creates pores of macromolecule size, which permits leakage of 
intracellular components and cell lysis. In addition, pores allow α-defensins to enter 
and target other intracellular components, resulting in DNA, RNA and protein 
synthesis inhibition
46
. A collapse in membrane potential has also been reported to 
occur as well the formation of voltage gated channels, resulting in intracellular ion 
imbalances
47
. HNP1-3 comprises of 5-7% of the total amount of protein within 
human PMNs, and between 35-50% within azurophil granules with much less 
abundance of HNP4
48
. α-Defensins also display potent anti-viral activity as 
demonstrated in the prevention of HIV-1 entry into cells through direct binding to 
viral glycoproteins
49,50
. Their aggregation with Influenza A virus has also been 
shown to mediate neutrophil uptake, as well as prevent Adenovirus capsid 
disassembly required for infection
51,52
. In addition, they have demonstrated an ability 
to neutralize a large number of bacterial toxins including Staphylococcus aureus and 
anthrax lethal factor
53-55
, as well as prevent synthesis of bacterial cell wall precursor 
lipid II
56
. α-Defensins have also been shown to induce IL-8 secretion in intestinal 
epithelial cells
57
. The property of hydrophobicity with the ability to form canonical 
dimers and even quaternary structures are essential to their antimicrobial functions as 
elegantly studied and published by the Professor Wuyuan Lu research group by the 
single point substitution of key amino acids
58,59
. Further immunomodulatory 
properties of α-defensins will be introduced later in this chapter and in Chapter 3. 
 
Macrophages: sentinel cells in immunity 
At sites of inflamed tissue, recruited neutrophils engage in complex bidirectional 
cellular crosstalk with macrophages, dendritic cells, natural killer cells, lymphocytes 
and mesenchyme stem cells
24
. The state of neutrophil activity plays a pivotal role in 
the macrophage physiology, which are key immune effector cells in the initiation, 
propagation and resolution of inflammation. Macrophages are derived from 
hematopoietic granulocyte-monocyte progenitor cells within the bone marrow and 
enter the blood stream as monocytes and differentiate into macrophages or immature 
dendritic cells upon tissue entry
60,61
. Under resting state tissue-resident macrophages 
fulfil ‘housekeeping’ duties, clearing cellular debris and apoptotic cells by 






In response to tissue trauma macrophages become classically activated – designated 
as phenotype ‘M1’ - by released DAMPs, cytokines and exogenous PAMPs 
recognised by TLRs, intracellular pattern-recognition receptors and interleukin 1 
receptor (IL1-R). Most inflammatory signal transduction takes place via the adaptor 
molecule myeloid differentiation primary response gene 88 (MyD88) and 
downstream signalling via the Nuclear Factor Kappa B (NFκB) and the Mitogen-
Activated Protein Kinase (MAPK) signalling pathways
63-65
. Subsequently-activated 
transcription factors upregulate gene expression of proteases, eicosanoids, pro-
inflammatory cytokines (e.g. TNF-α, IL-12, IL-23), and reactive oxygen and 
nitrogen intermediates (ROIs and RNI, respectively)
1
. Activated macrophages also 
display an increased phagocytic capacity for invading microbes. By processing their 
components for antigen presentation to T-cells together with dendritic cells (DCs), 
they provide a critical link to the adaptive immune system. 
 
The M2 macrophage classification or ‘alternatively’ activated macrophages broadly 
classifies a range of other macrophage phenotypes. These are defined by the subtypes 
M2a (after exposure to IL-4 and/or IL-13), M2b (immune complexes in combination 
with IL-1β or LPS) and M2c (IL-10, TGF-β or glucocorticoids)
66
. In general, 
alternatively activated macrophages are associated with response to parasitic 
infections (M2a)
67
, producing anti-inflammatory IL-10 and TGF-β with abrogated 
IL-12. They are therefore regarded as being immunosuppressive in function. 
 
In a recent review of macrophage phenotyping, Mosser and Edwards (2008)
68
 
suggested that macrophages are more accurately characterised as having a degree of 
phenotypic plasticity as opposed to being solely classical or alternatively activated. 
Instead, they suggest that macrophages should be interchangeably grouped according 
to their function as either being involved in host defence, wound healing or immune 
regulation. Indeed in the rapidly changing tissue environment that is a milieu of 
cytokines, chemokines and tissue growth factors, it would seem feasible that 
macrophages should be considered readily adaptable to change and shape its function 




controlling inflammation from the point of initial infiltration to the eventual 
resolution and tissue regeneration. 
 
 Inflammation regulation 1.2
Leukocytes and their role in inflammation clearly benefit the host in providing 
protection against infections and avoiding often fatal septicaemia through multiple 
organ failure. As a consequence of defective inflammation regulation, chronic 
inflammation can often lead to extensive tissue damage. In severe cases of chronic 
inflammatory disorders such as rheumatoid arthritis, it can often result in chronic 
pain, permanent disfiguration and debilitation as a result of irreversible tissue and 
joint destruction
69
. Not only is inflammation pathophysiology detrimental in chronic 







 and cardiovascular diseases
73
. 
Thus it is imperative to the host that the inflammatory event, when required, be 
effective in its function while transitioning (when appropriate) to bring about tissue 
regeneration and eventual tissue homeostasis. For this to occur, inflammation must 
be tightly regulated. 
 
The regulation of inflammation is diverse and complex process, occurring at multiple 
stages during the inflammatory cascade. Neutrophils play a role in early stage 
checkpoints with one such mechanism involving switching from the production of 
pro-inflammatory lipid autocoids such as leukotrienes and prostaglandins to anti-
inflammatory lipoxins, a distinct lipoxygenase-derived eicosanoids that carry stop 
signals for inflammation
74
. For example, Lipoxin A4 inhibits further neutrophil 
migration mediated through formyl peptide 1 receptor (FPR-1) and also initiates non-
phlogistic recruitment of monocytes and phagocytosis of apoptotic neutrophils by 
macrophages
75
. Efferocytosis brings with it the release of resolvins and protectins 
from neutrophils
76
. These mediators bring about pro-resolving actions in neutrophils 
(tissue infiltration inhibition), macrophages (non-phlogistic phagocytosis of 
apoptotic neutrophils), dendritic cells (blocks IL-12 production) and T cells (CCR5 







Clearance of apoptotic neutrophils is an anti-inflammatory event 
The clearance of cells dying by programmed cell death was previously considered as 
a very low impact event in shaping tissue homeostasis. Indeed the engulfment and 
elimination of these no longer required cells by phagocytes was considered to be a 
refuse and recycling process without much consequence. Besides normal cell 
turnover under homeostatic conditions, apoptosis occurs during times of infection, 
wound healing and in disease states
77
. Over the last decade extensive research has 
shown that timely removal of apoptotic bodies by phagocytes dampens inflammation 
and promotes pro-resolution. Clearance of neutrophil corpses no longer required 
during the inflammatory cascade have a direct bearing on the physiological state of 
phagocytes
78
. Apoptotic neutrophil clearance by macrophages brought about a 
release of anti-inflammatory TGF-β, prostaglandin E2 and platelet-activating factor 
(PAF) which were found to mediate the decrease in inflammatory cytokines GM-
CSF, IL-1β, IL-8 and TNF-α
79
. In addition ingestion of apoptotic cells by immature 
DCs alters their maturation while promoting TGB-β secretion and induces 
tolerogenic CD4+Foxp3+ regulatory T cells
80
. Ingestion of circulating apoptotic 
leukocyte ingestion by splenic marginal zone DCs lead to decreased mRNA levels of 




Studies have suggested the involvement of two key factors mediating this effect. The 
first is by the release of ‘find me’ signals by apoptotic cells, which are recognised by 
receptors on scavenger cells and direct their migration. To date four released signals 
and their associate receptors have been identified: lysophosphatidylcholine (LPC) 
and G2A, fractalkine (CX3CL1) and CX3CR1, sphingosine 1-phosphate (S1P) and 
S1P1-5, and lastly the nucleotides ATP and UTP with P2Y
82
. The second factor is 
through the receptor-mediated recognition of ‘eat me’ signals presented on the 
surface of apoptotic cells. Most notably is the recognition of membrane translocated 
phosphatidylserine (PtdSer) by phagocytic receptors including TIM4, BAI1, RAGE 
and stabilin-2
9
. While debate continues as to whether presented PtdSer alone is 
sufficient to mediate receptor interaction and uptake by phagocytes, it is appreciated 
that PtdSer does play an integral part together with currently unidentified signals and 




activation of PtdSerR triggers the release of TGF-β
83
. Fadok et al. (2001)
84
 found 
that membranes of lysed neutrophils were able to suppress the expression of pro-
inflammatory mediators and upregulate TGF-β, believed to be PtdSer-mediated. 
 
While timely apoptotic cell clearance shapes the tissue environment, impaired 
clearance leads to gradual accumulation in the tissue. In some cases this can lead to a 





Dying neutrophils release anti-inflammatory α-defensins 
Inflamed tissue brings with it large scale uncontrolled cell death and the release of 
DAMPs from necrotic cells, ultimately leading to further macrophage activation. 
Neutrophils dying by necrosis are widely regarded as inflammatory through the 
release of danger signals, of which serine proteases and elastase are key 
contributors
84
. However not all cellular components released from dying neutrophils 
are inflammatory to macrophages and do quite the opposite, perhaps acting as a 
counteroffensive to an overly exaggerated inflammatory response. 
 
The inhibitory effect of α-defensins on pro-inflammatory macrophages was 
published by the Dr Mohini Gray lab group
87
 and forms the groundwork to the 
research in this thesis. This paper showed for the first time that apoptotic human 
neutrophils release soluble factor/s that significantly attenuate secreted TNF-α in 
classically activated human monocyte derived macrophages (HMDMs) in vitro. This 
was achieved by the use of a Transwell system to separate apoptotic cells from 
macrophages and also by ultracentrifugation to clear soluble contents of apoptotic 
bodies. Crucially this effect was independent of both direct cell contact with 
macrophages and the anti-inflammatory modulator TGF-β.  
 
More striking were the anti-inflammatory soluble contents of neutrophils that were 
made necrotic by freeze/thawing were cleared of their membrane components by 
ultracentrifugation, yet these resulting neutrophil supernatants were profoundly 
inhibitory (12×10
6 




amounts of these necrotic neutrophil supernatants were found to significantly 
attenuate a multitude of pro-inflammatory mediators, notably cytokines TNF-α, IL-
1β, IL-6 and IL-8 as well as the ROS agent nitric oxide. Interestingly these also lead 
to a decrease in the anti-inflammatory IL-10. This effect remained exclusive to 
human neutrophils as human thymocytes and murine neutrophils (which lack α-
defensin) displayed no anti-inflammatory effect on macrophages. 
 
Through extensive testing neutrophil lysates were depleted of α-defensins by non-
specific hydrophobic protein depletion using a bead depletion assay. Resulting 
electrophoretic protein gels identified α-defensins as a prominent protein band 
removed from these fractions. Confirmation of the key modulatory role of α-
defensins was confirmed when hydrophobic protein-depleted fractions, which had 
subsequently lost its anti-inflammatory potential, regained this property when 
purified α-defensins were added back at physiological concentrations. The anti-
inflammatory effects of purified, neutrophil-derived as well as synthetic HNP on pro-
inflammatory HMDMs in cell culture experiments reiterated the direct 
immunomodulatory properties of this peptide. Crucially it was found that neutrophils 
in culture display a gradual release of HNP1-3 over 24hrs, peaking at 9hrs. These 
studies also highlighted structural importance of HNP function, as the linearised and 
D-enantiomer peptide form showed no inhibitory effect. Furthermore the human 
cathelicidin LL-37 was tested with no effects on secreted TNF-α observed. It is 
worth noting that, contrary to this finding, a number of other publications have 
reported on the ability of LL-37 to reduce TNF-α and NO production in bone marrow 




Importantly the effect of α-defensins was not attributed to a decrease in macrophage 
viability. In fact macrophages in culture exposed to α-defensins for 1hr or 24hrs, and 
then allowed to rest in culture, gradually restored their full propensity to produce 
TNF-α upon LPS activation after 20hrs and 72hrs respectively. Whilst the capability 
of HNP treated macrophages to produce cytokines was limited, functionally, 




in culture and showed enhanced phagocytosis of fluorescent beads compared to 
untreated cells.  
 
In vivo, mice infected with Salmonella enterica were administered with necrotic 
human neutrophil supernatants and after seven days showed a reduction in serum 
TNF-α concentration as well as fewer bacterial colonies from lysed splenocytes 
when plated onto agar. The therapeutic effect of α-defensin in a sterile inflammatory 
model was also demonstrated; mice induced with peritonitis by thioglycolate 
injection alongside HNP1 or necrotic human neutrophil supernatants showed a 
reduction in infiltrating GR-1
+




And finally, in a clinical setting, studies from synovial fluid extracted from 
rheumatoid arthritis patients undergoing arthrocentesis have been reported to contain 
high concentrations of α-defensins in the range of 3 – 25μg/mL, with a mean of 
12.4μg/mL. 
 
 Key concepts 1.3
Within this thesis, key research concepts pertaining to the role of α-defensins were 
performed. Of note, the role of autophagy, classical activation of macrophages via 
the TLR7/8 agonist R848, and Rheumatoid Arthritis with the potential involvement 
of α-defensins. These three concepts will be briefly introduced. 
 
1.3.1 Autophagy 
Autophagy (‘self-eating’) is largely defined as a catabolic process whereby cellular 
components are digested by lysosomes for metabolic recycling (Figure 1.2). In 
addition to homeostatic organelle turnover, the onset of autophagy can occur as a 
consequence to nutrient deprivation, infection as well as regulation of the innate 
immune response
89-91
. A major subtype of autophagy, termed macroautophagy is 
generally defined as a process where cellular components are compartmentalised into 
phagosomes followed by fusion with lysosomes for degradation during periods of 
nutrient starvation. Macroautophagy (hereafter referred to as autophagy) in this 




immune-related response in the degradation of intracellular bacteria and viruses 





One of the most common markers for monitoring autophagy in mammalian cells is 
the conversion and incorporation of soluble LC3B-I (microtubule-associated protein 
light chain 3, homolog B) situated within the cytoplasm to lipid-bound LC3B-II, 
which is conjugated with phosphatidylethanolamine (PE). LC3B-II thus forms part of 
the autophagosome containing sequestered macromolecules after which these 
vesicles fuse with lysosomes (autophagolysomes) and are degraded
93,94
. 
Interestingly, an abnormality of key autophagy proteins within murine intestinal 
Paneth cells has been linked to an increased susceptibility to Crohn’s disease as a 
result of defective exocytosis of granule proteins
95
. In addition, defective cellular 
autophagy is implicated in pathophysiological processes that include 







Figure 1.2: Overview of the autophagy pathway 
The development of an autophagosome forms from membrane formation and 
extension, followed by envelopment of cellular organelles to be degraded. The 






1.3.2 Macrophage activation through R848 stimulation 
Imperative to the research investigating the effects of α-defensins on macrophages 
was their means of ‘classical’ activation by TLRs. These pattern recognition 
receptors are grouped by their preferences for conserved structural motifs of 
pathogens. Specifically TLR 3, 7, 8 and 9 located on the membranes of endosomes 
are able to recognize and respond to viral infections through the recognition of 
genomic DNA or RNA
97
. The activation of TLR 7/8 is notably in response to single 
stranded RNA viruses (ssRNA40), for example retroviruses including Human 
Immunodeficiency Virus -1 (HIV-1) and the influenza virus
98,99
. Macrophage and 
dendritic cell response to TLR7/8 activation is through signaling via the NF-κB 
pathway resulting in the production of inflammatory cytokines including TNF-
α
100
(Figure 1.3).  
 
R848 is an amidazoquinoline compound with potent anti-viral activity that activates 
immune cells via TLR7/8 through the MyD88-dependent signalling pathway and 
NF-κB activation
101,102
. Not only was R848 selected as the ideal choice of agonist for 
macrophage activation against viral infection, but the hindrance of this activation 
pathway by α-defensins had implications against potential protection against 
autoimmunity. In particular, self-RNA and DNA can inappropriately be recognized 
by TLR7 (and TLR9). As a consequence, this self-directed immune response can 









Figure 1.3: R848 activation of the TLR7/8 signalling pathway 
The activation of toll-like receptors (TLRs) 7 and 8 (TLRs) by R848 and viral 
ssRNA. Activation leads to signaling via the MyD88-dependent pathway. Generation 
of interferon-α and -β gene expression is the result of activated IRAK4 (interleukin-1 
receptor-associated kinase) phosphorylation of IRAK1, followed by phosphorylation 
of transcription factor interferon regulatory factor 7 (IFR7). IRAK4/1 activation also 
results in activation of TRAF6 (TNF receptor associated factor) and downstream 
protein kinase TAK1 and TAB1, resulting in the activation of the Mitogen Activated 
Protein kinase (MAPK) and NF-κB signaling pathway. Phosphorylation of ERK 
(extracellular signal-regulated kinase), JNK (c-jun N-terminal kinases) and p38 lead 
to the phosphorylation and nucleus translocation of transcription factor AP-1 
(activator protein-1), inducing pro-inflammatory mediator gene expression. In 
addition, phosphorylation of IKKβ activates the IκBα/NFκB complex, resulting in 
the release and translocation of NFκB (and proteolytic degradation of IκBα). 
Activated NFκB promotes the gene expression of pro-inflammatory mediators for 





1.3.3 Rheumatoid Arthritis 
In addition to the potential influence of α-defensins in SLE, direct influences of 
dying neutrophils and the release of α-defensins on the counter-development of 
Rheumatoid arthritis (RA) are proposed and discussed throughout this thesis. RA is a 
chronic, progressive and systemic inflammatory disorder affecting approximately 1-
2% of the population. RA is a debilitating disease and is characterised by chronic 
joint pain, inflammation and disability as a result of cartilage and bone destruction
69
. 
Although the direct cause of RA remains unknown, evidence has linked the onset to 
genetic and environmental factors, with genome-wide analysis relating immune 




Key to the development of RA is the increase in rheumatoid factor within the joint 
synovium, which is a high-affinity autoantibody against the Fc portion of 
immunoglobulins
69
. Measured rheumatoid factor within the vasculature has been a 
long-standing test used by rheumatologists to diagnose RA. Complement activation 
is also implicated in the initial pathogenesis of RA, triggering subsequent activation 
of resident leukocytes within the synovial fluid, notably synovial fibroblasts and 
resident macrophages
106
. Activation of these cells results in the release of pro-
inflammatory cytokines including TNF-α, IL-1 and IL-6, as well as mediators of 
vascular growth (e.g. VEGF)
107,108
. VEGF-induced angiogenesis results in increased 
trafficking of activated leukocytes, particularly neutrophils which are one of the 
earliest and influential inflammatory cells to infiltrate the synovium
109,110
. Cartilage-
degrading factors such as released matrix metalloproteinases (MMPs) contribute to 
pannus formation and resultant cartilage erosion. Continued cartilage erosion 
exposes bone to inflammatory cells and subsequent activation of osteoclasts and 
chondrocytes, further contributing to the heightened inflammatory state that destroys 
cartilage and bone through the release of MMPs
111
. Notably excessive TNF-α and 
RANKL co-stimulate osteoclastogenesis of monocytes within the bone marrow, 
resulting in precursor osteoclast development and maturation into osteoclasts, 







Ultimately RA results in irreversible cartilage damage and joint space narrowing. 
Thus it is the importance of TNF-α activity within RA joints that has spurned the 





 Aims of this thesis 1.4
The aims of this thesis were to elucidate the mechanistic actions of α-defensins on 
macrophages. At the point of undertaking this project, very little was established into 
the molecular mechanisms underlying the inhibitory actions of this peptide. In the 
paper published by the Dr Mohini Gray group on defensins, it was established that 
the effect was not due to the prevention of inflammatory cytokine exocytosis. This 
finding contradicted another report showing that α-defensins specifically blocked 
secretion of IL-1β (and not TNF-α) in LPS stimulated murine monocytes
115
.  
Given this information, pinpointing the underlying effects α-defensins in the 
complexities of cell biology was somewhat of an undertaking. In a cycle of trial and 
error, coupled with a continuous reassessment of the mechanistic hypothesis, a 
collection of evidence was puzzled together to characterize the inhibitory effects. 
Below is a summary from each chapter, highlighting the general studies performed 
and the working hypothesis where applicable. 
 
Chapter 3  
Initial investigations went into recapitulating the previously published anti-
inflammatory effects of necrotic neutrophil supernatants on human macrophages. 
These effects were then extended to include purified HNP and single amino acid 
mutations thereof in order to identify the key functional components. The inhibitory 
actions of α-defensins on other cell types were studied. In addition, the potential 
wound healing effects of mouse macrophages treated with human necrotic neutrophil 
supernatants were assessed in vivo. The impact of α-defensins on inflammatory 
mRNA expression was also addressed in order to begin addressing the inhibitory 






Overall de novo protein synthesis of macrophages was assessed leading to the 
hypothesis of HNP-induced mRNA translation regulation caused by the onset of 
endoplasmic reticulum (ER) stress. Studies assessing key contributory factors 
involved in ER stress were carried out, namely: calcium homeostasis and 
upregulation of genes regulating translation initiation. 
 
Chapter 5 
The inhibitory actions of HNP on translation were examined in further detail, using 
cell-free systems and reporter mRNAs. Assays addressing the hypothesis of HNP 
binding to RNA were assessed using electrophoretic mobility shift assays (EMSAs) 
using synthesised oligonucleotide sequences as well as human macrophage-derived 
RNA (continued in chapter 6). The hypothesis was furthered to propose that HNP 
directly impaired ribosome function through direct binding to ribosomal RNA 
(rRNA). Macrophage polysome analysis was performed to pinpoint clues into the 
state of translating ribosomes in HNP-treated HMDMs in vitro. 
 
Chapter 6 
The ribosome binding hypothesis was further examined using immunocytochemistry 
to assess the co-localisation of HNP with ribosomes in HMDMs by confocal 
microscopy. Experiments were performed in an attempt to confirm HNP-ribosome 
binding hypothesis, namely by immunoprecipitation and ultracentrifugation. The fate 








2 Materials and Methods 
 
 Reagents 2.1
Reagents were purchased from Sigma Aldrich (St Louis, U.S.A) unless otherwise 
stated. 
 
 Cell culture 2.2
2.2.1 Human Monocyte Derived Macrophage (HMDM) derivation 
Peripheral Blood Mononuclear Cells (PBMCs) were purified from whole blood 
obtained from healthy donors within the Centre for Inflammation Research (REC 
reference number 08/S1103/03) or from blood obtained from buffy coats obtained 
from the NHS Blood Transfusion Unit (Lauriston Place, Edinburgh). Buffy coats 
were obtained normally 2-3 days after donation having been kept at room 
temperature in the interim period at the blood transfusion centre. Cells were isolated 
using dextran sedimentation and a Percoll gradient accordingly to Haslett et al. 
(1985)
116
: 4mL 3.8% sodium citrate was added to 50mL of blood to prevent 
coagulation during preparation. Plasma, separated from remaining blood volume by 
centrifugation (Rotina 420R, Hettich, Tuttlingen, Germany), was cleared of 
aggregated platelets by the addition of 200μL 1M calcium chloride (CaCl2) in 10mL 
glass tubes. This serum would be retained for inclusion in cell culture medium. 
Leukocytes were separated from red blood cells by the addition of 6% dextran 
(Pharmocosmos; Holbaek, Denmark) and removed for Percoll (GE Healthcare; 
Waukesha, U.S.A) gradient separation. Following centrifugation cell pellets were 
mixed with 55% (v/v) Percoll solution and layered onto 68% and 81% (v/v) Percoll 
gradients. Centrifugation was performed at 720 × g for 20min with no rotor 
acceleration or deceleration to separate PBMCs from polymorphonuclear leukocytes 
(PMNs). PBMCs were aspirated, washed twice in 1xPBS (PAA Laboratories, 
Pasching, Austria) and counted using a cell counting chamber (Hawksley; Sussex, 
U.K). PBMCs were seeded at 4 × 10
6 
cells/mL in Iscove’s Modified Dulbecco’s 




and 0.1mg/mL streptomycin (all PAA Laboratories GmbH) in cultured in T75cm
2 
flasks (Corning Inc,; Corning, U.S.A).  
Flasks were incubated (SANYO Electric Biomedical, Osaka, Japan) for 1hr at 37°C, 
5% CO2 (carbon dioxide), 80% humidity which are the standard incubation 
conditions for the remainder of this thesis. Media and non-adherent cells were then 
aspirated and supplemented IMDM containing 10% (v/v) heat-inactivated autologous 
serum (referred to as ‘complete IMDM’). Note that for buffy coat-derived cell 
culture IMDM was supplemented with heat-inactivated Fetal Bovine Serum (FBS, 
BioSera; Ringmer, East Sussex, UK). Culture media was replaced every three days. 
On day six adherent Human Monocyte Derived Macrophages (HMDMs) were lifted 
off flasks using 1x Cell Dissociation Solution (Sigma) with gentle scraping, counted, 
and seeded in flat bottomed 96-well culture plates (Corning Inc.) at 20 000 cells/well 
(unless otherwise stated) the day before commencing experiments. All cell culture 
experiments were performed in serum-free culture media unless stated otherwise. In 
addition HMDMs from fresh donations were used unless mentioned otherwise. 
 
2.2.2 Generation of human necrotic neutrophils (NN) 
Fresh neutrophils were obtained from the above-mentioned protocol. Neutrophils 
were seeded in serum free IMDM at 50 × 10
6
cells/mL and made necrotic by 
freeze/thawing five times on dry ice. Cell volume was then centrifuged at 100 000 × 
g using the S100-AT6 fixed angle rotor and the RC M150 GX ultracentrifuge 
(Thermo Scientific Sorvall, Waltham, U.S.A) for 60min at 4°C. Supernatants were 
removed from discarded pellet and used directly in cell culture assays (abbreviated as 
‘NN’). 
 
2.2.3 Bone Marrow Derived Macrophages (BMDMs) 
Bone marrow was harvested from murine femur and tibia bones by aseptic flushing 
using a 19G needle containing DMEM F12 Glutamax™ (Gibco/Life Technologies, 
Carlsbad, U.S.A) supplemented with 20% (v/v) sterile-filtered L929 cell culture 
supernatant (produced in-house), 10% FBS and 100U/mL penicillin and 0.1mg/mL 
streptomycin. Cells were incubated in a humidified incubator at 37°C, 5% CO2 in 




BMDMs were used between days 7-10. Where appropriate, BMDMs were stimulated 
with FGK-45 and murine IFN-γ (PeproTech, Rocky Hill, U.S.A). 
 
BMDMs obtained from mice containing a Tristetraprolin protein knockout (TTP
-/-
) 
on a C57 BL/6 background were kindly donated by Dr Jonathan Dean (Department 
of Medicine, Imperial College London) and cultured as described above. 
 
2.2.4 Cell lines 
THP-1 monocytic cell line: Low passage number THP-1 cells (P26) were obtained 
from Shalini Rajagopal from the Centre for Reproductive Health, Queen’s Medical 
Research Institute, Edinburgh University. The suspension cells were maintained in 
cultured in flasks containing Dulbecco’s Modified Eagle Medium (DMEM, PAA 
Laboratories) supplemented with 2mM L-glutamine, 100U/mL penicillin, 0.1mg/mL 
streptomycin and 10% FBS (referred to as ‘complete DMEM’). For passaging, a 1:10 
split of cell suspension was performed every 3-4 days. Maturation into macrophages 
was performed by seeding cells into culture wells in complete DMEM containing 
10ng/mL phorbol 12-myristate 13-acetate (PMA) as per recommended 
concentration
117
. Treated cells were incubated for 48hrs prior to being checked for 
adherence, followed by washing in 1× PBS (phosphate buffered saline) prior to use 
in experiments. 
 
Mutu-1: The Burkitt lymphoma cell line Mutu-1 was received from Professor Chris 
Gregory (Centre for Inflammation Research, University of Edinburgh). Cell were 
grown in suspension and cultured in T25cm
2 
flasks containing RPMI1640 
supplemented with 2mM L-glutamine, 100U/mL penicillin and 0.1mg/mL 
streptomycin and 10% FBS. Cells were passaged every 3-4 days. For experiments, 
cells were seeded in round-bottom 96 well plates at 20 000/well in 200μL culture 
media.  
 
2.2.5 α-defensin peptides 
Natural, purified HNP1-3 was purchased from Hycult Biotech (Uden, The 




(University of Maryland School of Medicine, Baltimore, U.S.A). Mutant derivatives 
were also donated which included: LHNP1 (structurally linearized HNP1 by the 
substitution of cysteine amino acids with alanine), and W26A-HNP1 (tryptophan 
substitution with alanine at residue position 26). All peptides donated were prepared 
by solid-phase synthesis as described in Wu et al. (2004)
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. These peptides were 
supplied in lyophilized form, with the exception of LHNP1 which was supplied in 
reconstituted form at a predetermined stock concentration. Upon receipt lyophilized 
peptides were weighed out in 1mg amounts using a microbalance (MT5, Mettler-
Toledo, Greifensee, Switzerland) and reconstituted in sterile dH2O (deionized H2O) 
containing 0.01% acetic acid (VWR International, Radnor, U.S.A). Protein 
absorbance at A280nm was measured on a NanoDrop 1000 (Thermo Fisher 
Scientific) and used to calculate the molar (M) concentration of peptide using the 








C is the peptide concentration (M). 
A is the absorbance at A280nm. 
ℓ is the path length (cm).  











Quantitated protein concentrations were aliquoted into small volumes and vacuum 
dried for 1hr in an Alpha rotational vacuum concentrator (Martin Christ, Osterode 
am Harz, Germany). Aliquots were stored at -20°C until needed and reconstituted 
when required in sterile 0.01% acetic acid at desired stock concentration. 
 
2.2.6 HMDM and THP-1 stimulants  
Stimulants commonly used to stimulate primary cells and cell lines included the 
amidazoquinoline compound R848 purchased from Invivogen (Toulouse, France) 
and used at 1μg/mL unless otherwise stated. In addition, other stimulants used were: 




(LPS), Protein A from Staphylococcus aureus Cowan Strain (SAC), Peptidoglycan 





2.2.7 HNP1 treated POPC liposomes  
5mg POPC liposomes (1-palmitoyle-2-oleoyl-sn-glycerol-3-phosphocholine; Avanti 
Polar Lipids Inc., Alabaster, U.S.A) were dissolved in 250μL chloroform within 
glass vials to obtain a clear lipid solution. Organic solvent was then evaporated with 
a steady stream of N2 further dried by rotatory vacuum for 2hrs. Multilamellar 
vesicles (MLVs) were hydrated by dispersing dry lipid films in >18MΩ/cm (25°C) 
serum free IMDM media at a concentration of 10mg/mL with slight frequent 
agitation containing either 0% mol HNP1 (nil) or 2% mol HNP1 (i.e. 100ug HNP1 in 
5mg POPC). Prior to treatment working concentrations of liposomes were aliquoted 
into eppendorf tubes and sonicated for 2min in a sonicating waterbath (Ultrawave, 
Cardiff, UK) at 37°C. Liposomes were pelleted by centrifugation at 3500 × g for 
20min (4°C) and resuspended at working concentration required. HNP1 treated 
liposome volumes were used in downstream experiments with R848-stimulated 
HMDMs to assess the effect on secreted TNF-α. 
 
 Colourimetric assays 2.3
2.3.1 Enzyme Linked Immunosorbant Assay (ELISA)  
This protocol describes the general method used to detect secreted cytokines from 
cell culture experiments. Human TNF-α, mouse IL-1β (donated by Dr Kevin 
Dhaliwal, Edinburgh University), human IL-6, IL-8, IL-10 (mouse and human) were 
purchased from R&D Systems (Minneapolis, U.S.A) and performed according to 
manufacturer’s protocol and working concentrations. The assay was performed in 96 
well EIA/RIA plates (Corning Life Sciences; New York, U.S.A) which were initially 
coated overnight in capture antibody. After washing the wells with 1× PBS/0.05% 
Tween-20, plates were patted dry and samples from cell culture supernatants were 
added to wells, diluted if necessary in 1× Reagent Diluent (R&D Systems) in a final 
volume of 50μL per well. Standards of known cytokine concentration were included 
on plates and a two-fold dilution series was performed in duplicate for comparison. 
Plates were incubated at room temperature for 1.5hrs after which wells were washed 
and incubated with detection antibody and incubated for 1hr at room temperature. 
Wells were washed and incubated with streptavidin HRP (horseradish peroxidase; 




50μL of SureBlue™ TMB Microwell Peroxidase substrate (KPL Inc., Gaithersburg, 
Maryland, U.S.A) was added. After 10-15min and upon sample solution turning 
blue, the enzymatic reaction was stopped using 50μL 0.6N sulphuric acid and 
absorbance values were read at A450nm on a Synergy HT plate reader (Biotech, 
Winnoski, U.S.A) using Gen5 (version V.1.01.14) software from BioTek. The plate 
background absorbance was corrected by subtracting the absorbance readings at 
A570nm from the A450nm values. Absorbance readings from standards were plotted 
graphically using Microsoft Excel (Redmont, U.S.A) to obtain a line equation of 
absorbance versus protein concentration. This equation was then used to calculate the 
appropriate cytokine concentration of samples which were then plotted on a graph 
using GraphPad Prism software, V4 (GraphPad Software Inc.; San Diego, U.S.A). 
 
2.3.2 Alamar Blue assay 
alamarBLUE (AdB Serotec, Kidlington, UK) was added together with cells in 
culture media at a final volume of 10% (v/v) as per manufacturer’s guidelines as a 
measure of cellular metabolic activity. At specified time points, the culture plate was 
read on a Synergy HT plate reader using Gen5 software at A570nm and A600nm. 
The percentage reduction of alamarBlue was calculated using the equation: 
 
% reduction of alamarBlue = (O2 × A1) – (O1 × A2)  × 100 
(R1 × N2) – (R2 × N1) 
 
Where:  





















A1 = absorbance of test wells at A570nm  
A2 = absorbance of test wells at A600nm  





N2 = absorbance of negative control well (media plus alamarBlue but no cells) at 
A600nm 
 
Absorbance readings were then plotted graphically using GraphPad Prism. 
 
 Protein purification and determination 2.4
Cells in culture plates were washed in 1× PBS and air-dried briefly before being 
lysed in 100μL lysis buffer (on ice) consisting of: 
 50mM Tris-HCl (pH7.5) 
 150mM NaCl (sodium chloride) 
 1% Triton X-100 
 0.5% Deoxycholic acid 
 0.1% SDS 
 1mM PMSF (phenylmethylsulfonyl fluoride) 
 1x Complete protease inhibitor cocktail with EDTA (Roche) 
 1mM NaF (Sodium Fluoride) 
 1mM Na3VO4 (Sodium Orthovanadate) 
 
After 10min incubation on ice with intermittent pipetting, samples were centrifuged 
at 10 000 × g for 10min, 4°C after which supernatants were collected in fresh tubes. 
Protein concentrations were first quantitated using the Bio-Rad protein assay and if 
necessary, concentrated by precipitation and purified using either the ProteoExtract 
Protein Precipitation kit (Merck Millipore, Billerica, U.S.A) as per manufacturer’s 
protocol or by Trichloroacetic acid (TCA) precipitation. 
 
2.4.1 Bio-Rad protein assay 
Protein determination of samples was performed using the DC Protein Assay kit 
(Bio-Rad, Hercules, California, U.S.A) which is based on the Lowry assay 
principle
120
. Samples containing cell lysates were diluted to suitable concentrations 
while a protein standard range using bovine serum albumin (BSA; VWR 
International) was obtained by a two-fold dilution series in a 96 well plate. The 




originally in each respective assay. 5μL of protein sample was then added to 25μL of 
Reagent A containing 2% (v/v) Reagent S (performed in triplicate). 200μL of 
Reagent B was then added to each well and incubated for 15min at room temperature 
with gentle rocking. Sample absorbance readings were then read at A750nm using 
the Synergy HT plate reader using Gen5 (version V.1.01.14) software. Absorbance 
readings from protein standards versus known protein concentrations were then 
plotted to obtain a line equation of the resulting plot. This equation was then used to 
calculate the protein concentration of samples for use in downstream applications.  
 
2.4.2 Trichloroacetic acid (TCA) protein precipitation 
One volume of 20% (v/v) TCA was added to one volume lysate, vortexed and 
incubated on ice for 1hr. Samples were then centrifuged using a bench top IEC 
MicroCL 17R (Thermo Scientific) centrifuge at 14 000 × g for 5min, 4°C after which 
TCA was aspirated and 100μL ice cold 20% (v/v) acetone (VWR International) was 
added to pellet and incubated for a further 30min on ice. Samples were again 
centrifuged at 14 000 × g for 5min, 4°C and supernatant aspirated. The acetone 
incubation step was repeated after which pellets were air dried for 5min at room 
temperature and 30μL of 1x Laemmli buffer [2% SDS, 10% Glycerol, 5% 2-
mercaptoethanol, 0.002% Bromophenol Blue, 63mM Tris-HCl, pH6.8] was added to 
each sample. Tubes were incubated on a thermomixer (Eppendorf; Hamburg, 
Germany) at 75°C, 700rpm (revolutions per minute) for 1hr or until pellets were 
visibly solubilised. 
 
 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 2.5
(SDS-PAGE) and Western Blotting  
Protein samples were prepared for polyacrylamide gel electrophoresis by adding 2× 
Laemmli sample buffer to obtain a 1× dilution. Samples were heated for 5min at 
95°C followed by 5min incubation on ice and brief centrifugation. Samples were 
loaded onto a NuPage Novex 10% Bis-Tris precast mini-gel within an XCell 
SureLock Mini-cell gel tank containing 1× NuPage MOPS SDS Running buffer (all 
purchased from Invitrogen/Life Technologies, Carlsbad, U.S.A). Gel tank was then 
connected to a power pack (PowerPac™ 300, Bio-Rad) and run at 100 volts (V) for 





Alternatively SDS-PAGE gels were made in-house using Sigma reagents. Two glass 
plates were assembled into the Bio-Rad gel loading cassette and running gel buffer 
(Table 2.1) was poured approximately up to 2cm from the top of the glass plates and 
left to set with dH2O. Upon polymerisation, water was removed off and loading gel 
buffer (Table 2.2) was poured, gel comb inserted and left to set. Samples were loaded 
as before and run at 80V for 90mins.  
For the approximate molecular weight determination of separated proteins, 10μL of 
1× SeeBlue® Plus2 pre-stained protein standard (Invitrogen) was loaded in a well 
alongside samples. 
  
Following electrophoresis, the proteins were transferred onto a Hybond-P PVDF 
(Polyvinylidene difluoride) membrane (GE Healthcare) pre-soaked in methanol. The 
gel/membrane was sandwiched between blotting paper (Bio-Rad) inserted into an 
XCell II Blot Module (Invitrogen) which was placed inside the XCell SureLock gel 
tank and filled with western transfer buffer [20% (v/v) methanol, 38.6mM glycine, 
47.9mM Tris, 0.04% SDS]. The system was connected to a power pack and run at a 
constant current 1mA (milliamp)/cm
2 
of gel surface area for 2hrs at room 
temperature, or alternatively overnight at 4°C. Protein transfer from gel to membrane 
was confirmed by the transfer of molecular weight standards. Membranes were then 
rinsed briefly in 1x TBS [20mM Tris, 150mM NaCl; pH7.4] and blocked overnight 
at 4°C in 1× TBS/0.1% Tween-20 containing 5% (w/v) milk powder (Marvel, 
Premier International Foods UK Ltd., St Albans, UK). Membranes were 
immunoblotted in 1× TBS/0.1% Tween20/1% BSA (unless otherwise stated) with 
antibodies stipulated in relevant results chapter for 2hrs at room temperature with 
rotation. As a loading control for protein amounts in each sample, membranes were 
also immunoblotted for polyclonal rabbit anti β-Actin (Abcam, Cambridge, UK) at a 
1:5000 dilution. The membranes were then washed three times for 15min in 1× 
TBS/0.1% Tween20. The appropriate HRP-conjugated secondary antibody (Dako, 
Glostrup, Denmark) was diluted in 1× TBS/0.1% Tween20/1% BSA and membranes 
were incubated for 2hrs at room temperature. Following incubation, membranes were 




by chemiluminescence using the West FEMTO substrate kit (Thermo Fisher 
Scientific) imaged on the VersaDoc™ Imaging System (Bio-Rad) using the Quantity 
One software program (version 4.5.0, Bio-Rad). Alternatively BioMax Light X-ray 
film was sandwiched with membranes in an X-ray film cassette (GE Healthcare) for 
1-3 minutes followed by development using a Konica SRX -101A X-ray developer. 
 
Table 2.5.1: Electrophoretic resolving gel buffer 
Reagent Volumes (mL) 
 10% 12% 15% 
dH2O 4.05 3.3 2.3 
10% SDS 0.1 0.1 0.1 
1.5M Tris-HCl, 0.4% SDS (pH8.8) 2.5 2.5 2.5 
30% (v/v) acrylamide/bisacrylamide [37.5:1] 3.3 4 5 
10% (w/v) ammonium persulphate  0.1 0.1 0.1 
TEMED  
(N,N,N´,N´-tetramethylethylenediamine) 
0.01 0.01 0.01 
 
Table 2.5.2: Electrophoretic stacking gel buffer 
Reagent Volumes (mL) 
 10% 12% 15% 
dH2O 3.05 3.05 3.05 
10% SDS 0.05 0.05 0.05 
0.5M Tris-HCl, 0.4% SDS (pH8.8) 1.25 1.25 1.25 
30% (v/v) acrylamide/bisacrylamide [37.5:1] 0.65 0.65 0.65 
10% (w/v) ammonium persulphate  0.05 0.05 0.05 
TEMED 0.01 0.01 0.01 
 
 
 Preparation of total RNA 2.6
 
2.6.1 Nuclease-free procedures 
The use of sterile, nuclease-free dH2O was used in all assays and was sourced either 
through suppliers (Sigma-Aldrich) or from dH2O treated overnight in 0.1% DEPC 




Pipette tips and eppendorf tubes used were purchased as sterile or autoclaved prior to 
use. Pipettes, work bench, gloves and general equipment were all sprayed with 
RNase AWAY (Sigma-Aldrich) prior to, and regularly throughout, work procedure. 
 
2.6.2 RNA extraction 
For RNA extraction from all biological material, two methods of RNA extraction 
were employed. Initial RNA extraction was performed using kits; namely the 
NucleoSpin RNA II (Macherey-Nagel, Dueren, Germany) and the ISOLATE RNA 
mini-kit (Bioline Reagents Ltd., London, UK) according to manufacturer’s 
instructions  
 
Alternatively samples were extracted using the TRIzol assay using TRI Reagent 
(Ambion/Life Technologies). 100μL TRI Reagent was added to washed cells in a 
monolayer or three volumes to samples in solution. After mixing and 5min 
incubation at room temperature, 1/3
rd
 volume of chloroform was added, vortexed for 
15sec and incubated on ice for 5min. Samples were centrifuged at 12 000 × g for 
15min, 4°C and the aqueous top phase removed containing soluble RNA. In new 
tubes, 1/3
rd
 volume 2-Propanol was added to solution together with 1μL of 20mg/mL 
glycogen (Invitrogen/Life Technologies) and left for 1hr at -20°C to precipitate. 
Samples were then centrifuged at 12 000 × g for 10min, 4°C after which the 
supernatant was aspirated and 100μL 80% ethanol (AnalaR NORMAPUR, VWR 
International) added to each sample. Tubes were pulse-vortexed and incubated at 
room temperature for 10min followed by centrifugation at 5000 × g, 5min, 4°C. 
Ethanol was removed and pellets air-dried for 5min and resuspended in 8μL nuclease 
free water.  
Residual DNA was digested using the RQ1 RNase-free DNase kit (Promega; 
Madison, Wisconsin) where 1μL 10× RQ1 DNase Reaction Buffer was added 
together with 1μL (1U) RQ1 RNase-free DNase into sample tubes and incubated at 
37°C, 30min. 1μL of RQ1 10× Stop Reaction Buffer was then added to samples and 
incubated at 65°C, 10min. 30μL nuclease free water and 55μL 2-Propanol was then 
added and tubes were incubated for 10min, room temperature. Samples were 




100μL 80% ethanol added to the pellet. After 15min incubation at room temperature 
samples were centrifuged at 12 000 × g for 5min. Resultant pellet were air dried for 
5min, room temperature after which RNA was re-solubilised in 15μL nuclease free 
water and stored at -80°C.  
 
2.6.3 Quantitation of total RNA 
RNA concentration was determined using the NanoDrop ND-1000 
spectrophotometer using 2μL of sample (diluted 1 in 10). RNA purity was assessed 
by the A260:A280 absorbance ratios as well as at A260:230. Ratios above 1.9 and 
2.0 respectively were considered to be pure RNA. In addition the quality of RNA 
was assessed on a 1% agarose gel. 0.5g SeaKem ® LE agarose powder (Lonza, 
Basel, Switzerland) was dissolved in 50mL 1×TBE [90mM Tris, 90mM Boric Acid, 
2mM EDTA, pH8.0] in DEPC-dH2O containing Gel Red nucleic acid stain (Biotium, 
Hayward, U.S.A), microwaved for 1min (LG Intellowave, Yeouido-dong, South 
Korea), and cooled to room temperature in a horizontal gel cast system. Volume for 
500ng RNA was added to 6× blue/orange loading dye (Promega) to obtain a 1× 
dilution and loaded into wells. Gels were run for 20min at 100V in 1×TBE running 
buffer and RNA quality was assessed under UV light using the UVP transilluminator 
(Upland, U.S.A). Samples with clear, well separated 28S and 18S rRNA bands with 
no signs of degradation qualified for downstream applications. 
 
 Quantitave real-time Polymerase Chain Reaction (qPCR) 2.7
2.7.1 Reverse transcription reaction (RT-PCR) 
Unless otherwise specified, 500ng total RNA was reverse transcribed into cDNA 
using the High Capacity cDNA reverse transcriptase kit (Applied Biosystems/Life 
Technologies) according to the following protocol. Samples were prepared on ice in 






Table 2.7.1: RT-PCR master mix reagents and volumes 
Component Volume/Reaction (uL) 
10 x Reverse Transcription (RT) buffer 2.0 
25 x dNTP mix (100mM) 0.8 
10 x RT Random Primers  2.0 
MultiScribe™ Reverse Transcriptase (50U/uL) 1.0 
RNase inhibitor  1.0 
Nuclease-free H2O (Ambion) 3.2 
Sample RNA 10.0 
 
Reverse transcription was performed using the iCycler Thermal Cycler (Bio-Rad) 
with the recommended cycling conditions: annealing at 25°C for 10min, extension at 
37°C for 120min, and denaturation at 85°C for 5min. Resulting cDNA was stored at -
20°C until used. 
 
2.7.2 qPCR by Taqman assay 
qPCR was performed using the Taqman gene expression assay or by SYBR Green 
where indicated in individual chapters.  
 
For the Taqman assay, from the original cDNA samples with a starting RNA amount 
of 500ng, a 1in50 dilution was made and 10μL was pipetted into a MicroAmp® Fast 
optical 96-well, 0.1mL reaction plate (Applied Biosystems/Life Technologies) in 
duplicate. A reaction master mix was made consisting of (volume per reaction well): 
 12.5μL 2x Taqman Universal PCR Master Mix 
  1.25μL 20x Taqman probe 
 1.25μL dH2O  
The gene expression assays were used for the analysis of human TNF-α 
(HS99999043_m1) and IL-10 (HS00272002_m1). In order to allow for the relative 
gene expression between cDNA samples, separate wells were set up to quantitate the 
endogenous control gene 18S rRNA. 2μL of diluted cDNA sample was added per 
well to which 15μL of a master mix was added consisting of (per well): 
 12.5μL 2x Taqman Universal PCR Master Mix 
 1.25μL 20x Eukaryotic 18S rRNA Endogenous control (FAM™/MGB probe) 





Plates were covered with MicroAmp® Optical adhesive film (Applied 
Bioscience/Life Technologies). After centrifugation at 450 × g, 30sec, 4°C the plate 
was run on a 7900HT Fast-Real Time System (Applied Biosystems/Life 
Technologies) using SDS software (v2.4, Applied Biosystems/Life Technologies) 








Resulting threshold cycles (CT) values were obtained from the amplification plot and 
the automated threshold line. Data was analysed using the comparative CT  method 
(also known as the delta-delta CT), whereby the fold differences in gene expression 
between control and test samples (ΔCT) was normalised to their respective ΔCT of the 
18S rRNA reference gene.  
 
2.7.3 qPCR by SYBR Green 
For gene expression using SYBR Green, 1μL cDNA was pipetted in triplicate into a 
MicroAmp® Fast 96-well reaction plate to which 9μL master mix was added 
consisting of: 
 5μL 2x Power SYBR Green Master Mix (Applied Biosystems) 
 0.2μL forward primer 
 0.2μL reverse primer 
 3.6μL dH2O 
Plates were sealed and prepared as before and run on the 7900HT Fast-Real Time 











Each qPCR run was extended to include a dissociation step: 95°C for 15sec, 60°C for 
15sec, 95°C for 15sec to generate a melting curve. The resulting melting curve was 
used to verify that only one product was generated during the PCR reaction. 
 
For gene quantitation, a standard curve was generated from mRNA ranging from 2ng 
to 0.04pg in a 1 in 10; 1 in 2.5 sequential dilution series followed by RT-PCR to 
generate cDNA (performed using triplicate experimental repeats). The resulting CT 
values from qPCR was used to generate an amplification slope for which a linear 
equation was generated using Microsoft Excel. This equation was used to plot known 
CT  values from experiments to quantitate starting gene amounts. 
 
 Immunocytochemistry 2.8
HMDMs were lifted by a non-enzymatic dissociation buffer (Sigma) and seeded on 
13mm glass coverslips in culture overnight. Experiments were then performed with 
HNP1 or W26A at specified times. Media was removed and wells were washed with 
1× PBS and fixed in 3% paraformaldehyde (PFA) for 20min at room temperature. 
PFA was quenched with 50mM glycine for 10min followed by 1× PBS washing and 
cells were permeabilized with 0.1% Triton X-100 for 4min. Cells were blocked for 
1hr in 5% goat serum at room temperature followed by a 1hr incubation with primary 
antibody combinations in 1× PBS/0.1% Tween-20 at room temperature (listed in 
Table 2.4). After three washes cells were incubated with fluorochrome-conjugated 
secondary antibodies for 1hr at room temperature (listed in Table 2.5). Secondary 
antibodies used were affinity purified to react with IgG (immunoglobulin G) heavy 
and light chains. To minimize cross-reactivity, antibodies were adsorbed against 
IgGs from other commonly used host species. After washing nuclei were stained 




were mounted onto glass slides using Mowiol mounting medium [9.6% (w/v) 
Mowiol 4-88, 24% (w/v) glycerol, 0.1M Tris-HCl, pH8.5]. Images were acquired on 
a Leica TCS SP5 (Leica Microsystems, Wetzlar, Germany) confocal laser scanning 
microscope with a fixed stage inverted microscope DMI6000CS, equipped with 
helium/neon lasers (633nm and 543nm), an argon laser (457-514nm), a diode laser 
(405nm) and a HCX PL APO 63x/1.33 NA oil immersion objective. The acquisition 
software used was the LAS AF software (Leica Microsystems) and images were 
acquired from fluorescent channels by sequential scanning to prevent crosstalk 
between channels. Obtained images were modified from 8-bit mode to RGB (red, 
green blue) using ImageJ (v1.37c, NIH) with resolution set to 600 dpi (dots per inch). 
 
Table 2.8.1: Immunocytochemistry primary antibodies 
Name  Clone Host Supplier Dilution 
HNP1-3 mono Mouse Hycult Biotech 1in100 
Rps20 poly Rabbit Abcam 1in250 
LC3B mono Mouse nanoTools 10µg/mL  
     
 
 
Table 2.8.2: Immunocytochemistry secondary antibodies 
Name Host Target Supplier Dilution 
Alexa Fluor® 647 (H+L) IgG Goat  Rabbit Invitrogen 1in400 
Alexa Fluor® 555 (H+L) IgG Goat  Mouse Invitrogen 1in400 
Alexa Fluor® 488 (H+L) IgG Goat Mouse Invitrogen 1in400 
 
 
2.8.1 Quantitative image analysis 
2.8.1.1 Corrected Total Cell Fluorescence (CTCF) 
To quantitate rsp20 fluorescence in HNP1 treated cells and controls, ten random field 
images were taken of cells at 24hrs without adjusting the settings on the confocal 
microscope between each slide. Using single fluorescent channel images obtained for 
rps20, three cells were chosen at random and a region was drawn around each cell to 
be measured using ImageJ software (v1.44p; National Institutes of Health, U.S.A). 
The Integrated Density (product of the mean grey value and area) was measured for 





CTCF = Integrated Density – (Area of selected cell × mean fluorescence 
of three background readings) 
 
The CTCF method was taken from Potapova et al. (2011)
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. The means of the 
corrected cell fluorescence were calculated for each image and plotted graphically 
for comparison between treatments and statistical significance.  
 
2.8.1.2 Pearson correlation coefficient 
The Pearson correlation coefficient was applied to confocal images as a means to 
calculate the co-localisation of HNP1 and rps20 using ImageJ (v.1.37c) software. 
Single fluorescent channels for HNP1 and rps20 staining were converted from RGB 
colour to 8-bit greyscale and an automated Otsu Threshold setting was applied for 
each image. Correlation analysis was performed for both images resulting in a 
frequency scatter plot with tabulated Pearson correlation values. This was performed 
for ten random field images of each sample at 4hr and 24hr time points and plotted 
graphically for statistical significance. 
 
 35S-Methionine labelling 2.9
HMDMs were seeded at 1.2x10
5 
cells/well in 24 well culture plates and incubated in 
L-methionine free DMEM (MP Biomedicals; Santa Ana, U.S.A) for 2hrs. At 2hrs 
supernatant was removed and, in triplicate, cells were treated with HNP1 (12.5 or 
25µg/mL) alone or stimulated with CD40L and IFN-γ alongside untreated controls. 
Radiolabelled 
35
S-Methionine (Perkin Elmer, Waltham, U.S.A) was added to media 
at 100µCi (microcurie)/mL and incubated for 4hrs and overnight. At time points 
culture media was collected for TNF-α ELISA and TCA protein precipitation. 
Protein pellets were resolubilised in 100uL 1× Laemmli buffer (Invitrogen/Life 
Technologies). Washed cells were lysed in 100µL 1× Laemmli buffer and purified 
by passing the lysate through an RNeasy Microkit filter column (Qiagen; Hilden, 
Germany). 25μL and 20μL of secreted and cellular fractions, respectively, were 
separated by SDS-PAGE using NuPage® Novex ® 4-12% Bis-Tris gradient gels 
(Invitrogen/Life Technologies) run at 200V. Gels were fixed for 15min in 50% 




Scientific; Waltham, U.S.A) overnight. After overnight destaining in dH2O, gels 
were dried (Model 583, Bio-Rad) and visualised on an Image Scanner 3 (GE 
Healthcare, Waukesha, Wisconsin). Radioactive protein images were developed on a 
Phospho cassette (GE Healthcare) and visualised using a Typhoon 9400 imager 
(Amersham Biosciences; Piscataway, U.S.A). From phosphorimaging, total protein 
band volumes in gel lanes were semi-quantitated from images using ImageQuant TL 
7.0 software (GE Healthcare), applying a rolling ball method set at ‘200’ for lane 
background subtraction. 
 
Radioactive proteins were also quantitated by scintillation counting by adding 10µL 
sample to 1mL Optiphase HiSafe 2 scintillation cocktail (Perkin Elmer). Radioactive 
emission was measured on a Wallac 1450 Micobeta TriLux liquid scintillation 
counter (Perkin Elmer). 
 
 In vitro translation 2.10
2.10.1 Plasmids and in vitro transcription 





. Plasmids together with an aliquot of Chemically 
Competent Cells (E.coli, X01 Blue strain) was kindly donated by Dr Nicola Gray 
(Centre for Reproductive Health, University of Edinburgh) and thawed on ice. CCC 
cells were incubated with 0.5μg plasmid for 30min on ice followed by heat shock for 
45sec at 42°C and returned to ice for 2min. Cells were incubated on agar culture 
plates containing 100μg/mL ampicillin overnight at 37°C in a humidified incubator. 
A single bacterial colony was picked and scaled up by incubation in 2mL Luria 
Broth (LB) containing 100μg/mL ampicillin for 5hrs at 37°C in an orbital incubator 
(Kallenkamp) at 200rpm. 50μL of culture was then added to 100mL LB broth (with 
100μg/mL ampicillin) in an Erlenmeyer flask and further incubated. Bacterial culture 
was then centrifuged at 3000 × g for 10min at 4°C to obtain a cell pellet and plasmid 
DNA was extracted using the Endofree® Plasmid Maxi kit (Qiagen, Hilden, 
Germany) according to manufacturer’s protocol. The resultant purified DNA 




Scientific) and purity was confirmed by the absorbance ratio at A260nm and 
A280nm.  
 
2.10.2 DNA digestion 
For both plasmids 10μg plasmid DNA was digested with 2μL of Bgl II restriction 
enzyme (Roche) in 10μL of 10x SuRE/cut Buffer M (Roche) in a total volume of 
100μL. This mixture was incubated for 1hr at 37°C after which 0.5μL of restriction 
enzyme was added and further incubated for 30min at 37°C. Following incubation, 
the digested plasmid was purified using the Qiaprep® Miniprep kit by adding 5 
volumes of buffer PB to 1 volume of DNA solution, added to Qiaprep spin columns 
and centrifuged for 1min at 3000xg. The flow through was discarded and columns 
were washed with 750μL buffer PE and centrifuged for 30s at 3000 × g, followed by 
a brief centrifugation at 14 000 × g for 1min to discard residual buffer. DNA was 
eluted by adding 50μL buffer EB, incubating for 1min and centrifuging for 1min at 
3000 × g. Resultant DNA was measured on the NanoDrop 1000 (Thermo Scientific) 
to determine concentration and purity using the absorbance values at A260nm and 
A280nm. 
 
2.10.3 In vitro transcription 
Transcription was performed from digested plasmid DNA to yield reporter mRNA 
Luc-A0 (containing a gene for Luciferase expression) and CSFV-Gal (containing a 
gene for β-galactosidase expression). The following reagents were added in an 
RNase-free tube for the transcription of each mRNA transcript: 
 
Table 2.10.1: in vitro transcription reagents (Luc-Ao mRNA) 
Reagent Supplier Vol 
(µL) 
T7 transcription buffer (5x) Stratagene 10.00 
Dithiothreitol (DTT; 1mM) Sigma 1.50 
m7G (5’)ppp(5')G RNA cap structure analogue (40mM)  New England 
Biolabs 
8.75 
Nucleic acid mix (Adenine, Uracil, Cytosine, 25mM) GE Healthcare 2.00 
Rnasin® RNase inhibitor (40U/µL) Promega 2.50 
T7 RNA polymerase  Agilent 3.00 





Table 2.10.2: in vitro translation transcription reagents (CSFV-Gal 
mRNA) 
Reagent Supplier Vol 
(µL) 
SP6 transcription buffer (10x) Stratagene 5.00 
ApE (G’(5)ppp(5’)A RNA cap structure analogue (40mM) New England 
Biolabs 
8.75 
Nucleic acid mix (Adenine, Uracil, Cytosine, 25mM) GE Healthcare 2.00 
Rnasin® RNase inhibitor (40U/µL) Promega 2.50 
SP6 RNase polymerase Roche 3.00 
DNA template N/A 23.75 
 
Mixtures were incubated for 10min, 37°C after which 5μL of 10mM GTP (GE 
Healthcare) was added. The mRNA transcription reaction was allowed to continue 
for 2hrs incubation at 37°C. Following incubation DNA was digested with 5μL RQ1 
RNase-free DNase (Promega) for 30min, 37°C. mRNA was then purified by adding 
70μL RNase-free dH2O followed by 100μL acid phenol:chloroform (CHCl3, 
Ambion), vortexed and centrifuged at 14 000 × g for 2min. The top aqueous phase 
was removed and step was repeated. ChromaSpin™ columns (Clontech, Mountain 
View, U.S.A) were then prepared by centrifuging twice at 700 × g, 2min after which 
mRNA volume was added into the column and centrifuged at 700 × g for 4min, 4°C. 
RNA was precipitated overnight at -30°C in 1/10
th
 volume (8μL) 3M sodium acetate 
(NaOA2, pH4.2) and 2.5 volumes (400μL) 100% ethanol, followed by centrifugation 
at 14 000 × g for 30min, 4°C. The pellet was washed twice in 80% ethanol and air 
dried on ice for 15min and resuspended in 15μL nuclease free water. Purity and 
concentration of the sample was determined using the Nanodrop spectrophotometer 
and concentration was adjusted to 1mg/mL. mRNA integrity was confirmed by 
applying 0.5μL of sample in 6× loading buffer (Promega) to a 1% agarose gel that 
was stained with Gel Red Nucleic Acid stain (Biotium). The gel was run for 10min at 






2.10.4 in vitro translation 
The following reagents from the nuclease treated rabbit reticulocyte lysate in vitro 
translation kit (Promega) were added in an RNase-free tube: 
 Rabbit reticulocyte lysate (35μL) 
 Amino acid mixture minus leucine, 1mM (0.5μL) 
 Amino acid mixture minus methionine, 1mM (0.5μL) 
 RNasin® RNase inhibitor (1μL) 
 Nuclease free dH2O (6μL) 
 
In duplicate samples HNP1, LHNP1 or W26A were added to individual tubes for a 
total sample volume of 50μL. Samples were incubated for 30min at 30°C on an 
Eppendorf thermo mixer (Hamburg, Germany) set at 300rpm. At 30min 2μL Luc-A0 
mRNA (1μg/mL) and CSFV-Gal mRNA (1μg/mL) were added to each tube. 5μL of 
reaction mixture was immediately removed from each sample, snap frozen on dry ice 
and stored for pre-translation mRNA quantitation. Samples were incubated for 90min 
at 30°C, 300rpm after which 5μL was removed, snap frozen on dry ice and stored at -
80°C for post-translation mRNA quantitation. Protein expression was then 
quantitated by luminescence for both Luciferase and β-gal reporters as follows: 
For luciferase protein expression, two 5μL aliquots were removed from each sample 
and placed in separate FACS tubes. The Lumat LB 9507 luminometer (Berthold 
Technologies, Bad Wildbad, Germany) was primed twice with Luciferase Assay 
Reagent (Promega) before samples were read. For β-galactosidase expression the 
detection substrate Tropix® Galacton Plus (Applied Biosystems) was diluted 1:100 
in Tropix® Galacto reaction buffer diluent (Applied Biosystems) before adding 5μL 
of sample (in duplicate) and incubating for 1hr in the dark at room temperature. The 
luminometer was primed twice with Tropix® Accelerator II (Applied Biosystems) 
before quantitation. The average of duplicate samples was taken for data analysis. 
 
2.10.5 mRNA quantitation 
To validate the integrity of mRNA pre- and post-translation, RNA extraction of 
frozen samples was performed using the Trizol method. mRNA was then assessed 





For electrophoresis 1% agarose gel was made up by dissolving 1.5g agarose (Biogen 
Idec, Zug, Switzerland) powder in 130mL DEPC-dH2O and microwave heated. 
15mL 10x MOPS buffer [0.2M MOPS, 50mM Sodium Acetate, 10mM EDTA, 
pH7.0] was added once cooled together with 5mL formaldehyde solution and gel 
cast. For sample preparation, 13μL RNA was added to 2.6μL 5x RNA loading buffer 
[20% (v/v) glycerol, 30.9% (v/v) foramide, 40% (v/v) 10x MOPS buffer, 2.79% (v/v) 
formaldehyde, 4mM EDTA, pH8.0, trace amount Bromophenol Blue, Xylene 
Cyanol]. Samples were heated to 65°C for 10min followed by 5min on ice before 
being loaded onto the gel. The gel was run at 100V for 4hrs in 1x MOPS running 
buffer, after which the gel was stained using a 1:20 000 dilution of Gel Red Nucleic 
acid stain in 1x MOPS buffer for 1hr at room temperature. Gel images were captured 
using by FLA-5100 Fluorescent Image Analyser (FujiFilm, Tokyo, Japan), using the 
Image Reader FLA-5000 series V1.0 software, at laser wavelength 473nm. 
 
For Luc gene quantitation by qPCR, 1μg purified RNA was reverse transcribed and 
1μL from a 1 in 10 cDNA dilution was used for subsequent Luc gene quantitation by 
SYBR Green qPCR (as previously described in section 2.7.3). Gene targets were 
analyzed using custom made primers for Firefly Luciferase purchased from 
Integrated DNA Technologies (Coralville, U.S.A)  
(Forward sequence (100μM):GGCGCGGTCGGTAAAGTT; Reverse (100μM): 
AGCGTTTTCCCGGTATCCA)  
 
2.10.6 Immunoprecipitation (IP) 
The experimental set for in vitro translation assays (as described in section 2.10.4) 
were utilized for IP studies. Rabbit reticulocyte lysate reaction mixtures were 
incubated with 25μg/mL HNP1, W26A or vehicle (0.01% acetic acid) 30min prior to 
20ng Luc-A0 mRNA addition followed by 90min incubation at 30°C. 
IP of HNP1 and analysis of rps20 expression was performed from an adapted 
protocol detailed in Park et al. (1998)
124
. Reaction mixtures were divided into two 
equal volumes and added to separate tubes containing 1mL NET-2 buffer [150mM 




cocktail, and 40U RNasin in DEPC-dH2O]. Duplicate samples were then incubated 
with either 500ng monoclonal mouse anti-human HNP1-3 antibody or 500ng IgG1, κ 
isotype control antibody (BD Biosciences, Franklin Lakes, U.S.A) for 2hrs at 4°C on 
a head-over-end eppendorf rotator. 
Protein G Sepharose beads (GE Healthcare) to be used (10μL per sample) were 
washed in 1mL NET-2 buffer, vortexed briefly and pelleted by centrifugation prior to 
being added to IP mixtures. Samples were returned to rotator for overnight 
incubation at 4°C. Beads were then washed five times in 1mL NET-2 buffer and 
pelleted, keeping supernatant from first wash for protein precipitation. From the first 
supernatant wash a volume was removed for TCA protein precipitation, equivalent to 
0.5μL of rabbit reticulocyte lysate. Pelleted beads and precipitated proteins from 
supernatants were resuspended in 1× Laemmli buffer boiled at 95°C for 10min, 
centrifuged and electrophoresed by 12% SDS-PAGE as previously described (section 
2.5) using home-made gels. As a positive control for rps20 detection, samples of 
0.5μL pure rabbit reticulocyte lysate were included. Membranes were immunoblotted 
using polyclonal rabbit anti-rps20 (1:2000 dilution) followed by incubation with 
Clean-Blot IP detection reagent (Thermo Fisher Scientific, dilution 1:500). Protein 
bands were detected by chemiluminescence using West FEMTO Supersignal kit and 
BioMax Light X-ray film on the Konica SRX-101A X-ray developer.  
 
 
 Electrophoretic Mobility Shift Assays (EMSAs) 2.11
Oligonucleotides consisting of 25bp Adenine (Poly A), Cytosine (Poly C) and Uracil 
(Poly U) labelled with a Cy5 flourophore at the 5’ end were purchased from 
Eurogentec (Seraing, Belgium). 10pmol (picomole) of oligo was incubated with 
titrated pmol ratios of HNP1 or W26A in 10μL binding buffer adapted from Sladic et 
al.(2004)
125
 [20mM Tris-HCl, pH8.0, 20% (v/v) glycerol, 0.1% (v/v) IgePal CA-630, 
2mM DTT, 140mM KCl (potassium chloride), 200ng/mL BSA, 3mM MgCl2 
(magnesium chloride)]. Samples were incubated on ice for 30min after which 5× 
loading buffer [10% [v/v] Glycerol, 5% DMSO, 0.1% Bromophenol Blue] was 
added for a 1× dilution. Binding reactions were electrophoresed in a non-denaturing 




persulphate, 0.1% TEMED] for 5hrs at 150V, 4°C (gel were pre-run overnight at 
150V). Gels images were obtained using the FLA-5100 image reader using a 635nm 
laser to detect Cy5 and free, migrated oligonucleotide was quantitated using AIDA 
Image Analyser software (Raytest, Straubenhardt, Germany). Note that early binding 
buffer optimisations involved comparing above used buffer (termed buffer ‘SL’) to 
binding buffer used for EMSA experiments below (termed buffer ‘GT’). 
 
For EMSAs investigating peptide interactions with HMDM RNA, total RNA was 
extracted using the NucleoSpin RNAII kit (Thermo Fisher Scientific). 1μg RNA was 
incubated with titrated amounts (μg) of HNP1, LHNP1 or W26A in 20μL binding 
buffer ‘GT’ adapted from Park et al. (1998)
124
 [10mM Tris-HCl, pH8.0, 5% (v/v) 
glycerol, 1mM EDTA, 1mM DTT, 20mM KCl, 50μg/mL BSA, 1μL (20U) Rnasin®] 
and incubated for 1hr at room temperature. Note that at this point for supershift 
EMSA experiments, monoclonal mouse anti-HNP1-3 antibody was added to samples 
(1ng/μL) and incubated for a further 30min at room temperature. 6× blue/orange 
loading dye (Promega) was added for a 1× dilution and electrophoresed on a 1% 
agarose gel [1xTBE, GelRed nucleic acid stain (Biotium), 1:10 000 dilution] for 1hr 
at 125V. Gels images were obtained on a transilluminator (UVP) or the FLA-5000. 
18S and 28S rRNA band volumes were semi-quantitated using the AIDA Image 
Analyser software. In initial experiments, 28S and 18S rRNA mean grey values were 
semi-quantitated using ImageJ. 
 
 Calcium flux 2.12
HMDMs were seeded in Teflon pots and treated overnight with 25μg/mL HNP 1-3 
or left untreated. After washing the cells in cation-free 1× PBS the Ca
2+ 
fluorescent 
probe Fura 2-AM was added at 2µM and cells were incubated at 37°C for 30min in 
cation-free 1× Hanks Balanced Salt Solution (HBSS, PAA Laboratories GmbH). 
Cells were washed, incubated at 37°C for a further 10min and seeded in calcium-
containing 1× HBSS. Real time cytoplasmic calcium mobilisation was quantitated 
using the LS50B Fluorescence Spectrometer (Perkin Elmer) using dual wavelength 
excitation (340nm and 380nm) and emission at 510nm. To quantitate calcium 




added to cells 30sec after real time recording began. To calibrate fluorescence 
values, maximal (Rmax) and minimal (Rmin) values were determined by adding 10% 
Triton X-100 and 0.1M EGTA respectively. [Ca
2+
]i was calculated from the 
relationship [Ca
2+
]i = Kd.(R- Rmin)/ (Rmax-R).b, where: 
[Ca
2+
]i is the cytoplasmic calcium concentration, 
R is the ratio of fluorescence obtained at 340nm and 380nm in the cuvette before 
calibration, 
Rmax is the fluorescence ratio under saturating [Ca
2+
]i, 
Rmin is the fluorescence ratio in the absence of Ca
2+
, 
Kd is the dissociation constant for Fura 2-AM, taken as 224nm at 37°C and, 
b is the fluorescence ratio at 340nm of cells in the absence and presence of Ca
2+
. 
Cytoplasmic calcium values were assessed by measuring the approximate area under 
the curve after mean basal calcium levels had been subtracted for each curve. Time 
point intervals were then divided into parallelogram segments and calculated, 
followed by the addition of all the segments to obtain total area under the curve.  
 
 Endoplasmic Reticulum stress 2.13
2.13.1 BiP, CHOP and spliced XBP-1 gene expression 
HMDMs in culture were stimulated with R848 either alone or in the presence of 25% 
NN, 12.5μg/mL HNP1 or LHNP1. ER stress inducer thapsigargin was included in 
experiments as a positive control. Cells were incubated at time intervals over 24hrs 
after which cells were lysed and RNA extracted using the ISOLATE RNA mini kit 
(Bioline) and cDNA synthesised using the High Capacity cDNA RT kit (Applied 
Biosystems) as per manufacturer’s instructions. cDNA samples were then sent to 
collaborators Professor Pieter Hiemstra and Emily van’t Wout (Department of 
Pulmonology, Leiden University Medical Centre, Albinusdreef 2, The Netherlands) 
for gene expression by qPCR. From cDNA samples gene expression was quantitated 
by SYBR Green qPCR for the molecular chaperone BiP (immunoglobulin binding 
protein), spliced XBP-1 (X-box binding protein-1) and CHOP (C/EBP-homologous 
protein) according to previously published methods
126
. For spliced XBP-1 




obtain the spliced XBP-1 mRNA (XBP-1spl) (forward: 5′-TGCTGAGTCCGCAGC 
AGGTG-3′; reverse: ′GCTGGCAGGCTCTGGGGAAG-3′). 
Primers used for CHOP (forward: 5′-GCACCTCCCAGAGCCCTCACTCTCC-3′; 
reverse: 5′-GTCTACTCCAAGCCTTCCCCCTGCG-3′) and BiP (forward: 5’-
CGAGGAGGAGGACAAGAAGG-3’; reverse 5’-CACCTGAACGGCAAGAA CT-
3’) mRNA expression were used. 
Quantitative PCR was carried out at the following conditions: 95°C for 3 min 
followed by 40 cycles of denaturation at 95°C for 10s, annealing at 62°C for 15s and 
extension at 72°C for 30s using IQ SYBRGreen supermix (Bio-Rad, Hercules, CA, 
USA). Each assay was run on a Bio-Rad CFX Real-time PCR system in triplicate 
and arbitrary mRNA concentrations were calculated by the Bio-Rad software, using 
the relative standard curve method. Stable housekeeping genes were selected using 
the Genorm software
127
. Relative mRNA concentrations of ATP5B and RPL13A 
(GeNorm, Primerdesign, Southampton, UK) were used as reference genes to 
calculate the normalized expression of the XBP-1spl mRNA. The identity of the PCR 
products obtained with the XBP-1 spliced primers was verified by DNA sequencing. 
 
2.13.2 Eukaryotic Initiation Factor (eIF) 2α phosphorylation  
HMDMs seeded in 24 well plates at 1.8 × 10
5 
cells/well were (in triplicate wells) 
stimulated with R848 alone together with 12.5μg/mL or 1μM thapsigargin and 
incubated time intervals over 24hrs. After time points, cells were lysed on ice for 
10min in 50μL lysis buffer [20mM Tris-HCl (pH7.5), 150mM NaCl, 1% (v/v) Triton 
X-100, 10% (v/v) glycerol, 1mM Na3VO4, 100mM NaF and Complete™ protease 
inhibitor cocktail with EDTA (Roche)].  
Samples were centrifuged at 10 000 × g for 10min, 4°C and protein concentrations 
were determined in supernatants by Bio-Rad protein assay. 20µg protein was 
electrophoresed by 10% SDS-PAGE followed by Western blotting. Membranes were 
blocked and immunoblotted against phosphorylated eIF2α using monoclonal rabbit 
anti-eIF2 (phospho S51) (Abcam, dilution 1:250). Membranes were then incubated 
with polyclonal goat anti-rabbit Ig/HRP secondary antibody (Dako, dilution 1:2000) 





Membranes were then stripped of bound antibody by a 20min incubation with 
Restore Western Blot stripping buffer (Thermo Fisher Scientific), followed by a 1hr 
wash in 1× TBS/0.1% Tween-20. Complete antibody absence was confirmed by 
chemiluminescent detection. The membranes were immunoblotted against β-actin as 
previously described. 
 
 Polysome analysis 2.14
HMDMs were seeded in 60mm culture dishes (Corning) and stimulated with R848 
alone or with HNP1 alongside untreated controls. At time points specified after 
incubation, spent media was removed for TNF-α ELISA quantitation while cells 
were incubated with 150μg/mL cycloheximide for 30min. 
After washing in 1× PBS (with 150μg/mL cycloheximide), cells were lysed in 200μL 
1× lysis buffer containing: 
 20mM Hepes buffer (pH7.6) 
 2mM MgCl2 
 150mM KCl 
 2mM DTT 
 0.5% IgePal CA-630 (NP-40) 
 7μL RNase inhibitor (100U/mL) 
 150μg/mL cycloheximide 
 1x Complete protease inhibitor cocktail (with EDTA) 
 1mM Na3VO4 
 25mM NaF 
 
After 10min incubation on ice, cells were scraped and collected in 0.6mL eppendorf 
tubes and centrifuged at 10 000 x g for 10min, 4°C. Supernatant were collected into 
new tubes and KCl concentration adjusted to 0.25M. 
Sucrose gradients were prepared by dissolving sucrose powder in dH2O and adding 
to 2× gradient buffer for a 1× dilution. Sucrose gradient range was from 50, 42, 34, 
26, 18 to 10 (% w/v). 1× gradient buffer consisted of: 
 40mM Hepes buffer (pH7.6) 




 500mM KCl 
 5mM DTT 
 1μg/mL heparin 
 
Gradients were layered from 50% to 10% with 650μL per gradient in a 4.4mL 
Sorvall 3P thin walled polyallomer tube (Thermo Fisher Scientific), freezing each 
gradient at -80°C for 20min before adding the next gradient. Gradients were stored at 
-80°C until used. 
Lysates were layered onto thawed gradients and centrifuged using a Sorval Ultra Pro 
80 ultracentrifuge at 274 823.9 × g (45 000rpm) in a Sorval TH-660 rotor for 80min, 
4°C. Tubes were then set up to fractionating equipment (Foxy Jr, Teledyne ISCO, 
Lincoln, U.S.A) and a UA-6 UV/Vis detector (Teledyne ISCO) to measure the 
absorbance of samples passing through the detector at 254nm. Peak profiles were 
plotted on graph paper attached to the detector and digitally recorded using the 
PeakTrak software, v1.10. 
Collected eluent fractions were divided into two fresh eppendorf tubes for TRIzol 
RNA extraction and protein purification using the ProteoExtract RNA was 
electrophoresed in a 1% non-denaturing agarose gel. Protein samples were 
electrophoresed by 10% SDS-PAGE followed by Western blotting. Membranes were 
immunoblotted using antibodies to rps20 (dilution 1:1000) or rabbit anti-Poly(A)-
binding protein (PABP1, 1:100 000 dilution, produced in house). Membranes were 
then incubated with polyclonal goat anti-rabbit Ig/HRP secondary antibody (Dako, 
dilution 1:100 0000) and protein bands were visualised by chemiluminescence using 
the VersaDoc imaging system. 
 
Where appropriate, amounts of TNF-α mRNA were quantified within each collected 
fraction by SYBR Green qPCR (as previously described in section 2.7.3). For 
normalisation of quantitated TNF-α, 2μL of 10ng/μL Luc-A0 mRNA was added to 
each fraction (obtained from section 2.10.3). 250ng of purified RNA was reverse 
transcribed followed by the addition of 1μL cDNA (diluted 1 in 10) added in wells 




forward and reverse TNF-α primers purchased from Eurogentec (Forward sequence 
(100μM): CCATGTTGTACGAAACC; 
Reverse sequence (100μM): TCTCAGCTCCACGCCTT). In a separate qPCR 
reaction, quantitation of Luc-A0 mRNA was performed as previously described 
(section 2.10.5). 
 
 Sucrose density gradient centrifugation 2.15
Sucrose density ultracentrifugation was performed on samples derived from the in 
vitro translation assay described above using Luc-A0 reporter mRNA. 
The reaction mixtures were incubated with HNP1 or W26A at 25µg/mL in duplicate 
incubate for 30min at 30°C, after which 40ng Luc-A0 mRNA was added to each 
reaction mixture and incubated for a further 90min at 30°C. 5μL sample was 
removed post incubation for luciferase quantitation using the Lumat luminometer. To 
the remaining lysate, two volumes of translation stop buffer was added (in DEPC-
dH2O): 
 20mM DTT 
 150μg/mL cycloheximide 
 665μg/mL heparin 
 1x Complete protease inhibitor cocktail (with EDTA) 
 1.5μL RNase inhibitor (100U/mL, Applied Biosystems) 
 
Lysates were layered onto a 1.2mL 15-40% (15, 24, 32, 40) sucrose gradient as 
described for polysome analysis (section 2.14). Tubes were centrifuged at 215 000 × 
g for 80min at 4°C using the Sorvall RC M150 GX (fixed rotor S100 AT6). Ten, 
120μL fractions were removed, placed into fresh eppendorf tubes and RNA was 
extracted the Trizol extraction method, keeping the phenol-ethanol portion 
containing proteins. RNA fractions were electrophoresed in a 1% non-denaturing 
agarose gel for the confirmation of rRNA in each fraction as assessed from resulting 
gel images. Fractions containing rRNA had their corresponding phenol-ethanol 
fractions pooled together for protein extraction as per TRIzol protocol guidelines. 
DNA was first removed by adding 30% (v/v) ethanol (100%), incubating for 3min at 




Supernatant was removed to which 1.5 volumes isopropanol was added to Trizol 
volume followed by incubation at room temperature for 10min and centrifuged at 12 
000 × g for 10min at 4°C. Protein pellet was washed and incubated twice with 0.3M 
Guanidine Hydrochloride in 95% ethanol for 20min at room temperature. Tubes 
were centrifuged at 7500 × g for 5min, 4°C to remove supernatant. 100% ethanol 
was then added and incubated for 20min at room temperature followed by 
centrifugation at 7500 × g for 5min, 4°C. After air drying the pellet, proteins were 
solubilised in 1× Laemmli buffer and electrophoresed on a 12% SDS-PAGE gel. A 
Western Blot was performed for the detection of HNP1/W26A using monoclonal 
mouse anti-HNP1-3 antibody as previously described. 
 
 Wound healing 2.16
Eight week old female CD1 mice were anaesthetised and a full-thickness 10mm × 
2mm excision was made aseptically on the shaved dorsal skin. BMDMs to be 
injected into the wound were prepared from CD1 female mice as described in 2.2.3. 
Day 6 BMDMs were incubated in Teflon pots for 24hrs in serum free DMEM F12 
Glutamax™ media only or containing 25% human NN supernatant. 100μL saline 
containing 3 × 10
6 
BMDMs were injected subcutaneously at four points around the 
wound. Control mice received 100μL of saline. Wounds were photographed daily 
over a nine day period. From obtained images the area of the wound sizes were 
measured according to scale using a ruler placed within the image in the same plain 
as the wound. These measurements were plotted on a percentage graph relative to the 
area of the original wound size. This experiment was performed in accordance with 
project licence number (PPL) 60/3948. 
 
 Statistical methods 2.17
Statistical analysis was performed under the guidance of a course provided by the 
Institute for Academic Development, University of Edinburgh. The course was 
presented by Professor Amanda Lee (Medical Statistics Team, Division of Applied 
Health Sciences, University of Aberdeen) and Gillian McHugh (Centre for 
Population Health Sciences, University of Edinburgh). All statistical analysis was 




Where appropriate, results from single experiments are reported as mean ± Standard 
Deviation (SD) with triplicate repeats. For n distinct observations results are reported 
as mean ± Standard Error of the Mean (SEM). Parametric statistics was used for 
assessments of normally distributed data. Comparisons between two groups was 
determined with the Student’s t-test while data containing more than two groups was 
analysed by Analysis of Variance (ANOVA) showing similar variance between 
samples using Barlett’s test where appropriate. Post hoc analysis between groups 
was assessed using the Dunnett’s or Bonferroni test as appropriate for the group 
comparison. For non-parametric statistical analysis where normal distribution of data 
was not assumed, comparisons of more than two groups was performed using the 
Kruskal-Wallis ANOVA, using Dunn’s multiple comparison test for post hoc 
analysis. P-values below 0.05 were considered significant to reject the null 
hypothesis. In the figures, P-values smaller than 0.05, 0.01, and 0.001 are presented 











The immunomodulatory functions of α-defensin have been extensively studied and 
date back to the early 1980’s from pioneers in the field, notably Professors R. I. 
Lehrer, T. Ganz, W. Lu and Dr A.K. Lichtenstein. Their early work not only began 
examining the antimicrobial properties of defensins and other antimicrobial peptides 
but also their effects on various mammalian cells. It is their research that has paved 
the way for a large collection of publications on α-defensins over the last 30 years 
which is still growing. The published functions of α-defensins vary greatly between 
the different cell types studied. This introduction summarises the collective 
immunomodulatory findings of α-defensins with an emphasis on leukocyte activity. 
 
α-Defensins have been found to be released not only from dying human neutrophils
87
 
but also when activated
128
. Released HNP1 and 2 (but not HNP3) were demonstrated 
to act as chemotactic factors for monocytes in nanomolar concentrations
129
, 
suggesting that released α-defensins not only fulfil immediate antimicrobial actions 
but most likely further recruit leukocytes to combat invading pathogens. 
Not only do they act as chemokines but they also stimulate the release of chemokines 
and cytokines from cells. α-Defensin concentrations between 5-10μg/mL stimulated 
the release of IL-8 and MCP-1 (monocyte chemoattractant protein -1) in human 
bronchial (BEAS-2B) and alveolar (A549) epithelial cells
130
. In moderate to high 
concentrations (10-20μg/mL), α-defensins elicited caspase-3 activation in these cells 
resulting in apoptosis 24hrs after exposure. α-Defensin concentrations below 
10μg/mL not only stimulated a host of inflammatory mediators in monocyte derived 
immature dendritic cells (IL-8, TNF-α, IL-1β, IL-12p40, IL-10), but also lead to their 
maturation in vitro by way of increased cell surface expression CD86, CD83 and 
HLA-DR
131
. Conversely higher concentrations of α-defensins lead to a decrease in 




Shi et al. (2007) suggested that HNP1 (20-100μg/mL) blocked IL-1β secretion 




The cytotoxicity of α-defensins has also been studied at great length. HNP1-3 at 
concentrations of 25-100μg/mL effectively induced cytolysis in a variety of human 
lymphoma cells and non-malignant target cells
132
. Interestingly cytolysis was 
induced in cell lines made resistant to TNF and NK-cytolytic factor killing. In a 
comparative cytotoxic study of PMN granule constituents, defensin-containing 
fractions were the most lethal against human leukaemia, carcinoma and lung 
fibroblasts
44
. In the same study defensin cytotoxicity appeared to be synergistic with 
released hydrogen peroxide, suggesting that these two components released from 
neutrophils work in tandem to sacrifice cells in the general vicinity of infection.  
 
In a mechanistic study using erythroleukemia cells (K562) and 50μg/mL HNP1-3, 
data showed that defensin-mediated cytolysis occurs as a result of initial membrane 
binding, internalisation and critically interference with cellular metabolism by way of 
glycolysis and ion transport
133
. Cytolysis could not be reversed by the blocking 
actions of serum on HNP1-3 if serum was administered more than 30min after of 
HNP exposure. This gave an indication of the rapid cytotoxic actions of α-defensins 
on cells which require more than simply membrane binding to exert their effect, as 
was demonstrated by defensin-resistant murine cell line L929 which still showed 
comparable binding to that of K562 cells.  
 
From what it appears, α-defensin cytotoxicity is more harmful than microbial 
infection itself. The consolation is in the limitations of peptide function beyond the 
immediate extracellular spaces. In a review on this topic by Ganz (1987)
128
, 
suggestions are that half of released defensins become incorporated into the PMN 
membrane and of the remaining half, functionality will be limited to intercellular 
spaces that exclude macromolecules which inhibit their function, for example 
through lectin-like binding to glycosylated proteins in serum. Thus it would appear 




dying neutrophils, do α-defensins facilitate this function of perhaps required 
collateral damage. 
 
With regard to their inhibitory effect on macrophages, the actions of α-defensins 
appear to be specific to peptide concentration. Miles et al. (2009)
87
 showed all 
inflammatory mediators tested to be inhibited by α-defensin in the range 12-25μg/mL 
(TNF-α, IL-1β, IL-6, IL-8, IL-10 and nitric oxide). Other research groups showed the 
presence of HNP1-3 (<1μg/mL) boosted macrophage phagocytosis of IgG-opsonized 
Staphylococcus aureus through increased expression of the Fcγ receptors CD32 and 
CD64 while releasing TNF-α and IFN-γ
134
. 
This chapter sets out to recapitulate the inhibitory findings of α-defensins on human 







3.2.1 Optimization assays of buffy coat-derived HMDM stimulants 
Previously, HMDMs were obtained from whole blood donations taken on the same 
day from healthy volunteers within the Centre for Inflammation Research. Blood 
from unused buffy coats also became a readily available source of HMDMs. Initial 
cell culture assays were focussed on optimising the appropriate agonist for 
downstream studies involving necrotic neutrophil supernatants and human neutrophil 
peptide (HNP). These optimisation experiments were performed since buffy-coat 
derived HMDMs did not become activated with CD40L and IFN-γ stimulation, 
which was the conventional stimulation method used in Miles et al. (2009). Details 
on the results of these optimisation experiments can be found in Appendix A. 
 
Levels of secreted cytokines in culture supernatants were quantitated by ELISA in a 
series of experiments assessing the inhibitory effect of α-defensins on macrophages. 
Initial experiments investigated the inhibitory effect of Necrotic Neutrophil 
supernatants (NN), which consist of a milieu including α-defensins, cathelicidin and 
pro-inflammatory stimulants such as proteases and elastase. These NN supernatants 
were made from freeze/thawed neutrophils, purified by ultracentrifugation to pellet 
membrane material. NN was able to effectively inhibit TNF-α production in buffy 
coat-derived HMDMs when added together with LPS, with the amount of added NN 
expressed as a percentage of total cell culture volume (Figure 3.1). Inhibition was 
observed with 5% NN (equivalent to 2.5x10
6
 neutrophils), 15% NN (7.5x10
6
 
neutrophils) and 25% NN (12.5x10
6
 neutrophils).  
 
With TNF-α reproducibly attenuated in R848-stimulated buffy coat HMDMs with 
NN treatment (see Appendix A), further experiments continued to assess this effect 
on other cytokines. Results from Figure 3.2 showed the inhibitory effect of 25% NN 
together with R848 at concentrations 2.5μg/mL and 1μg/mL. This was assessed in 
secreted levels of IL-6, IL-8 and IL-10 at 4hrs and 24hrs incubation. Levels of IL-6 
were strongly attenuated by 25% NN at both time points, in excess of 100 fold 




inhibition was noticeable at 24hrs. A similar pattern was observed with IL-10 
expression even though basal IL-10 levels were moderately high at around 100pg/mL 
seen with untreated control cells. R848 stimulation at 2.5μg/mL clearly elevated 
levels of IL-10 in comparison to untreated controls. Since stimulation with 2.5μg/mL 
R848 sufficiently upregulated all cytokines tested, the decision was made to proceed 











Figure 3.1: The effect of Necrotic Neutrophil supernatants in LPS 
stimulated HMDMs 
Secreted TNF-α quantitated by ELISA of buffy coat HMDMs stimulated with 
1ng/mL LPS alone or in the presence of titrated necrotic neutrophils supernatants 
(NN) from three neutrophil donors, expressed as the final volume percentage in 
culture wells (% v/v). Graph represents the mean ±SD of a single experiment with 











Figure 3.2: Quantitated IL-6, IL-8 and IL-10 secretion in R848-stimulated 
buffy coat HMDMs with NN 
ELISA results of quantitated IL-6 (A), IL-8 (B) and IL-10 (C) in supernatants at 4hrs 
(i) and 24hrs (ii) after stimulation with 2.5 and 1µg/mL R848 with 25% NN. Error 





3.2.2 HNP amino acid composition is essential to inhibitory function  
Assessments of the inhibitory properties of NN were established in R848-stimulated 
HMDMs. Further experiments were performed to confirm the inhibitory properties of 
HNP on TNF-α as previously published
87
, adapting the agonist to effectively 
stimulate buffy coat HMDMs. 
 
Stimulation using R848 (5μg/mL), SAC (Staphylococcus aureus Cowan strain; 
0.1%) and Poly I:C (5μg/mL) were tested together with 25μg/mL HNP1-3 for 18hrs 
(Figure 3.3). HNP1-3 attenuated quantitated TNF-α in R848 stimulated cells but not 
in SAC, while Poly I:C showed no stimulation compared to untreated controls. It is 
thought that SAC most likely neutralised α-defensins at this concentration through 
binding, thus explaining the lack of inhibitory actions on stimulated HMDMs. In a 
separate experiment R848 concentrations were reduced to 2.5 and 0.5μg/mL while 
SAC concentrations were reduced to 0.01% and 0.001% (Figure 3.4). HNP1-3 at 
25μg/mL was again effective at reducing secreted TNF-α at all concentrations tested 
and this time in both R848 and SAC stimulated HMDMs. 
 
In more extensive experiments in the second half of the research period, access to a 
second chemically synthesized HNP1 mutant became available courtesy of our 
collaborator, Professor Wuyuan Lu. This was in addition to previous use of linear 
HNP1 (LHNP1) published in Miles et al. (2009) showing no inhibitory effect. This 
mutant peptide, W26A, was a single amino acid substitute of tryptophan at residue 
position 26 with alanine (W26A) which was previously found to be the most 
deleterious mutation in its ability to kill Staphylococcus aureus, inhibit anthrax lethal 
factor, and bind to HIV-1 gp120 protein
58
. This was attributed to the peptide’s altered 
hydrophobicity and ability to dimerise and possibly form higher order oligomers with 
itself. 
 
Figure 3.5A represents the results (n=3) of R848-stimulated HMDMs together with 
12.5 or 7.5μg/mL HNP1, LHNP1 and W26A. HNP1 at 7.5μg/mL and 12.5μg/mL 




controls in the three HMDM donors tested, while W26A and LHNP1 showed no 
inhibitory effect on secreted TNF-α.  
 
When available, frozen PBMCs obtained from clinically diagnosed Rheumatoid 
Arthritis (RA) patients were thawed and processed as normal following PMBC 
isolation from blood preparations to obtain HMDMs, as described in Chapter 2, 
section 2.2.1. In three attempts to differentiate PBMCs into mature HMDMs of 
sufficient cell number for experiments involving HNP1, only a single donor was 
successful. Mature HMDMs from the RA patient were subsequently stimulated with 
1μg/mL R848 together with 12.5μg/mL HNP1, which showed effective inhibition of 
secreted TNF-α (Figure 3.6A). Frozen PBMCs from healthy donors thawed and 
matured into HMDMs as performed for RA donor cells showed a similar trend of 
TNF-α attenuation with HNP1 (Figure 3.6B and C). 
 
In a series of experiments to ascertain the minimal inhibitory threshold of HNP1, 
R848 stimulated HMDMs were treated together with HNP1 concentrations 1, 5, 10 
and 12.5μg/mL, alongside LHNP1 and W26A. HNP1 showed no inhibitory effect at 
1 and 5μg/mL as TNF-α values remained similar to R848-stimulated alone controls 
(Figure 3.7). HNP1 remained inhibitory at a concentration of 10μg/mL. 
 
As the actions of α-defensins are sensitive to the presence of serum proteins, the 
concept of incorporating HNP1 into liposomes for treatment in serum-containing 
media was briefly addressed. POPC liposomes were formulated with the 
incorporation of 2% mol HNP1 as described in Chapter 2, section 2.2.7 (alongside 
empty liposome controls). From this formulation, titrated liposome concentrations 
were tested in R848-stimulated HMDMs in culture media containing 10% human 
serum or without. No effect on TNF-α was observed on cells treated with liposomes 
added at 300 and 600μg/mL in both culture media conditions (Figure 3.8A). No 
significant effect was observed using 1.2mg/mL liposomes in a single experiment 






Figure 3.3: The effect of HNP1-3 on buffy coat HMDMs stimulated with 
R848, SAC and Poly I:C 
Secreted TNF-α values obtained after 18hrs incubation in agonist-stimulated 
HMDMs alone or together with 25μg/mL HNP1-3. Results represent the mean ±SD 
for treatments from a single experiment (n=1) with three experimental replicates. 
 
 
Figure 3.4: The effect of HNP1-3 in fresh HMDMs stimulated with R848 
and SAC 
Quantitated TNF-α by ELISA at 18hrs incubation post treatment. HMDMs obtained 
from a fresh blood donation were R848-stimulated alone or together with 25μg/mL 











Figure 3.5: The effect of HNP1 and mutant derivatives on R848-
stimulated HMDMs 
Secreted TNF-α quantitation of fresh HMDMs stimulated with 1μg/mL R848 in 
culture with HNP1, LHNP1 or W26A after 18hrs incubation. Peptide concentrations 
of 12.5μg/mL and 7.5μg/mL were used. (A) Secreted TNF-α values were normalised 
to cells stimulated with R848 alone obtained from three independent experiments 
(n=3) with each sample performed in triplicate. Values are of the median with error 
bars representing the interquartile range. Nonparametric statistical analysis was 
performed between peptide groups of the same concentrations using the Kruskal-












Figure 3.5 (continued): The effect of HNP1 and mutant derivatives on 
R848-stimulated HMDMs 
(B) Representative graph indicating quantified TNF-α amounts (in pg/mL) from one 
of the three repeat experiments. Error bars represent the mean ±SD for samples with 












Figure 3.6: The effect of HNP1 in Rheumatoid Arthritis HMDMs 
Secreted TNF-α from rheumatoid arthritis HMDMs (A) or healthy donors (B and C) 
taken from fresh blood donations and stimulated with 1µg/mL R848 alone with 
12.5µg/mL HNP1 at 24hrs. Error bars represent the mean ±SD of n=1 with three 















Figure 3.7: Minimum inhibitory HNP1 concentrations 
(A) Secreted TNF-α from buffy coat HMDMs stimulated with 2.5μg/mL R848 alone 
or with 1, 5 or 12.5µg/mL HNP1 or W26A alongside unstimulated controls (at 
24hrs). 
(B) Secreted TNF-α from buffy coat HMDMs stimulated with 2.5μg/mL R848 alone 
or in the presence of 1µg/mL HNP1 or W26A (18hrs). 
(C) Secreted TNF-α in from buffy coat HMDMs stimulated with 2.5μg/mL R848 
alone or the presence of 10µg/mL HNP1 or LHNP1 (24hrs). 







Figure 3.8: The addition of HNP1-treated liposomes in stimulated 
HMDMs 
TNF-α ELISA results of HMDMs (fresh blood donations) stimulated with 1µg/mL 
R848 alone (black bar) or with titrated POPC liposome concentrations containing 2% 
mol HNP1 or empty liposomes after 24hrs. (A - i) Results from treatments performed 
in the absence of serum along with HNP1 alone, liposomes alone and an untreated 
control. (ii) Treatments in serum-containing media. (B) A repeat experiment with 
higher liposome concentrations in the absence of serum. Error bars represent the 





3.2.3 The effect of α-defensins on cytokine gene expression 
The section above described the inhibitory actions of α-defensins on secreted 
cytokines which supports previously published results. The next section investigated 
the question concerning TNF-α mRNA expression over the critical time points (i.e. 
<24hrs). This was to establish whether the anti-inflammatory effect seen was due to 
the prevention of mRNA expression of key inflammatory cytokines. 
 
Previous (unpublished) mRNA quantitation experiments were performed by 
Katherine Miles, from the Dr Mohini Gray research group, using freshly-prepared 
HMDMs stimulated with 3μg/mL CD40L + 5ng/mL IFN-γ (CI), with validated TNF-
α secretion inhibition by HNP1 as represented in (Figure 3.9B-ii). CI stimulated 
HMDMs were treated with 25μg/mL HNP1 and cells were harvested over a 24hr 
period for RNA and subsequent qPCR for TNF-α and IL-10 mRNA expression 
(Figure 3.9A). Results show a similar gene expression of both cytokines over 24hrs 
compared with CI-stimulated alone controls. Expression of TNF-α mRNA was 
analysed in repeated experiments over 6hrs (Figure 3.9B – D) with varying degrees 
of expression between experiments. In (B), TNF-α mRNA declined sharply in HNP-
treated cells between 1.5 and 2hrs and remained approximately 25% lower over 2hrs 
compared to CI-stimulated alone controls. In (C) mRNA values remained similar 
over 3hrs. While expression in controls remained steady over the time course, 
expression declined in HNP-treated samples by approximately half at 4hrs and 6hrs. 
In (D) TNF-α gene expression showed a similar trend between treatments although a 
sharper decline was observed between 2-3hrs in HNP-treated samples. In all 
experiments the initial upregulation of mRNA expression was similar in the presence 
of HNP1 compared to stimulated controls in all experiments. This suggests that 
signal transduction pathways leading to TNF-α and IL-10 mRNA transcription 
appear unaffected in the presence of HNP.  
 
From the above results it was hypothesized that the rapid decline of TNF-α mRNA 
over short time periods might be attributed to a decrease in mRNA stability with 
HNP addition, possibly explaining the lack of secreted TNF-α. Within cells, 




mRNAs by binding to adenine-uridine (AU)-rich regions resulting in deadenylation 
or removal of the poly-(A) tail
135
. p38 MAPK activation stabilizes inflammatory 
mRNAs (including TNF-α) by the phosphorylation of TTP by MK2, a downstream 
kinase of p38
136
. Thus it was hypothesized that HNP1 might prevent TTP 
phosphorylation in stimulated cells, resulting in increased TTP activity and 
explaining the reduction of secreted TNF-α. To test this hypothesis, TTP
-/- 
knock out 
bone marrow derived macrophages (BMDMs) derived from C57 BL/6 mice were 
kindly donated by Dr Jonathan Dean (Department of Medicine, Imperial College 
London) and cultured as described in Chapter 2, section 2.2.3. TTP BMDMs were 
stimulated with FGK45 (the murine equivalent of CD40L) and murine IFN-γ alone 
or together with HNP1 or LHNP1. Wild type BMDMs from the same background 
were included as controls (Figure 3.10). After 18hrs incubation, quantitated TNF-α 
by ELISA from collected supernatants showed that HNP1 remained inhibitory in 
TTP
-/-
 BMDMs, as shown in a representative result from three independent 
experiments (Figure 3.10A). Normalising TNF-α expression of HNP1 and FGK/IFN-
γ-stimulated alone values to LHNP1 values from n=3 experiments (Figure 3.10B), 
results showed a significant reduction (P<0.01) of TNF-α in wild type and TTP
-/-
 
BMDMs. These results effectively ruled out the hypothesis that increased TTP 
activity was the cause of the decline in TNF-α mRNA expression with HNP1 
treatment. 
 
HMDM TNF-α mRNA expression studies were continued for further clarification 
using buffy coat HMDMs stimulated with R848 and treated with 5% NN over 24hrs 
(Figure 3.11). In addition to simultaneous treatments of NN and R848, test samples 
also included HMDMs pre-treated with NN for 1hr and 24hr prior to stimulation. 
This was in order assess if longer incubation with α-defensins would lead to the 
further manifestation of the slight differences initially observed.  
qPCR results of TNF-α mRNA expression showed very similar patterns of gene 
expression in HMDMs which had 1hr NN pretreatment and HMDMs with NN added 
at the time of stimulation over 24hrs (Figure 3.11A-i). Interestingly, initial increases 
in TNF-α mRNA with α-defensins were about 1.3 fold higher in value than 




TNF-α mRNA to levels similarly observed in stimulated-alone controls. Where the 
treatments differed was in secreted TNF-α protein. While R848 alone HMDMs 
showed unhindered TNF-α production, 1hr NN pretreatment showed a greater level 
of inhibition compared to NN added at the time of stimulation (Figure 3.11A-ii). This 
provided early suggestions that the inhibitory actions of NN occurred not at the level 
of transcription but at a later stage. It also suggested that the degree of inhibition 
became greater with longer exposure to NN. 
 
A different trend was observed in 24hr NN pretreated HMDMs which questioned if 
longer NN exposure affected TNF-α mRNA inhibition differently to that observed at 
shorter time intervals. Cells pretreated with NN for 24hrs prior to stimulation showed 
a similar pattern of initial upregulation of TNF-α mRNA, but declined sharply to 
near basal levels after 4hrs. Secreted TNF-α in these 24hr pretreated samples was 
substantially lower in value to near baseline levels throughout the time course.  
 
Contrary to the minor differences in TNF-α mRNA expression with NN treatment, 
the assessment of IL-10 mRNA over 24hrs showed similar expression across all 
treatments over 24hrs while secreted IL-10 values were markedly reduced in all NN-
treated cells from 8hrs onwards (Figure 3.11B). This result agreed with the 
suggestion that α-defensins did not affect mRNA expression yet still inhibited 
secreted cytokines, proposing an inhibitory effect at a later stage, possibly during the 
translation process. Between the assessments of TNF-α and IL-10 in this single 
experiment, the only conflicting result was that of TNF-α mRNA expression in 24hr 
NN pretreated samples. This would, however, require further repeat testing to 
confirm these results. Based on these findings, this result brought into question if 
mRNA stability was a factor with prolonged NN exposure and required further 
assessment. 
 
In order to specifically assess TNF-α mRNA stability with NN, mRNA decay rates 
were assessed using actinomycin D, an antineoplastic antibiotic which inhibits DNA-
primed RNA synthesis by binding to deoxyguanosine residues on double-stranded 




transcription. Actinomycin D was added 1hr post R848 stimulation – at the peak of 
TNF-α mRNA expression - in HMDMs pretreated with 5% NN for 24hrs alongside 
stimulated-alone controls (Figure 3.12). The resulting data from time points collected 
over 2hrs after actinomycin D treatment suggested a similar pattern of mRNA decay 
in NN treated and R848-stimulated alone HMDMs. This result suggested that NN 
were not affecting the stability of transcribed mRNA, even in prolonged exposures, 
and that the inhibitory actions were perhaps mediated by other mechanisms. 
 
This experiment analysing TNF-α decay rates over 2hrs was repeated in buffy coat 
HMDMs treated with 12.5μg/mL HNP1 or LHNP1 alongside R848-stimulated alone 
controls (Figure 3.13A and B). This was performed since earlier experiments 
assessing TNF-α mRNA expression in HNP-treated HMDMs might have suggested a 
sharper decline in expression compared to R848-stimulated alone controls (Figure 
3.9). Decay rates between treatments appeared similar over 2hrs incubation with 
actinomycin D, with the slight exception of a short (20min) decline in decay in 
HNP1-treated HMDMs after 10mins of actinomycin D incubation (Figure 3.13A-i). 
Meanwhile, a more gradual TNF-α decay was observed in LHNP1 and stimulated-
alone controls. For the validation of HNP1-mediated inhibition on secreted TNF-α, a 
parallel set of cells receiving treatments, with the exception of added actinomycin D, 
confirmed the inhibitory effect of HNP1 not observed in LHNP1 controls (Figure 
3.13A-ii). Secreted TNF-α from stimulated controls containing actinomycin D treated 
were included in ELISA quantitation as a positive control for the effect of the 
antibiotic. This single experiment would suggest an increase in decay for a short 
interval, but it is uncertain if this apparent increased decay period had any bearings 
on the overall inhibition on secreted TNF-α. This is especially considering that TNF-
α mRNA levels near-paralleled that of LHNP1 while secreted TNF-α between the 
two treatments showed a clear difference. 
 
In a repeat experiment (Figure 3.13B), results appeared contradictory to the above 
findings. TNF-α decay rates in HNP1 and LHNP1 treated HMDMs showed similar 
patterns of decline following actinomycin D. This observed similarity was despite 




unaffected in LHNP1-treated cells compared to stimulated-alone controls. 
Quantitated TNF-α mRNA in R848-stimulated alone controls showed unusual decay 
patterns, which made it difficult to use as a comparative control. 
 
Overall, the data in this section could not confidently conclude a link between the 
profound inhibitory effects of α-defensins on secreted cytokines with differences in 
mRNA expression or decreased stability. A more substantial hypothesis emerged 
during the same period of research with an alternative suggestion to the inhibitory 
mechanism. It was decided to pursue this hypothesis in more detail and will be 







Figure 3.9: TNF-α and IL-10 mRNA expression in HNP1 treated HMDMs 
qPCR of gene expression in HMDMs (fresh blood donations) stimulated with 
3µg/mL CD40L + 5ng/mL IFN-γ alone or in the presence of 25µg/mL HNP1. 
(A) TNF-α (i) and IL-10 (ii) mRNA expression over 24hrs. 
(B-i) Quantitated TNF-α mRNA with secreted cytokine proteins (ii) over 6hrs. 
(C and D) Repeat TNF-α mRNA expression experiments over 6hrs.  
In all experiments mRNA expression was normalised to 18S rRNA and plotted 
relative to untreated control cells. Data represents the mean ±SD of single 
experiments (n=1) performed using triplicate repeats for each sample. Experiments 








Figure 3.10: The effect of HNP1 in TTP-/- BMDMs 
Secreted TNF-α quantitated at 18hrs incubation. Bone Marrow Derived Macrophages 
obtained from the femurs of C57 BL/6 female mice (2x WT, 2x TTP
-/-
 KO) and 
stimulated using 50μg/mL FGK-45 + 5ng/mL IFN-γ alone or in the presence of 
25μg/mL HNP1 or LHNP1. (A) One representative graph from three repeat 
experiments, with error bars showing the mean ±SD. (B) Secreted TNF-α plotted 
relative to LHNP1 controls with values of the mean ± SEM from three independent 
experiments, with triplicate samples for each treatment. Statistical analysis was 











Figure 3.11: TNF-α mRNA expression in NN treated HMDMs 
(A) TNF-α mRNA expression over 24hrs in R848 stimulated buffy coat HMDMs 
with 5% NN added in simultaneously or added 1 or 24hrs prior to stimulation (i). 
Results represent mRNA expression normalised to 18S rRNA and plotted relative to 
untreated control cells. (ii) Secreted TNF-α quantitated by ELISA. Data represents 










Figure 3.11 (continued): IL-10 mRNA expression in NN treated HMDMs 
(B) IL-10 mRNA expression over 24hrs in R848 stimulated buffy coat HMDMs with 
5% NN added in simultaneously or added 1 or 24hrs prior to stimulation (i). Results 
represent mRNA expression normalised to 18S rRNA and plotted relative to 
untreated control cells. (ii) Secreted IL-10 quantitated by ELISA. Data represents the 










Figure 3.12: TNF-α mRNA decay rate in NN treated HMDMs 
qPCR of buffy coat HMDMs pre-treated for 24hrs with 5% NN alongside untreated 
controls. After 1hr R848 stimulation, actinomycin D was added to cells and TNF-α 
mRNA decay rates were assessed. Results are from a single experiment (n=1) with 









Figure 3.13: TNF-α mRNA decay in HNP1 treated HMDMs 
Two independent experiments (A and B) of quantitated TNF-α mRNA in HMDMs 
(fresh blood donations) stimulated either alone with 12.5μg/mL HNP1 or LHNP1. (i) 
Actinomycin D was added 1hr after stimulation and TNF-α mRNA quantitated over 
2hrs. (ii) Secreted TNF-α results taken from samples performed in parallel to (A) 
without actinomycin D treatment (at 4hrs). In addition, secreted TNF-α from 
actinomycin D treated controls were included for TNF-α ELISA analysis. Results are 
from single experiments (n=1) with error bars representing the mean ± SD from 











3.2.4 The effect of HNP1 on other cell types 
While the main focus of research was in investigating the immunomodulatory effect 
of α-defensins on human macrophages, the diversity of the inhibitory effect was 
questioned in other cell types. In a limited number of studies, experiments were 
conducted in primary murine B cell and tumour cell lines. 
 
Figure 3.14 illustrates the NN effect on CD19
+ 
B cells isolated from fresh blood 
donations in a single experiment. After 72hrs of stimulation with CpG, peptidoglycan 
(PGN), LPS or R848 alone together with 5% or 25% NN, IL-10 ELISAs showed an 
inhibition across agonists with both NN concentrations compared to controls groups. 
 
HNP1 was further tested in B cell lymphomas (Mutu-1) and the effect was assessed 
by measuring metabolic activity as well as cell proliferation. Using the reduction of 
the added Alamar Blue reagent as a readout for metabolic activity, Mutu-1 cells were 
incubated over 72hrs with 12.5 or 50μg/mL HNP1 or LHNP1 alongside untreated 
controls. 5μg/mL actinomycin D was added as a positive control for arrested cell 
metabolism and apoptosis induction in tumour cells
137
. The results demonstrated that 
HNP1 was unable to inhibit Mutu-1 cell metabolism, as Alamar Blue reduction was 
near identical to untreated controls. Actinomycin D meanwhile showed almost 
complete prevention of Alamar Blue reduction as a positive control (Figure 3.15A-i). 
Simultaneously, cell proliferation and cell viability (by Trypan Blue exclusion) were 
assessed in Mutu-1 cells seeded at 20 000 cells/well and counted 72hrs after 
treatment with 50μg/mL HNP1 or LHNP1 alongside untreated controls (A-ii). Total 
cell number appeared less in HNP1 treated cells compared to controls with a 
suggestion of increased cell death. It was noticed, however, that Mutu-1 cells were 
failing to proliferate under the given culture conditions with the thought that starting 
cell numbers were exhausting cell culture growth nutrients. A repeat experiment was 
performed for proliferation assays with the number of seeded cells reduced to 11 000 
cells/well (Figure 3.15B). After 72hrs treatment with 50μg/mL HNP1, LHNP1, 
untreated controls or actinomycin D, cell proliferation appeared to be stagnated in all 
treatments. Actinomycin D treatment resulted in near 100% cell death, as measured 




cells was tested for rates of proliferation in culture media containing titrated fetal 
bovine serum (Figure 3.15C). Cells seeded at 20 000 per well showed strong 
proliferation with 10% FBS, reaching approximately 140 000 cells after 72hrs. A 10 
fold reduction in FBS immediately resulted in limited proliferation. As HNP1 
activity is impeded in the presence of serum proteins, experiments were discontinued 









Figure 3.14: Secreted IL-10 in murine B cells treated with human NN 
Splenic CD19
+
 B cells from fresh blood donations isolated in culture and stimulated 
with CpG (1μg/mL), PGN (10μg/mL), LPS (2μg/mL) or R848 (0.1μg/mL) alone or 
with NN for 72hrs alongside untreated controls. Results of secreted IL-10 were 
quantitated by ELISA and represent the mean ±SD from a single experiment (n=1) 


















Figure 3.15: HNP1 effect on Mutu-1 metabolism and cell proliferation 
(A-i) Reduction of Alamar Blue in Mutu-1 cells with HNP1 or LHNP1 treatment at 
12.5 or 50μg/mL over 72hrs. Included controls were 5µg/mL actinomycin D treated 
cells and wells containing media alone. (ii) Live and dead cell counts at 72hrs with 
50µg/mL HNP/LHNP alongside untreated controls with a starting cell number of 20 
000 per well. 
(B) Repeat of (A) with cells seeded at 11 000 per well. Actinomycin D treatment 
added as a proliferation control. 
(C) Mutu-1 cell counts at 72hrs in FBS-containing media with a starting cell number 
of 20 000 per well. Results are of single experiments (n=1) with error bars 





3.2.5 The effect of NN-treated BMDMs in wound healing in vivo 
Since α-defensins rendered macrophages limited in their inflammatory potential in 
vitro, the question was asked if this new (although transient) macrophage phenotype 
had any influence under physiological conditions. More specifically it was 
questioned if these macrophages facilitated enhanced resolution and tissue 
regeneration in an in vivo murine wound healing experiment.  
 
Pilot experiments were set up to compare the influence of injected BMDMs treated 
for 24hrs with 25% NN (human) compared to untreated BMDMs. For these 
experiments, BMDMs obtained from CD1 female mice were harvested from bone 
marrow as described in Chapter 2, section 2.2.3 with the experimental procedure 
detailed in section 2.16. With two mice per treatment group for each BMDM 
treatment (plus a single added saline control), rates of wound closure of a 10mm x 
2mm excision made on the dorsum of each animal were assessed relative to original 
wound dimensions on Day 0. 
 
Figure 3.16A shows captured images on rates of wound closure between the 
treatment groups. Day 7 images show near complete wound closures in NN treated 
groups compared to untreated controls. Day 9 wounds appeared closed in NN treated 
controls, with the underside tissue showing signs of angiogenesis with limited 
redness in the dermal layer. At the same point, control mice with untreated BMDMs 
displayed signs of unclosed wounds at Day 9 with the underside dermal tissue 
showing a reddish colour and scarring. The saline control group visually showed a 
similarity in wound healing rate compared to mice that received NN-treated BMDMs 
throughout the nine day period. Graphed wound closure rates re-emphasized this 
observation between the two groups with both showing a clear improvement 
compared to untreated BMDM control mice. The underside dermal tissue of the 
saline control mouse still showed a reddish colour with few signs of scarring. 
 
The experiment was repeated with n=5 per group comparing BMDMs treated for 
4hrs with 25% NN to untreated BMDM controls (Figure 3.17). Over an assessment 




two groups. This was confirmed in both the images taken (A) and the recorded 








Figure 3.16: Influence of human NN treated BMDMs on wound healing 
in CD1 mice (Run 1) 
(A) Mature BMDMs obtained from female CD1 mice treated for 24hrs with 25% NN 
and injected into 8 week old CD1 female mice alongside untreated BMDMs (two 
mice per treatment). 3x 10
6 
BMDMs were injected around a dorsal 10mm x 2mm 
wound with dimensions recorded daily over 9 days. A single saline control was 
added for comparison. (B) Percentage graph plotted relative to the original wound 








Figure 3.17: Influence of human NN treated BMDMs on wound healing 
in CD1 mice (Run 2) 
A modified experiment of the experiment performed for Figure 3.16 with mature 
CD1 BMDMs treated for 4hrs with 25% NN (ii) alongside untreated BMDMs (i). 3x 
10
6 
BMDMs were injected around a dorsal 10mm x 2mm wound (5 mice per group) 









Figure 3.17 (continued): Influence of human NN treated BMDMs on 
wound healing in CD1 mice (Run 2) 
Percentage graph was plotted relative to the original wound size with error bars of 













Results from this chapter provided supporting evidence to previously published 
findings by our research group. It also provided initial insight into the anti-
inflammatory mechanisms of necrotic neutrophil supernatants and purified HNP on 
macrophages. 
 
Preliminary data demonstrated the potent inhibitory effect of human NN supernatants 
on the E. coli-derived LPS ability to stimulate HMDMs. This was assessed using 
three human neutrophil donors all showing similar inhibitory effects on TNF-α 
production. It is worth mentioning at this point that TNF-α was the chosen cytokine 
measured for most cell culture assays investigating the impact of α-defensins. This is 
because secreted TNF-α is regarded as the earliest inflammatory response signal 
which triggers numerous downstream inflammatory responses
113
. The anti-
inflammatory effect of NN can be, in part, attested to the effect of α-defensins. This 
was previously shown by our group where NN depleted of hydrophobic proteins 
regained their inhibitory effect on stimulated HMDMs with purified α-defensin 
added into culture. This effect was further demonstrated to be specific for human 
neutrophils as murine neutrophils, lacking human α-defensin homologues, showed 
no similar property
87
. Still, it is appreciated that other immunomodulatory 
components do exist in human neutrophil supernatants (e.g. LL-37), which are likely 
to contribute to the observed inhibitory effect on secreted cytokines. 
 
The inhibitory effects of α-defensin with necrotic neutrophil supernatants on LPS-
stimulated macrophages, or any stimulation using bacterial cell wall components 
(e.g. Staphylococcus aureus Cowan Strain), are likely to be attributed to two modes 
of action: The first being neutralization of the agonist as α-defensins display strong 
lectin-like properties and bind in a multivalent fashion to carbohydrates and 
glycosylated proteins on bacterial cell walls
50
. The second mode being similar in 
function to the hypothesized inhibitory mechanism observed in T cell surrogate 
stimulation (CD40L/IFN-γ) and the anti-viral amidazoquinoline compound R848. 
Although the binding properties of α-defensins to these two agonists is untested and 




qPCR data shows unhindered TNF-α mRNA expression similar to that of R848-
stimulated alone controls (section 3.2.3). 
 
As buffy coat-derived HMDMs were more readily available for utilization compared 
to fresh donations, continued used of CD40L/IFN-γ for stimulation was the preferred 
option. It soon became apparent that the physiological condition of buffy coat 
HMDMs were different to that of HMDMs from fresh blood donations, as CI 
stimulation of the former was inadequate. Extensive testing ensued to find an 
alternative agonist in the form of R848, SAC, PGN and CpG. Switching to THP-1 
cells was considered but displayed slight physiological differences to HMDMs in 
regard to adequate R848 stimulation (see Appendix A, Figure A.4). In addition, the 
inhibitory properties of α-defensin on THP-1 cells had not been researched to date. 
Since stimulation using R848 was favoured, buffy coat HMDMs were selected to 
proceed with as they effectively expressed all cytokines tested (TNF-α, IL-6, IL-8 
and IL-10). Also, it was deemed important to continue investigations into the 
inhibitory mechanisms on already published cell types. 
 
The inhibitory findings of NN in this chapter differ from other published findings 
from similar studies. Fadok et al. (2001)
84
 showed lysed neutrophil supernatants to 
be pro-inflammatory with increased TNF-α, IL-8 (and IL-10). The inflammatory 
effects of lysed neutrophil supernatants were directly attributed to the release of 
elastase and serine protease as assessed by the use of antibodies and chemical 
inhibitors (PMSF), respectively. Where the differences were likely to be between 
results in this chapter and those published by Fadok et al. (2001) was perhaps in the 
use of the bacterial cell wall component zymosan at 50μg/mL for stimulation. At 
such a high agonist concentration, zymosan more than likely neutralized α-defensins 
by direct binding, possibly explaining the lack of inhibition. This neutralisation could 
possibly be similar to the lack of HNP1 inhibition observed with 0.1% SAC (Figure 
3.3). The cell equivalent of NN used might also explain the difference as the number 
neutrophils used to obtain supernatants was 10 fold less compared to experiments in 
this chapter. What is unclear (and untested to date) is the viability of HMDMs treated 




inflammatory effect of NN as one that influences HMDM physiology as opposed to 
inducing cell death. Increased cell viability was previously ruled out for α-defensins 
(25μg/mL), with no changes to Alamar Blue reduction compared to untreated 





α-Defensins have been shown to be resistant to proteolytic activity by way of a 
conserved salt-bridge between Arg5 and Glu15
138
. This coupled with the fact that it 
they constitute approximately 30-50% of the total protein in azurophil granules and 
5-7% of the total protein content
48
, it would seem reasonable to suggest that the 
inhibitory actions might serve to counterbalance the effects of inflammatory 
mediators in tissue containing large neutrophil numbers undergoing necrosis. 
 
Focussing on the structural importance of HNP1 for inhibition, results clearly 
demonstrate that key amino acids within the 30aa residue are essential to the 
inhibitory effect on HMDMs (Figure 3.5). HNP1 was selected since it is the most 
abundantly expressed out of the four isoforms within neutrophils (~72.2%)
139
. 
Substitution of the six cysteines in LHNP1 with alanine results in altered 
conformation as cysteines are required for disulphide bond pairing which give 
defensins their structure and function
55
. The substitution of tryptophan at residue 26 
(W26A) with alanine results in complete loss of inhibitory activity, owing to a 
change in peptide hydrophobicity as well as the ability to form dimers or even higher 
order oligomers
58
. Thus the data so far suggests that the hydrophobicity of HNP1 
coupled with dimerization is an important component of inhibitory function. 
 
Importantly the inhibitory effect of HNP1 was reproduced in HMDMs from 
Rheumatoid Arthritis patients (Figure 3.6). This provided very early stage indications 
of a new therapeutic potential in the treatment of this disease. From these data it is 
also suggested that the minimal inhibitory concentrations of HNP1 are about 
7.5μg/mL on HMDMs under these experimental conditions. No pro-inflammatory 








Analysis of the mRNA expression profiles suggests that NN might induce a higher 
than normal initial upregulation of TNF-α. This this may be in part due to a 
synergistic effect of R848 stimulation together with inflammatory mediators 
including serine protease and elastase in the supernatant. However, the resultant 
secreted TNF-α remains attenuated from as early as 4hrs with the indication that 
longer exposure to NN results in even greater inhibition. Even so, it is interesting that 
TNF-α mRNA levels in 1hr NN pre-treated HMDMs are nearly identical to that of 
NN added at the time of stimulation. This would suggest that the effects of HNP are 
taking place elsewhere, possibly affecting mRNA following transcription and 
possibly becoming more inhibitory over time. IL-10 mRNA appears similar in 
expression to R848-stimulated alone controls across the 24hr period. This is while 
secreted IL-10 is markedly reduced, providing further support to the suggestion that 
the inhibitory effect of NN appears to be post-transcriptional. It is appreciated that 
these findings using NN are based on evidence from a single HMDM donor and 
there are, therefore, limitations to the interpretation of these findings. Extensive 
repeated testing would be required to confirm the trends observed. 
 
The rapid decline in TNF-α mRNA in 24hr NN-pretreated HMDMs could not be 
overlooked since TNF-α mRNA was attenuated by ~100 fold between the hours of 
1hr and 4hrs post stimulation. To specifically determine if mRNA stability was 
affected, actinomycin D was used to block transcription in 24hr NN-pretreated 
HMDMs one hour after stimulation. Subsequent TNF-α mRNA decay rates over 2hrs 
paralleled that observed in R848-stimulated alone controls, suggesting that decay 
rates were similar to stimulated-alone controls. 
 
There were inconclusive results in TNF-α mRNA expression observed in four 
repeats of CI stimulated HMDMs treated with HNP. Although initial levels of TNF-α 
mRNA appeared similar, expression appeared somewhat lower after 2-3hrs in two of 
the repeat experiments (Figure 3.9B and C). On the contrary, an experiment over 
24hrs and a repeat over 6hrs (Figure 3.9A and D, respectively) showed little 




To clarify if HNP affected TNF-α mRNA decay, actinomycin D treatment was 
applied to R848-stimulated buffy coat HMDMs with HNP1. Data from the first run 
showed a slight decline in mRNA with HNP between 10-30min post-actinomycin D 
treatment compared to controls (Figure 3.13A). It suggested that TNF-α decay was 
increased with HNP in a fairly tight time period followed by a levelling off similar to 
that of LHNP1 and R848-stimulated alone controls. It is uncertain at this stage 
whether this period of decay is critical to the overall TNF-α gene expression. In 
contrast a repeat experiment showed a steady TNF-α decay in HNP1 treated cells 
(and LHNP1) while R848-stimulated alone decay appeared more erratic (Figure 
3.13B). Secreted TNF-α confirmed the typical inhibitory profile with HNP1 and 
actinomycin D treatments compared to controls. Thus assessing TNF-α mRNA decay 
profile in HNP treated HMDMs using actinomycin D did not definitively provide 
consistent results and would require further testing.  
 
In the limited published literature, no evidence exists that suggests HNP1 has an 
inhibitory effect on inflammatory cytokine gene production. This has been addressed 
in human bronchial epithelial cells (HBECS) and Rheumatoid Arthritis fibroblast-
like synoviocytes (FLS) using similar peptide concentrations
140,141
. Although an 
increase in IL-6, IL-8 and MMP1 mRNA expression was observed in RA FLS using 
10μg/mL HNP1, no follow on experiments confirmed whether secreted cytokines 
levels were altered. 
 
What was further established is that Tristetraprolin (TTP) activity is not implicated in 
the decreased expression of secreted TNF-α with HNP1. This effectively rejected the 
hypothesis of enhanced TTP-mediated mRNA decay brought on by HNP 
interference of TTP-mediated regulation. Although TNF-α mRNA stability cannot be 
ruled out based on these results alone, collective evidence from mRNA expression 
suggests that other factors must be involved that explain the overall inhibitory 
actions of HNP1. Indeed it would not be inconceivable to speculate at this point that 
the inhibitory effects of α-defensins may perhaps be multi-functional, possibly 





Evidence suggested that the inhibitory effects of NN may be extended to other 
leukocytes, as suggested by the attenuation of IL-10 in CpG stimulated primary 
CD19+ B lymphocytes. This was, however, observed in a single experiment and 
would need to be repeated along with the effects on other cell types of interest e.g. 
neutrophils, T lymphocytes and dendritic cells. 
 
At the HNP1 concentrations used, with the highest being 50μg/mL, HNP1 appeared 
unable to inhibit the metabolic activity in Mutu-1 lymphoma cells (Figure 3.15). It 
was unclear if HNP1 would have affected Mutu-1 proliferation without the 
experimental necessity of added serum to the culture media. It has been published 
that purified defensins are cytotoxic to human and murine tumour cells in the 
concentration range of 25 – 100μg/mL after 6hrs in culture, assessed using 
intracellular chromium release and dye exclusion assays
132
. As Mutu-1 cells showed 
resistance to HNP1 at concentrations tested, higher titration assays would be able to 
determine the concentration threshold needed to kill these lymphoma cells. 
Determining this would offer up the potential to apply HNP1 as an antitumourigenic 
therapy but for the limitations of serum inhibition
133
. The idea of packaged HNP1 for 
delivery, i.e. into liposome vesicles, would be one strategy to overcome this obstacle. 
This strategy was briefly tested on stimulated HMDMs in serum-containing culture 
media with no success (Figure 3.8). Given the pharmacological complexity in 
formulating this compound (HNP1 membrane binding interactions for one), 
extensive optimisation would be required to develop this further. A suggested 
strategy would be to use bioengineering techniques to develop HNP1 peptides 
chemically adjoined to an inhibitory pro-piece by an ester link incorporated within 
liposomes. This would inhibit HNP1 activity until inside the cell after which bond 
cleavage by cellular esterase would release a ‘Trojan horse’ effect. 
 
Lastly, Miles et al. (2009) described a phenotypic defensin-treated macrophage 
unable to elicit a pro-inflammatory response whilst displaying enhanced phagocytic 
capability. On the basis of these results, it was asked if α-defensin-treated BMDMs 
could accelerate wound healing in mice (Figure 3.16). BMDMs treated with NN 




compared to untreated BMDM controls with fewer signs of inflammation after nine 
days. Limitations to this pilot study were numbers of test specimens. This study 
included only one saline injected control which showed a similar rate of wound 
closure to NN treated BMDMs. If the saline control result were to hold true in 
repeated experiments, it would infer the possible activation of the injected untreated 
BMDMs which contribute towards inflammation, as opposed to the pro-resolution 
properties of NN-treated BMDMs. 
 
The limitations to this experiment using HNP (which was attempted without success) 
were the large number of cells required coupled with the amount of proportional 
HNP needed to culture cells in large volumes within Teflon pots. The experiment 
was repeated, however, using 4hr NN-treated BMDMs and compared to untreated 
control cells, this time using five mice per treatment in each group (Figure 3.17). 
Results suggested no difference in wound healing rates between the two groups. 
Thus it is yet to be determined if macrophages treated with α-defensins are able to 











Based on the findings from the previous chapter, the observation was made that 
initial mRNA upregulation of inflammatory cytokines was unaffected by the 
presence of α-defensins. This signified that HMDM pattern recognition receptors 
remained functional, namely the external surface receptor CD40 for CD40L binding 
and internal TLR7/8 receptors for R848 stimulation. It also suggested that the 
signalling pathways involved and subsequent transcription activation remained 
unaffected.  
 
How α-defensins inhibit the inflammatory functioning of human macrophages was 
unknown up until this point. For a modulatory agent to have such a profound effect 
on all secreted cytokines tested (and nitric oxide) as was published in Miles et al. 
(2009)
87
, questions arose concerning the impact on not just secreted proteins but 
overall protein synthesis. Upon detection of cellular stresses such as heat and osmotic 
shock, UV treatment and nutrient deprivation, cells are rapidly able to halt global 
protein synthesis at the level of translation through several key regulatory pathways, 
whilst still facilitating the translation of a subset of mRNAs required for an 
appropriate response to the stimulus. Therefore, it was proposed to investigate 
whether α-defensins were disrupting global protein synthesis and if so, by what 
mechanism. Research into this question requires a brief overview into the regulatory 
mechanisms governing translation initiation. 
 
Ribosomes are the cell’s protein synthesis factories, rapidly translating mRNA that 
has been exported from the nucleus into the cytoplasm. The molecular process of 
translation initiation is highly complex and involves the binding of a number of 
proteins that mark the translational competency of an mRNA in order to license the 
binding of the pre-translation initiation complex
142




(40S) in association with initiator ternary complex, consisting of methionine (Met) 
bound to its cognate transfer RNA (tRNA) and guanosine triphosphate (GTP)-bound 
eukaryotic initiation factor (eIF) 2α (eIF2α-tRNAi
Met
), is recruited to the 5’ end of an 
mRNA and scans along the mRNA until it encounters an AUG start codon in an 
appropriate context (Figure 4.1, overleaf). Once aligned with AUG, the large 60S 
subunit completes full ribosome assembly (80S) and hydrolysis of GTP to GDP 
releases eIF2α and the tRNA for recycling. Subsequent tRNA-bound amino acids 
enter the ribosome sequentially to link amino acids together to begin polypeptide 
chain elongation. 
 
Translating ribosomes remain within the cytosol where proteins are synthesised for 
transport to the nucleus, mitochondria or peroxisomes. Ribosomes translating 
polypeptides destined for secretion, lysosomes or the plasma membrane become 
associated with the endoplasmic reticulum (ER)
143
. It is within the ER lumen that 
these newly synthesised proteins undergo folding into their functional conformations, 
facilitated by molecular chaperones, after which they will be transported to the Golgi 
for subsequent relocation to membranes or lysosomes, or secretion in the case of 
externalized proteins. 
 
The stage of translation initiation is the rate-limiting step of protein synthesis. 
Changes to homeostatic balances (e.g. ER stress, glucose deprivation, viral 
infections, heme deficiencies) result in the shutdown of all non-essential protein 
synthesis at the point of translation initiation. As the ER is an important organelle for 
protein synthesis, it also functions as a key sensory organelle to homeostatic 
imbalances. In addition, it is the major site of calcium storage within the cell and 
therefore undergoes rapid changes in Ca
2+ 
levels, depending on the metabolic needs 
of the cell
144
. Calcium-dependent chaperone proteins within the ER, notably the 
abundantly expressed BiP (binding immunoglobular proteins) are functionally 
sensitive to unregulated calcium fluctuations
145,146
. Calcium irregularities impair BiP 






Figure 4.1: Translation initiation regulation by eIF2α phosphorylation 
Eukaryotic initiation factor 2α (eIF2) is bound in a ternary complex by guanine 
triphosphate (GTP) to a methionine with cognate transfer RNA (tRNA). In complex 
with the small ribosomal subunit (40S), this complex is recruited to the 5’end of 
mRNA to align with the AUG start codon. Codon pairing with the tRNA anti-codon 
will initiate full ribosome assembly, with eIF2α mediating the binding of tRNAi
Met
 to 
the ribosome by GTP→GDP hydrolysis. Cellular stresses (e.g. ER stress) activate 
stress response kinases to phosphorylate the α-subunit of eIF2. This prevents the 
eIF2β-subunit (eIF2B), acting as guanine nucleotide exchange factor GTPase (GEF), 
from exchanging GDP for GTP, thus blocking functional ternary complex formation. 
 
 
An accumulation of mis-folded protein triggers an ER stress event that is recognised 
by three ER-resident transmembrane sensory proteins: the kinase and 
endoribonuclease IRE1 (inositol-requiring protein-1), PERK (protein kinase RNA-







These sensors are associated tightly with BiP and their dissociation triggers a series 
of events, collectively known as the Unfolded Protein Response (UPR) that 
effectively shuts off global translation while coping with the backlog of unfolded 
proteins. Notably autophosphorylation of PERK phosphorylates eIF2α which 
prevents the eIF2B-mediated exchange of GDP to GTP on the ternary complex 
required for translation initiation (Figure 4.1). Thus increasing eIF2α 
phosphorylation leads to translational inhibition and, as such, is a commonly assayed 




Dissociated ATF6 translocates to the Golgi where it undergoes protease cleavage-
mediated activation before it enters the nucleus to induce transcription of genes 
containing an ER stress response element (ERSE) in their promoter. These include 
the ER-chaperone protein BiP to regain protein folding homeostasis, transcription of 
the proapoptotic activator CHOP (C/EBP homologous protein), and XBP-1 (X-Box 
binding protein-1). Transcribed XBP-1 mRNA undergoes modification by splicing of 
a 26-nucleotide intron by activated kinase IRE1. Spliced XBP-1 is a potent 
transcription factor which regulates a subset of UPR genes that promote ER-
associated degradation of misfolded proteins and ER biogenesis
149,150
. Thus 
quantitation of BiP, CHOP and XBP-1 gene expression are also commonly used to 




It therefore seemed reasonable to question if α-defensins had elicited a global 
reduction in protein synthesis, given the prior knowledge of its inhibition of the 
biosynthesis of multiple cytokines. If so, it was necessary to assess whether this was 
due to HNP1-induced ER stress, possibly resulting from calcium modulation given 
that HNP1-treated membranes become rapidly permeable to calcium flow
151
. If 
intracellular calcium mobilisation was affected, it was essential to establish if this 
triggered UPR pathway activation, specifically phosphorylation of eIF2α and gene 







4.2.1 HNP1 inhibits protein synthesis  





S-Met) in HNP-treated HMDMs (method detailed in 
Chapter 2, section 2.9). After incubating HMDMs in methionine depleted culture 
media for 2hrs, 100μCi/mL 
35
S-Met was added to cells that were either left untreated, 
treated with 25μg/mL HNP1 or were stimulated with CD40L and IFN-γ in the 
presence and absence of 25μg/mL HNP1. Incorporation of radiolabelled methionine 
into secreted proteins (within the supernatant) and intracellular proteins (within the 
cell lysate) was assessed after 4hrs and following overnight incubations in three 
independent experiments. Protein electrophoresis was performed of all samples and 
radioactive protein bands were imaged by phosphorimaging. Total volumes of all 
protein bands were semi-quantitated and normalised to radiolabelled methionine 
incorporation in untreated HMDMs. 
 
Figure 4.2A shows the 
35
S-Met incorporation from two independent experiments at 
4hrs. Varying results showed no or minor decreases in levels of protein synthesis in 
intracellular proteins. Assessing the secreted proteins, there is a trend towards an 
attenuation of synthesis in HNP1 alone controls and to a lesser extent in stimulated 
cells treated with HNP1 as early as 4hrs. This result suggests a gradual reduction of 
de novo protein synthesis by HNP1. Overnight HNP1 treatment alone showed a 
significant drop in 
35
S–Met incorporation in intracellular proteins compared to 
incorporation in untreated HMDMs (P<0.05) (Figure 4.2B). This inhibition of 
intracellular protein synthesis by HNP1 was also seen in stimulated HMDMs, 
although it did not achieve statistical significance. The inhibitory impact of HNP1 
was maximally demonstrated in secreted proteins after overnight incubations. Here, 
there was a clear and significant inhibition in both stimulated and unstimulated cells, 
supporting the concept that HNP1 inhibits macrophages regardless of the phenotypes 
tested to date. There remains a clear difference between the inhibitory actions of 






Figure 4.3 is a representative depiction of gel images showing both total proteins and 
radiolabelled proteins from all experimental repeats. Images obtained from repeat 
experiments can be found in Appendix B, Figure B.1 and B.2. Total proteins, stained 
with Gelcode Blue showed visible patterns where protein bands became either feint 
with HNP1 treatment or even missing in some instances (depicted within green 
highlighted boxes). The absence of bands was particularly noticeable in secreted 
proteins after overnight incubations. Attempts to excise and identify proteins visually 
affected by HNP1 by mass spectrometry were unsuccessful, with outsourcing options 
limited given the radioactive nature of the samples. The gel images of 
35
S-Met 
incorporated proteins showed a profound drop in band intensity in both secreted and 
cellular proteins in all three experiments after overnight culture, visually confirming 
the results in Figure 4.2. Panel B in all repeats validated the anti-inflammatory effect 
of HNP1 on secreted TNF-α, quantitated by ELISA. 
 
Key investigative experiments using HNP1 were performed throughout the project at 
concentrations 25μg/mL and 12.5μg/mL. The inhibitory effect of HNP1 at the latter 
concentration was tested in 
35
S-Met incorporation experiments in a single experiment 
(Figure 4.4). Results show a similar inhibitory profile after 18hrs incubation, with 
HNP1 having a profound effect on synthesis of secreted proteins. No significant 
differences were observed in de novo synthesis of intracellular proteins, giving 
preliminary suggestions that higher HNP1 concentrations are required for an effect 







Figure 4.2: 35S-methionine incorporation in HNP1-treated HMDMs 
Quantitation of incorporated 
35
S-Met in HMDMs (fresh blood donations) from all 
three experiments performed (Figure 4.3 and Appendix B, Figure B.1 and B.2). 
Incorporation is expressed normalised to untreated controls at 4hrs from two 
independent repeats experiments (A-i, ii), and after overnight incubation (B) from 
n=3 experiments. Error bars are the mean ± SD (A) and mean ± SEM (B). Statistical 
analysis was performed for (B) using Tukey’s post hoc analysis following one way 
ANOVA. This was performed after sample data within each replicate was 
normalised to a single control replicate (Untreated). The mean values along with 
respective standard deviations from all three replicates were then combined to 






Figure 4.3: HNP1 effect on secreted and intracellular HMDM protein 
synthesis (Run1) 
(A) Protein gel images of HMDMs (fresh blood donations) treated with 25μg/mL 
HNP1 alone or simultaneously stimulated with 3μg/ml CD40L and 5ng/mL IFN-γ in 
culture at 4hrs and 24hrs (alongside untreated controls). Gelcode Blue stained gels 
showing total secreted (i) and intracellular (ii) proteins. Radiolabelled protein images 
of de novo secreted (iii) and intracellular (iv) protein synthesis, with green boxes 
indicating areas of reduced or absent proteins. (B) TNF-α ELISAs of secreted 
cytokine at 4hrs (i) and 24hrs (ii) with error bars of the mean ±SD of triplicate 






Figure 4.4: Secreted and intracellular HMDM protein synthesis using 
12.5μg/mL HNP1 
Repeat experiment of Figure 4.3 using 12.5μg/mL HNP1. (A) Gelcode Blue stained 
gels showing total intracellular (i) and secreted (ii) proteins at 18hrs incubation. 
Radiolabelled protein images of de novo intracellular (iii) and secreted (iv) protein 
synthesis, with green boxes indicating areas of reduced or absent proteins. (B) 
Quantitation of incorporated 
35
S-Met in HMDMs (fresh blood donations), normalised 
to untreated controls. (C) TNF-α ELISAs of secreted proteins at 18hrs. Error bars 
represent the mean ±SD from a single experiment (n=1). Experiment co-performed 





4.2.2 Inhibitory effects of HNP1 on HMDM intracellular calcium 
mobilization 
From the data described in the previous section it was apparent that HNP1 affected 
secreted protein synthesis in HMDMs within 24hrs of treatment, as well as 
intracellular protein synthesis to a lesser extent. Research questions subsequently 
addressed whether this was an ER stress-mediated halt on translation initiation. As 
addressed in the introduction, cell physiology requires tightly regulated calcium 
homeostasis for optimal ER function. BiP chaperone protein function is impaired if 
cellular calcium imbalances occur, causing an ER stress event with the onset of 
accumulated mis- or unfolded proteins. Given the evidence of an attenuation of 
protein synthesis, it was hypothesised that intracellular calcium homeostasis, a key 
effector in the induction of ER stress, may be impacted by α-defensins. 
 
The impact of HNP on cytoplasmic calcium mobilisation was tested by measuring 
real-time changes in fluorescence of a calcium sensitive probe, Fura-2/AM (detailed 
in Chapter 2, section 2.12). This probe, when incubated in cells, is cleaved by 
intracellular esterase enzymes to permit the binding of calcium to the active Fura-2 
component causing an excitation of the probe. The resulting emission wavelength 
can then be measured in real-time using a spectrofluorometer. Furthermore α-
defensins have not been shown to affect uptake of fluorophores in previously 
published findings
152
. To observe detectable differences in calcium mobilisation 
between untreated and HNP-treated HMDMs, two known inducers of macrophage 
calcium flux were used; C5a from complement component C5 and Platelet-
Activating Factor (PAF). These agonists were first used to confirm a calcium flux in 
untreated HMDMs as shown in Figure 4.5. Calcium flux, measured in nanomolar 
concentrations showed a positive initial flux in calcium using both PAF and C5a with 
a gradual tapering off to near basal levels. PAF was used for the induction of calcium 
mobilisation in further experiments. 
 
Buffy coat HMDMs were then treated overnight with 25μg/mL HNP1-3 alongside 
untreated controls followed by incubation with Fura-2/AM. Changes in calcium 
mobilisation between the two test groups were first analysed in cation-containing 




Using PAF to stimulate HMDMs, three independent experiments showed a sizeable 
reduction in calcium mobilisation in HNP-treated HMDMs. The graph is 
representative of two out of the three independent repeat experiments performed, and 
the remaining graphs can be found in Appendix B (Figure B.3B and C). Not only 
were initial PAF-induced fluxes attenuated but there was a clear lack of subsequent 
oscillations, characteristic of calcium upregulation within activated cells. By 
calculating the area under each curve from the point of PAF induction, the difference 
in calcium mobilisation highlights the effect of HNP (Table 4.2.1). Combining these 
differences in calcium mobilisation values from the three independent experiment 
repeats performed and plotting graphically resulted in no statistical significance 
achieved (Figure 4.7). 
 
Table 4.2.1: Comparisons of calcium mobilisation in HNP-treated 
HMDMs to untreated controls (with external cations) 
Figure  Untreated  HNP treated Difference (with HNP) 
A 31703.87 3066.33 - 28637.54 
B 39952.14 9936.42 - 30015.71 
C 5236.38 3069.15 - 2167.23 
 
In two of the experiments (Figure 3B and C, Appendix B) the observation was made 
that basal calcium levels were approximately 100nM and 200nM, respectively, 
higher in HNP1-3 treated HMDMs prior to calcium induction with PAF. Although 
further tests would need to confirm this trend and its significance, it suggests that 
HNP treatment causes elevated basal levels of calcium, possibly derived from the 
influx of calcium within the HBSS buffer (CaCl2 concentration of 1.26mM). Initial 
tests into this suggested that there was no detectable change to calcium levels upon 
HNP1-3 treatment i.e. within 5 minutes of treatment (Figure 4.8). 
 
The effects of HNP on calcium mobilisation were repeated in the absence of external 
cations. This way an assessment could be made as to whether the calcium signalling 
pathway (illustrated in Figure 4.15), which triggers calcium release from ER stores, 
was affected in HNP-treated HMDMs (Figure 4.9). In three independent 




calcium fluxes induced by PAF. In addition, negligible differences were observed in 
total calcium levels in HNP1 treated HMDMs compared to controls (values not 
shown). This suggested that calcium signalling pathways and the subsequent release 
of stored calcium remained unchanged. A representative graph of the results is 
depicted (A), with the graphs of the two repeat experiments located in Appendix B, 
Figure B4 (B and C). In addition, calcium oscillations were comparable to untreated 












Figure 4.5: Validation of PAF- and C5a-induced calcium flux in HMDMs 
Measurement of intracellular calcium flux in buffy coat HMDMs induced with 1μM 
Platelet-Activating Factor (PAF) followed by 0.1μM complement factor C5a (n=1). 
Flux was measured in real-time by the excitation of the fluorescent calcium indicator 















Figure 4.6: Calcium mobilisation in HNP treated HMDMs (with external 
Ca2+ ions) 
Calcium flux was induced using 1μM Platelet-Activating Factor (PAF) on buffy coat 
HMDMs treated overnight with HNP in Ca
2+
-containing HBSS buffer. Cytoplasmic 
calcium was measured in real-time and total amounts were calculated using the area 
under each curve (See Table 4.2.1). Result is a representative of two out of three 
independent experiments performed. 
 
 
Figure 4.7: Semi-quantitated calcium mobilisation in untreated HMDMs 
or treated with HNP1 
Combined results of three independent HMDM donors measuring the total amount of 
calcium mobilisation in HMDMs treated with 25μg/mL HNP1 or left untreated. The 
obtained values were of calculated areas under the curves from Figure 4.6, Figure B 
3 (B and C), and represented in Table 4.2.1. Error bars represent the mean ± SEM 










Figure 4.8: Intracellular calcium mobilisation in HNP pre-treated HMDMs 
in response to HNP1-3 
(A and B) Independent repeat experiments of buffy coat HMDMs pre-treated for 
24hrs with 25μg/mL HNP1-3 alongside untreated controls. Intracellular calcium 










Figure 4.9: Calcium mobilisation in HNP treated HMDMs (without 
external Ca2+ ions) 
Calcium flux was induced using 1μM Platelet-Activating Factor (PAF) on buffy coat 
HMDMs treated overnight with HNP in HBSS buffer free of Ca
2+ 
ions. Cytoplasmic 
calcium was measured in real-time and total amounts were calculated using the area 












4.2.3 Inhibitory actions of α-defensins on protein synthesis is not 
attributed to endoplasmic reticulum stress 
 
4.2.3.1 Expression of phosphorylated eukaryotic Initiation Factor 2α 
So far data pertaining to the effects of HNP displayed a reduced level of HMDM 
calcium mobilisation together with a reduction in protein synthesis. It was wondered 
if these two results indicated the onset of an ER stress event. ER stress, together with 
deficiencies in heme or amino acids and viral infections, triggers upstream kinase 
enzymes to phosphorylate the α-subunit of eIF2, thereby preventing the hydrolysis of 
GDP to GTP catalysed by eIF2B (a guanine nucleotide exchange factor)
147,153
. Thus 
experiments were performed in HMDMs to assess whether HNP1, which altered 
intracellular calcium homeostasis, triggered eIF2α phosphorylation and a subsequent 
inhibition of translation initiation. 
 
For these experiments western blotting was used to determine the expression of 
phosphorylated eIF2α (at amino acid serine 51), as described in Chapter 2, section 
2.13.2. The first experiments assessed the expression of phosphorylated eIF2α over 
2hrs in HMDMs stimulated with CD40L and IFN-γ (CI) alone or together with 
25μg/mL HNP1 as well as HNP1 in unstimulated cells (Figure 4.10). eIF2α 
phosphorylation levels showed no change over 2hrs across treatments (Figure 4.10 
A-i), although notably expression of protein bands were feint in this run. 
To observe eIF2α phosphorylation levels over a wider time period, the experiment 
was extended to include time points for 4, 8 and 24hrs (Figure 4.11). Protein bands in 
this run allowed for the comparison between all treatments across all time points, 
which did not show any increased levels of eIF2α phosphorylation (Figure 4.11 A-i), 
apart from a slightly enhanced level at 24hrs with CI stimulation alone. β-actin 
loading controls appeared consistent amongst samples (Figure 4.11 A-ii). 
 
A repeat experiment was performed over 24hrs again using CI stimulated cells 
(Figure 4.12). In this sample eIF2α phosphorylation (Figure 4.12A-i) appeared 
upregulated in HNP1 alone treated cells at 4hrs but in contrast remained unchanged 
in stimulated cells with HNP1 treatment at the same time point. At 8 and 24hrs, 




as in stimulated cells with HNP1 treatment, but not in HNP1 alone. β-Actin loading 
controls were consistent amongst samples (Figure 4.12A-ii). This would suggest that 
the enhanced eIF2α phosphorylation was caused by CI stimulation and not HNP1 
itself. 
 
In keeping with the conversion to using R848 stimulated buffy coat HMDMs, eIF2α 
phosphorylation was also assessed in these stimulated cells treated with 12.5μg/mL 
HNP1 (Figure 4.13). As an added positive control for eIF2α phosphorylation, 
HMDMs were treated with 1μM thapsigargin (TG), a plant-derived compound which 
impairs Ca
2+ 
transport across the endoplasmic reticulum and induces ER stress. At 
1hr, 2hrs and 24hrs incubation following stimulation, no difference was observed 
between R848-stimulated alone controls and HNP1 treated HMDMs, while transient 
eIF2α phosphorylation was observed with thapsigargin treatment at 2hrs and to a 
lesser extent at 24hrs. By the assessment of eIF2α phosphorylation, there were no 
strong indications of any ER stress-induced effects caused by α-defensins. This was 
examined further using gene expression markers of the Unfolded Protein Response 













Figure 4.10: Expression of phosphorylated eIF2α in HNP1 treated 
HMDMs over 2hrs 
HMDMs from fresh blood donations were treated with 25μg/mL HNP1 alone or 
stimulated with 3ug/mL CD40L + 5ng/mL IFN-γ over 2hrs prior to lysis and SDS-
PAGE. Western blot was performed for the detection of phosphorylated (S51) eIF2 

















Figure 4.11: Expression of phosphorylated eIF2α in HNP1 treated 
HMDMs over 24hrs (Run1) 
HMDMs from fresh blood donations were treated with 25μg/mL HNP1 alone or 
stimulated with 3ug/mL CD40L + 5ng/mL IFN-γ over 24hrs prior to lysis and SDS-
PAGE. Western blot was performed for the detection of phosphorylated (S51) eIF2 
















Figure 4.12: Expression of phosphorylated eIF2α in HNP1 treated 
HMDMs over 24hrs (Run 2) 
Repeat experiment of Figure 4.11. Western blot was performed for the detection of 
phosphorylated (S51) eIF2 (~36kDa) depicted in (i). Detection for β-Actin (~42kDa), 














Figure 4.13: Expression of phosphorylated eIF2α in R848 stimulated 
HMDMs treated with HNP1 
Western blot analysis of buffy coat HMDMs stimulated with 2.5μg/mL R848 and 
treated with 12.5μg/mL HNP1. Thapsigargin was added at 1μM as a positive control 
for ER stress. Western blotting was performed for phosphorylated (S51) eIF2 
(~36kDa) and β-actin (~42kDa). Non-contiguous lanes from the same gel but spliced 










4.2.3.2 Upregulation of ER stress-associated gene expression 
In order to reaffirm the results on eIF2α phosphorylation which gave no clear 
indication of an ER stress event caused by HNP1, the gene expression of key UPR 
modulators were assessed. As described in the introduction, upregulated expression 
of BiP, CHOP and spliced XBP-1 mRNA follow the activation of sensory proteins 
involved in early ER stress responses
147
. Thus the gene expression of these three ER 
stress markers were looked at in HMDMs treated with α-defensins. 
 
R848-stimulated HMDMs from three buffy coat donors were treated together with 
25% NN or 12.5μg/mL HNP1 or LHNP1 over a 24hr period. For the positive 
induction of ER stress, stimulated control HMDMs were treated with thapsigargin. 
RNA was extracted from the cells and resulting cDNA was sent to Professor Pieter 
Hiemstra and Emily van’t Wout (Department of Pulmonology, Leiden University 
Medical Centre, The Netherlands) who kindly performed qPCR for quantitation of 
BiP, spliced XBP-1, and CHOP (detailed in Chapter 2, section 2.13.1). 
Results from all three donors are shown, with a representative result shown in Figure 
4.14 and the remaining two repeat experiments included as Figure B.5 and B.6, 
Appendix B. Expression of BiP, spliced XBP-1 and CHOP (Figures A, B, and C in 
each figure, respectively) showed similar levels of expression in α-defensin treated 
HMDMs compared to R848 alone controls over the 24hr incubation period. 
Functionally though, α-defensin was still having an inhibitory effect on secreted 
TNF-α in all three donors (Figure D), strongly suggesting that the inhibitory actions 
of α-defensins on protein synthesis was not attributed to an ER stress-mediated 
event. Thapsigargin, however, rapidly enhanced the expression of all three ER stress 
markers in all three of the donors tested, confirming the positive induction of ER 









Figure 4.14: Gene expression of ER stress markers BiP, spliced XBP-1 
and CHOP with α-defensins (Run1) 
qPCR quantitation over 24hrs of ER stress markers BiP (A), spliced XBP-1 (B) and 
(C) CHOP normalised to basal levels in untreated cells. Buffy coat HMDMs were 
stimulated with R848 alone or in co-culture with 25% NN, 12.5µg/mL HNP1, 
LHNP1, or 1uM thapsigargin as a positive control. (D) Quantitated secreted TNF-α 
by ELISA at 24hrs. Values obtained are from triplicate repeats for all samples with 
mean ± SD for error bars. Results co-performed in conjunction with the Professor 








From an early point in the investigations of α-defensins, evidence alluded to a non-
discriminatory underlying mechanism. This was attributed to the inhibition of a 
range of secreted cytokines – both pro- and anti-inflammatory – as well as nitric 
oxide. Thus it was important to decipher if the role of α-defensins transcended from 
being just an immunomodulatory agent to one that has an even larger influence in 
overall cell metabolism.  
 
By temporarily depleting HMDMs of methionine and re-introducing radiolabelled 
methionine at the time of HNP1 treatment, it became possible assess the difference in 
the amount de novo synthesised proteins, for both cellular and secreted proteins. By 
quantitation of the radiolabelled protein bands separated by SDS-PAGE, results were 
able to show HNP1 was beginning to have an inhibitory effect on secreted proteins 
as early as 4hrs, since there was a slight attenuation observed with HNP1 treatment 
compared to untreated controls. This result is supported by the fact that secreted 
TNF-α was already attenuated at 4hrs (Figure 3.13), suggesting that HNP1 is rapidly 
efficacious. Within 18 – 24hrs the inhibitory impact of protein synthesis by HNP1 is 
evident; secreted protein synthesis was significantly impaired and so were 
intracellular proteins but to a lesser extent. It is unclear at present as to reason for the 
difference between intracellular and secreted protein synthesis which would require 
further investigation. A suggestion is that there might be a preferential inhibition of 
endoplasmic reticulum-associated ribosomes which could enhance the level of 
inhibition of secreted proteins versus non-secreted proteins. Alternatively HNP1 
could be directly implicated for this difference. Of the potentially multiple effects of 
HNP1, it is plausible that its effects may extend to impeding the translocation of 
ribosomes to the ER containing polypeptides destined for folding within the ER 
lumen. Final destinations for proteins folded within the ER are either for the 
secretory pathway, incorporation in the plasma membrane or lysosomes. If this 
scenario of impaired ribosome translocation to the ER were correct, then decreased 
plasma membrane and lysosome proteins could also be contributing toward the 





In a single experiment using 12.5μg/mL HNP1 (Figure 4.4), a similar trend showed 
the inhibitory effect on protein synthesis inhibition albeit with secreted proteins only. 
Only a slight inhibition of intracellular protein synthesis was detected in stimulated 
cells with HNP1 treatment. This would suggest that higher HNP1 concentrations are 
required to impair intracellular protein synthesis, although repeat experiments would 
be needed to confirm this observation. In addition, no distinct differences in HNP1-
mediated translation inhibition could be made between untreated or stimulated 
HMDMs, implying that the function of HNP was independent of phenotype. 
 
Comparing these new findings of attenuated protein synthesis by HNP1 to current 
literature, only two papers published in the 1980s have so far reported similar 
findings. Using 40μg/mL HNP1-3 on the human erythromyeloblastoid leukemia cell 
line K562, Lichtenstein et al. (1988)
133
 found no inhibition of protein synthesis prior 
to cell lysis by assessing inhibition of [
3
H] leucine incorporation simultaneously with 
cell lysis (chromium dye release). In a study using E.coli, Lehrer et al. (1989)
46
 
attributed cytotoxicity caused by HNP1 and -2 (50μg/mL) to inner membrane 
permeabilization and loss of intracellular contents for the cessation of DNA, RNA 
and protein synthesis. Granted, HNP cytotoxicity at these concentrations has not 
been ascertained in HMDMs and may very well cause irreversible cell membrane 
permeabilization. Thus the findings using 12.5 and 25μg/mL HNP, which correlate 
with concentrations determined in rheumatoid arthritis synovial fluid
87
, suggest an 
intermediate modulatory effect on the inflammatory macrophage. In the concluding 
chapter to this thesis, I will elaborate on the regulatory effects of α-defensins at 
low/medium/high concentrations, something which I have termed ‘the three tiers of 
α-defensin modulation’ which are governed by the severity of inflammation.  
 
Since HNP1 treatment had no effect on multiple markers of ER stress, it is 
appropriate to reject the hypothesis that induced ER stress is the mechanism of HNP-
mediated translation inhibition. Although it was observed that intracellular calcium 
mobilisation is notably impaired, it is uncertain at this stage as to what the 





Assessing intracellular calcium storage release (i.e. in the absence of external Ca
2+
), 
it would appear that the calcium signalling pathway was unaffected by HNP1 (Figure 
4.15). More specifically, cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) by 
phospholipase C (PLC) to yield diacylglycerol (DAG) and the secondary messenger 
inositol 1,4,5-triphosphate (IP3). Soluble IP3 migrates through the cytoplasm, 
activating IP3 receptors located on intracellular calcium stores, such as the ER, 
triggering the release of calcium into the cytoplasm. The impaired inhibition appears 
to take place when the cell requires a calcium boost from the extracellular matrix 
through the plasma membrane-situated calcium channels SOC (Store Operated 





Figure 4.15: Schematic diagram of intracellular calcium signalling 
This diagram depicts a common mechanism triggering the release of intracellular 
calcium in eukaryotic cells. Agonist binding to its cognate plasma membrane 
receptor activates a receptor-associated guanine nucleotide exchange factor (or GEF, 
not shown) to activate phospholipase C (PLC). PLC-mediated hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) produces diacylglycerol (DAG) and the 
secondary messenger inositol 1,4,5-triphosphate (IP3). Soluble IP3 binds to IP3 
receptors (IP3R) on ER membranes which open channels and release stored calcium. 
SOC (Store Operated Channels) and CRAC (Calcium Release Activated Channel) 
channels facilitate extracellular calcium influx when cytoplasmic calcium levels 





Studies have previously shown that α-defensins rapidly form voltage gated channels 
within the lipid bilayer membranes, assessed by Kagan et al. (1990)
151
. In this study 
voltages were applied across membranes which were impervious to the flow of 
electric current prior to HNP1 treatment. In as little as 20 seconds, 50μg/mL HNP1 
was able to generate a sustained transmembrane current. Membrane conductance is a 







Spectrofluorimetry studies were unable to show this rapid translocation of calcium in 
HMDMs treated with 25μg/mL HNP1 in the absence of PAF (Figure 4.8). While 
these studies were at half the HNP1 concentration used by Kagan et al., the lack of 
observed effect is most likely attributed to equipment sensitivity and would require 
further testing using the patch clamp technique. Interpreting the biophysical data of 
Kagan and colleagues, it is not inconceivable to suggest that HNP1 rapidly forms ion 
permeable pores within the HMDM plasma membrane. Therefore depolarisation of 
the membrane potential with the likelihood of intracellular calcium desensitization 
may explain the impaired calcium flux and lack of subsequent oscillations observed. 
This scenario would appear more feasible than the direct impairment of L-type 
calcium channels by α-defensins as briefly tested (supplementary data; Chapter 7). 
Here, attempts to chemically induce calcium channel opening in order to restore 
TNF-α production proved unsuccessful. In addition, attempts to chemically induce 
calcium influx by way of calcium ionophores as well as calcium-dependent Protein 
Kinase C activation also proved unsuccessful (supplementary data, Appendix B). 
 
Interestingly, the inhibitory effect of α-defensins on HMDMs is a transient one, 
shown previously in Dr Gray’s research. Here, observations showed the full 
restoration of TNF-α production 72hrs after a 24hr incubation with HNP1
87
. It would 
be interesting to determine if calcium flux is also restored 72hrs post HNP treatment, 
as this could provide further clues into the relevance the calcium data. If there is a 
correlation, only a single calcium-influenced event has been ruled out thus far (ER 
stress). Further research into other calcium-dependant pathways would need to be 
addressed if this observed calcium mobilisation impairment has any bearings on 





The final points in this chapter return to the impact on global translation inhibition. 
Since cytokine exocytosis is not implicated in α-defensin-mediated inhibition, and 
impaired cellular and secreted protein synthesis is not ER stress-mediated, it implies 
that the actions of α-defensins are likely upstream of these processing stages. These 
results, coupled with the as yet unconvincing data on pro-inflammatory mRNA 
expression and stability, effectively narrow down the mechanism to a pivotal stage in 







5 Elucidating the inhibitory mechanisms of α-
defensins on translation  
 
 Introduction 5.1
The results from Chapter 4 showed that HNP was an inhibitor of translation in 
HMDMs, thereby providing new mechanistic insight into how inflammatory 
cytokine expression is attenuated by α-defensins. While these results provided a 
clearer understanding of the overall inhibitory action, the molecular mechanistic 
actions of the peptide remained unclear. The inhibitory mechanism was not caused 
by a regulatory shut down of translation in response to an α-defensin-mediated 
cellular stress. Thus it was hypothesised that HNP1 may directly inhibit eukaryotic 
mRNA translation. 
 
In this chapter, this hypothesis was tested by comparing two functionally different 
modes of translation initiation using a cell-free translation system; cap-dependent 
versus cap-independent, internal ribosome entry site (IRES)-mediated translation. It 
was also examined if the extent of mRNA incorporation into translating 
polyribosomes (polysomes) might be altered in HNP1-treated HMDMs. Finally, the 
possibility that HNP1 may bind RNA to inhibit mRNA translation was assessed. The 
HNP1:RNA binding stoichiometry was assessed using Electrophoretic Mobility Shift 
Assays (EMSAs), as previously used in published literature to investigate the binding 




In eukaryotic cells, with the exception of histone-encoding mRNAs which lack a 
poly(A) (poly-adenylated) tail, mRNAs are capped and poly-adenylated and are 
translated via a canonical cap- and poly(A)-dependent mechanism of translation. 
mRNA capping is the co-transcriptional 5’ attachment of 7-methylguanylate 
(m7G(5’)ppp(5’)G) – abbreviated to m7G, and this ‘cap’ structure facilitates mRNA 
nuclear export, stability and translation initiation. Similarly, the mRNA is modified 




nucleotides in length. The cap and poly(A) tail are the major determinants of mRNA 
half-life and efficiency of translation. In the cytoplasm the 5’ cap is bound by the 
cap-binding protein eIF4E and the poly(A) tail is bound by Poly(A) binding protein 
(PABP). Both of these factors then associate with eIF4G which serves to bring the 5’ 
and 3’ ends of the mRNA into close proximity to one another and pseudo-circularise 
the mRNA into a structure termed the closed-loop. Furthermore, eIF4G binding 
simultaneously enhances both the interaction of eIF4E with the cap and the binding 
of PABP to poly(A)
123
, so stabilising the complex. These interactions result in the 
recruitment of the RNA helicase eIF4A, and this multi-protein complex is termed 
eIF4F (Figure 5.1). eIF4F facilitates 5’ end unwinding and recruits the key factor 
eIF3, which is required for recruitment of the 43S pre-initiation complex, consisting 
of the 40S subunit, the eIF2-GTP-Met-tRNA
Met
i, eIF1A, eIF1 and possibly eIF5. The 
eIF4F-eIF3-43S complex then scans the mRNA until it reaches an AUG initiation 
codon in the correct sequence context. Following initiator codon recognition and 48S 
complex formation, eIF5 and eIF5B promote the hydrolysis of the eIF2-bound GTP, 
causing subsequent eIF2-GDP to be released from the 48S complex. It also results in 
the release of initiator factors and the joining of the 60S subunit. Complete 80S 
ribosome formation then allows for polypeptide chain elongation to commence. This 
occurs by the entry of the cognate aminoacyl-tRNA into the entry site (referred to as 
the A-site, or acceptor site) within the 40S subunit, which binds to the corresponding 
codon. This binding is catalysed by eEF-1 (eukaryotic elongation factor) through the 
hydrolysis of a GTP. Once this aminoacyl-tRNA is bound the polypeptide chain is 
transferred from the aminoacyl-tRNA occupied in the P-site to the amino acid 
attached the tRNA in the A-site. This peptide bond formation between the 
polypeptide chain and the aminoacyl-tRNA in the A-site is catalysed by peptidyl 
transferase. eEF-2 and GTP hydrolysis facilitate the unlocking of the current 
ribosome formation, allowing for translocation of the tRNAs and mRNA within the 
ribosome. This shifts the empty tRNA molecule into the E-site for exiting the 
ribosome, while moving the polypeptide chain-containing tRNA into the P-site so 
that incoming aminoacyl-tRNAs can bind in the A-site containing the next sequential 
codon
156
. This completes once cycle of chain elongation. Chain termination 




UUA or UGA), which has no corresponding amino acid. Release factors will bind in 
the A-site causing the polypeptide chain to be cleaved from the tRNA. This releases 
the polypeptide to undergo folding, while the ribosome will dissociate into its 
subunits for translation initiation of the next available mRNA strand. 
 
 
Figure 5.1: Cap-dependent mRNA translation 
mRNA preparation for ribosome attachment is initiated by eIF4E binding to the 5’ 
m7G-cap structure and enhanced by Poly(A) binding protein (PABP) attachment to 
the poly-adenylated 3’ end. eIF4G binds eIF4E and PABP in close proximity to form 
an mRNA loop structure for stability. eIF4A completes the multicomplex eIF4F 
structure, which unwinds the 5’ cap-proximal region assisted by eIF4B. eIF3 binds to 
eIF4G, 40S, eIF1 and eIF5 and recruits the eIF2-GTP-tRNA
Met
i ternary complex for 
40S binding. This complex then scans downstream to the initiator codon. Translation 
commences with codon-anticodon pairing, induced by eIF5-mediated hydrolysis of 
GTP bound to eIF2α- tRNA
Met
i. eIF2 along with the remaining factors are 
dissociated from the complex by eIF5B, which through GTP hydrolysis permits the 






The effect of HNP1 on cap-dependent translation was compared with that of cap-
independent translation. This cap-independent mode of translation initiation is most 
commonly utilized by viruses to ‘hijack’ infected-cell translation machinery in order 
to synthesise proteins required for its replication. The virus blocks cap-dependent 
translation and then encodes its own mRNAs that contain secondary structures, 
known as IRES (Internal Ribosome Entry Sites), which recruit ribosomes directly to 
an internal position on the mRNA and are therefore cap-independent (Figure 5.2). 
Although IRES structures from some viruses can facilitate translation initiation 







Figure 5.2: Cap-independent, IRES-mediated translation initiation 
RNA structural elements, known as IRES (internal ribosome entry site), recruit 
ribosomes to internal locations in mRNA strands. This is independent of 5’ capping 




Given the complexities surrounding eukaryotic cap-dependent translation, it was 
proposed that α-defensins could be affecting one or more of the molecular events 
required during translation. These effects were studied using a cell-free in vitro 
translation system in rabbit reticulocyte lysates. This commonly used molecular 
research tool is a highly efficient in vitro eukaryotic protein synthesis system used 




mechanisms of translation independent of transcription regulation, pre-mRNA 
processing (e.g. splicing), transcript stability and turnover. In vitro translation 
systems are typically derived from cells that are engaged in high rates of protein 
synthesis, such as rabbit reticulocytes, wheat germ and E.coli. They are prepared as 
crude extracts containing all the macromolecular components required for translation 
of exogenous mRNA including: ribosomal subunits, amino acids, tRNAs, aminoacyl-
tRNA synthetases, initiation, elongation and termination factors. In addition they are 
supplemented with energy sources in the form of ATP and GTP and also contain 
energy regenerating systems, for example creatine phosphate and creatine 
phosphokinase for eukaryotic systems. More specifically, rabbit reticulocytes are 
immature red blood cells responsible for the synthesis of haemoglobin. These cells 
are nuclease-treated to remove all endogenous RNA and are thus a widely used as 
the RNA-dependent cell-free system for the application of exogenous mRNA. They 
subsequently possess low nuclease activity which allows for the detailed study of 







5.2.1 HNP1 inhibits both cap-dependent and cap-independent 
translation 
The impact of HNP1 on cap-dependent and cap-independent mRNA translation was 
assessed in the rabbit reticulocyte lysate (RRL) system (described in section 5.1) 
using two reporter mRNAs. To assess cap-dependent translation, a capped but not 
polyadenylated firefly luciferase-encoding mRNA was used (referred to as Luc-A0) 
(see Chapter 2, section 2.10 for mRNA synthesis methodology). Cap-independent 
translation was assessed using a non-adenylated β-galactosidase-encoding mRNA, 
which contained a classical swine fever virus (CSFV) IRES mRNA (referred to as 
CSFV-Gal). m7G capping of this mRNA was replaced with a non-physiological cap 
analogue (ApE (G’(5)ppp(5’)A). As a functional readout for the effect of HNP1 on 
both forms of translation initiation, the activity of synthesised luciferase and β-
galactosidase protein was quantitated by luminometry. For each experiment, a fresh 
batch of reporter mRNAs were synthesised by in vitro transcription from freshly 
digested plasmid DNA. Reaction mixtures were incubated with 25μg/mL HNP1, 
LHNP1, or W26A alongside a vehicle control (0.01% acetic acid) for 30min at 30°C 
prior to the addition of both reporter mRNAs, each at a final concentration of 
100ng/μL. After 90min of further incubation, protein expression from both reporter 
mRNAs was quantitated.  
 
Results from these findings uncovered an astounding and unambiguous impact on 
translation by HNP1. Cap-dependent translation of Luc-A0 mRNA was significantly 
inhibited in the presence of HNP1 and exhibited only ~9% of the luciferase 
expression of the control reaction (Figure 5.3A). Astonishingly this inhibition on cap-
dependent translation was completely absent in the presence of the mutant forms 
LHNP1 and W26A. This result convincingly demonstrated that HNP1 was in fact 
having a direct inhibitory effect on eukaryotic mRNA translation in agreement with 
the formulated hypothesis. It also suggested that this inhibitory mechanism must be 
due to a direct molecular interaction with the machinery that drives translation. 




hydrophobic and dimerization (W26A) properties of HNP1 are essential for this 
activity.  
 
Conventionally, the CSFV-Gal cap-independent reporter mRNA serves as an internal 
reference control to detect any changes to global translation and to normalise for 
variation between technical replicates. Rather surprisingly, results showed a 
significant translation inhibition of β-galactosidase by HNP1 compared with the 
LHNP1 sample, with only ~33% of protein expressed compared to vehicle control. 
This is while LHNP1 and W26A showed no effect on translation. This result further 
supports the suggestion the most simplest of mechanisms required for translation are 
inhibited by HNP1, since even fundamental IRES-mediated translation is attenuated. 
The differences in levels of inhibition between cap-dependent (~9% versus control) 
and IRES-mediated (~33% versus control) suggests that HNP1 inhibition may extend 
to interference with m7G cap-structure recruitment of initiation factors which bind 
ribosomes. This may explain the difference in inhibitory levels between the two 
modes of translation initiation but requires further testing.  
 
For the inhibitory actions of HNP1 on translation to be valid, it was important to 
negate any suggestions of mRNA degradation. For this, small volumes (5μL) of 
reaction mixture were removed and snap frozen on dry ice immediately after the 
addition of mRNA as well as after the 90min incubation period (termed ‘pre-‘ and 
‘post-translation’). Following RNA extraction, samples were electrophoresed on a 
denaturing agarose gel and stained for RNA. Images were developed for the semi-
quantitative comparison of mRNA pre- and post-translation with Figure 5.4 being a 
representative image from all three repeat experiments. Comparing the RNA band 
expression of samples to control lanes consisting of either reticulocyte lysate alone 
(lane 1, from left) or starting amounts of Luc-A0 and CSFV-Gal (lane 2 and 3, 
respectively), it became difficult to accurately identify the reporter mRNA bands. As 
a result it was not possible to compare mRNA pre- and post-translation using this 
method. However, quantitation of Luc-A0 was performed in follow-on experiments 
by qPCR analysis, described in the next paragraph. In addition to this, a parallel 




both mRNAs (Figure 5.5). In the vehicle solution used to reconstitute lyophilised 
peptide (0.01% acetic acid), both Luc-A0 and CSFV-Gal mRNA were incubated 
with 25μg/mL HNP1, LHNP1 or W26A alongside a vehicle control for 90min at 
30°C. Subsequent non-denaturing agarose gel electrophoresis of the samples and 
migrated band semi-quantitation suggested no nuclease-type degradative effects by 
HNP1 that could account for the lack of luciferase and β-galactosidase synthesis. 
 
Since 25μg/mL HNP1 caused a considerable reduction on cap-dependent translation, 
it was beneficial to determine the inhibitory concentration range to assess if it 
correlated with the concentration limitations of HNP1 seen with secreted TNF-α in 
HMDMs (Chapter 3, Figure 3.7). In essence the half maximal inhibitory 
concentration (IC50) of HNP1 on cap-dependent translation was determined. Figure 
5.6-i shows the result from three independent experiments determining the IC50 of 
HNP1 on cap-dependent translation. HNP1 concentrations were titrated down by two 
fold serial dilutions ranging from 14μM (45.3μg/mL) to 0.875μM (3.93μg/mL). 
Plotting the log10 luciferase expression of HNP1-containing samples relative to an 
untreated control showed a gradual decline in HNP1 efficacy. The mean IC50 was 
determined to be 2.5 ± 0.87μM (8.62 ± 3.0 μg/mL) which were similar in value to the 
minimum inhibitory concentrations used to inhibit TNF-α in HMDMs, which was 
between 5-10μg/mL (determined in Chapter 3). The phenomenal inhibitory actions 
of HNP1 were demonstrated at the maximum HNP1 concentration used 
(14μM/45.3μg/mL). Translation of Luc-A0 was virtually non-existent at this 
concentration compared to untreated, LHNP1 and W26A controls, further proving 
the potency of this peptide to inhibit eukaryotic translation (Figure 5.6B). 
 
In addition to IC50 determination, small volumes of reaction mixture were collected 
pre- and post-translation (as described above) from 14μM and 7μM (22.65μg/mL) 
HNP1-treated samples. This was also performed alongside untreated and vehicle 
control samples, after which RNA was extracted for qPCR analysis. Using custom-
made primers for the luciferase (luc) gene (kindly donated by Dr Richard Smith, 
Centre for Reproductive Health, Edinburgh University), qPCR was performed to 




translation, as an indication of mRNA stability (Figure 5.6-ii; n=3). Plotting 
expression relative to untreated control samples, no statistical changes to Luc-A0 
mRNA quantitation pre- and post-translation could account for the significant 
reduction in luciferase translation, which suggested sustained mRNA integrity 






Figure 5.3: The impact of HNP1 on cap-dependent and cap-independent 
translation 
(A) Luciferase protein expression following cap-dependent Luc-A0 reporter mRNA 
translation.  
(B) β-galactosidase protein expression following cap-independent, IRES-mediated 
translation of β-Gal reporter mRNA.  
Translation reaction mixtures were treated with HNP1, LHNP1 or W26A added at 
25μg/mL alongside a vehicle control (0.01% acetic acid). Protein expression was 
quantitated by luminometry and plotted relative to Vehicle control samples. Error 
bars represent the mean ±SEM of three independent experiments. ***P<0.001, 











Figure 5.4: Denaturing gel electrophoresis of rabbit reticulocyte RNA 
samples pre and post in vitro translation 
Representative image from Figure 5.3 of samples taken pre- and post-translation in 
the presence of HNP1, LHNP1, W26A and vehicle control (performed in duplicate). 
Agarose gels were run for the purpose of semi-quantitation of Luc-A0 and CSFV-
Gal mRNA pre- and post-incubation with HNP1. Included were lanes containing 
reticulocyte lysate alone (first lane, from left) as well as starting amounts (2μg) of 
















Figure 5.5: Validation of reporter mRNA integrity with HNP1 treatment 
Non-denaturing agarose gel electrophoresis results of Luc-A0 (A) and CSFV-Gal (B) 
mRNA post incubation with 25μg/mL HNP1, LHNP1 or W26A in 0.01% acetic acid 
(vehicle solution) under the same incubation conditions as in Figure 5.3. (i) Gel 
images were acquired followed by band volume determination (ii) expressed in 








Figure 5.6: Half maximal inhibitory concentration (IC50) of HNP1 in cap-
dependent translation 
(A) Result of luciferase protein expression following cap-dependent Luc-A0 mRNA 
translation following incubation with titrated HNP1 at micromolar concentrations. (i) 
Quantitated luciferase protein expression relative to untreated control samples with 
the IC50 of HNP1 inhibition indicated (calculated to be ~2.5 ± 0.87μM or 8.62 ± 
3.0μg/mL). (ii) Luc-A0 mRNA expression in samples pre- and post-translation 
incubation quantitated by qPCR and normalised to untreated control group. Error 
bars represent the mean ±SEM from three independent experiments (duplicate 
experimental replicates) with no statistical significance between post-translation 
HNP1 treated samples compared with post translation Vehicle control (one-way 
ANOVA). 
(B) Quantitation of luciferase protein expression following Luc-A0 mRNA 
translation in samples incubated with 14µM HNP1 (45.3µg/mL) and W26A 
(46.6μg/mL). A vehicle (0.01% acetic acid) and untreated control were included for 
comparison and luciferase expression was normalised to untreated control samples. 
Error bars represent the mean ±SEM from three independent experiments. 






5.2.2 Polysome analysis of HNP1 treated HMDMs 
In vitro translation data strongly indicated that HNP1 had a direct inhibitory effect on 
both cap-dependent and cap-independent translation. It was yet to be determined how 
mRNA translation was inhibited by HNP1. For over forty years the principle of 
mRNA sedimentation being affected by its incorporation within ribosomes within 
sucrose gradients has allowed researchers to study effects on translation in detail
158
. 
By in vitro assessment of attached ribosomes to strands of mRNA (collectively 
referred to as polysomes), polysome analysis has made it possible to decipher the de 
novo state of translation in cells. This method can make visual comparisons between 
ribosomes active at the point of translation initiation, polypeptide chain elongation 
and termination. Thus assessing the differences of polysomes distribution can reflect 
changes to translation efficiency and provide a global ‘snapshot’ of the overall 
ribosome distribution within a cell at a given moment. 
 
It was decided to utilise polysome analysis in HNP1-treated HMDMs with the 
methodology detailed in Chapter 2, section 2.14. The general principle was to 
HMDMs after a period of incubation with HNP1 in a lysis buffer which preserves 
polysome-mRNA interactions, notably by the addition of cycloheximide which acts 
as a stabilising agent preventing ribosome run-off. Lysed HMDMs were layered onto 
a sucrose gradient buffer of increasing sucrose density (10, 18, 26, 34, 42, 50% 
(w/v)). Following ultracentrifugation, samples were collected by fractionation across 
ten fractions while measuring RNA absorbance at 254nm in real-time. Thus it was 
possible to visualise the differences in ribosomal peaks ranging from: low density 
ribonuclear fractions containing unincorporated RNA material, increasingly dense 
ribosomal subunit material (40/43S and 60S), followed by monosomes as 80S 
assembled ribosomes, and dense fractions of translating polysomes. 
 
Preliminary optimisation experiments determined that 10
6
 HMDMs per sample 
contained sufficient biological material for detection by the UA-6 UV/Vis detector to 
measure RNA absorbance within samples. Further optimisation experiments assessed 
the inhibitory effect of cycloheximide to prevent ribosome run-off. This antibiotic 




translation inhibitor puromycin dihydrochloride was also tested, which disrupts 
peptide transfer on ribosomes causing premature chain termination and used as a 
positive indication for arrested translation. Polysome analysis confirmed the 
contrasting effects of these antibiotics on HMDM translation. Incubation with 
cycloheximide (Figure 5.7A) showed the presence of polysomes in the latter fractions 
(fractions 6-10). As a result, this positively indicated the effective use of 
cycloheximide in preventing ribosome run-off. However, diminutive polysome traces 
did suggest the requirement for either increased amounts of biological material or an 
adjustment of machine sensitivity, with the risk of creating distorted readings due to 
unacceptable levels of machine background ‘noise’. Incubation with puromycin 
showed the cessation of translation, indicated by the absence of polysomes with only 
a subtle peak visible of the trace, possibly indicating the presence of mRNA 
associated with fewer ribosomes. Translation inhibition was also signified by a single 
80S peak, suggesting stalled ribosomes. Dividing the collected fractions for RNA 
extraction and protein precipitation, non-denaturing agarose gel electrophoresis of 
RNA was unable to convincingly show differences in translation profiles by 
visualisation of 28S and 18S rRNA (within 60S and 40S subunits, respectively) in 
each fraction. Western blotting was used to assess the distribution of rps20 - a 
ribosome protein on the 40S subunit - across the fractions. Rps20 showed a more 
even distribution of 40S that spanned into polysome fractions (fractions 6-10) in 
cycloheximide-treated HMDMs. This indicated that ongoing translation within cells 
prior to cycloheximide treatment. The inhibitory effects of puromycin were seen with 
rps20 as this protein was largely accumulated in the pre-translation initiation stages 
(fractions 3 and 4) and in the 80S ribosome-containing fraction (fraction 5). 
 
Subsequent experiments assessing the effect of HNP1 on polysome analysis were 
less definitive. Figure 5.8A is representative of three experimental attempts where no 
visual presence of polysomes could be identified in R848-stimulated HMDMs alone 
or treated with 12.5μg/mL HNP1 or W26A for 6hrs. This was while the inhibitory 
effect of HNP1 on secreted TNF-α was still apparent (Figure 5.8B). The increase in 
machine sensitivity to detect subtle changes in polysomes meant that differences in 




chart and absorbency limitations. However, the primary objective of this assay was 
to gauge any differences in polysome distributions with added HNP1, so this was 
deemed a satisfactory trade-off. It was thought that differences in extracted RNA and 
translation-associated proteins within fractions could still harbour useful information 
into the inhibitory effect of HNP1. Inconsistent RNA quality meant it was difficult to 
effectively compare distributions of 28S and 18S between treatments. In addition, 
quality of precipitated proteins did not permit accurate distribution assessments of 





In a final attempt at polysome analysis with the RNA absorbance sensitivity settings 
finalised using 10
6
 HMDMs, cells were stimulated with R848 either alone or together 
with 12.5μg/mL HNP1 for 4hrs alongside untreated controls (Figure 5.9). RNA 
traces revealed similar patterns of polysomes and 60S/80S peaks. Comparing R848-
stimulated HMDMs with R848 and HNP1-treated samples, there was a noticeable 
absence of RNA material in the translation-inactive regions with HNP1 (fractions 1 - 
4). Untreated HMDMs showed a similar pattern of expression to HNP1 treated 
HMDMs, while the inhibitory effects of HNP1 on secreted TNF-α was confirmed. 
Given that this observation was made once after three previously unsuccessful 
attempts, it is currently uncertain if this result has any bearings on the early stage 
effects of HNP1 and would require further testing to confirm its relevance.  
 
Since previous attempts to analyse the distribution of rRNA across the fractions 
proved fruitless, extracted RNA from fractions was reverse transcribed by RT-PCR 
and subsequent qPCR was performed for TNF-α. This was in an attempt address the 
distribution of TNF-α mRNA incorporated within ribosomes with HNP1 treatment. 
As a normalisation control to compare the resulting TNF-α gene expression across 
the ten fractions in each treatment, fractions were spiked with 20ng of Luc-A0 
mRNA for subsequent luc gene quantitation by qPCR, as previously described 
previously for in vitro translation assays. qPCR for TNF-α mRNA was performed 
using custom-designed forward and reverse primers kindly donated by Professor Ken 




Quantitation by qPCR was unable to detect TNF-α mRNA across all fractions in all 
treatments. Simultaneous validation experiments of TNF-α primers used were able to 
quantitate baseline levels of TNF-α mRNA samples of primary human skeletal 
muscle satellite cells, kindly donated by Jennifer McLeish, Centre for Inflammation 
Research (data not shown). Going forward, a repeat of the qPCR experiment could 
be performed on these samples optimising the amount of starting cDNA in an 







Figure 5.7: Polysome analysis of R848-stimulated HMDMs with 
cycloheximide and puromycin treatment 
Results obtained of R848 stimulated HMDMs (4hrs) followed by 30min incubation 
with 150µg/mL cycloheximide (A) or 500µg/mL puromycin (B) prior to lysis and 
polysome analysis (n=1). Ribosome peaks are labelled for the indication of 40S, 60S, 
80S and disomes (‘ds’). Collected fractions were processed for downstream 
expression of 28S and 18S rRNA by non-denaturing agarose gel electrophoresis as 






Figure 5.8: Polysome analysis of R848 stimulated HMDMs with HNP1 
and W26A treatment 
(A) Results of HMDMs stimulated with 1µg/mL R848 alone or with 12.5µg/mL 
HNP1 or W26A for 6hrs prior to lysis and polysome analysis (n=1). Collected 
fractions were processed for RNA gel electrophoresis and Western blotting for 
PABP1.  
(B) TNF-α ELISAs were performed from supernatants (performed in triplicate) with 
mean ± SD for error bars.  
 
 
Figure 5.9: Polysome analysis of HMDMs with HNP1 treatment 
(A) Polysome analysis of HMDMs stimulated with 1µg/mL R848 alone or in culture 
with 12.5µg/mL HNP1 alongside untreated control after 4hrs incubation. (B) TNF-α 
ELISAs from collected supernatants (performed in triplicate) with mean ± SD for 





5.2.3 The binding affinity of HNP1 in Electrophoretic Migration Shift 
Assays (EMSAs) 
The technique of polysome analysis was utilized ideally to find clues into how α-
defensins might alter the distribution of translating ribosomes during mRNA 
translation. If the assay was successful in identifying an inhibition of translating 
polysomes, complementary assays would still need to pinpoint the underlying 
inhibitory mechanism to determine which part of the translation machinery is 
impaired within the cell. 
 
It is now widely accepted that the pathogen killing mechanisms of antimicrobial 
peptides include not only transmembrane pore formation or cell-wall synthesis 
prevention, but are also mediated through intracellular targets including inhibition of 
nucleic acid and protein synthesis as well as interference with enzyme activity
160
. In 
addition, studies by Park et al. (1998)
124
 studied the killing mechanisms of a 21 
amino acid antimicrobial peptide Buforin II obtained from the Asian toad Bufo bufo 
garagrizans. Results described a peptide mechanism independent of pore-formation 
which showed a strong affinity for binding to RNA and DNA. Given this prior 
knowledge and since HMDMs remained viable when treated with 25μg/mL HNP 
while inhibiting translation in both cells and cell-free systems, it became reasonable 
to hypothesise that HNP1 could bind to RNA-containing components involved in 
translation. 
 
Electrophoretic Mobility Shift Assays (EMSAs) were used to test the affinity and 
furthermore the stoichiometry of HNP1 for RNA. EMSAs, also known as gel 
shift/retardation assays, are a commonly used tool to visualise protein-RNA and 
protein-DNA interactions. It relies on the property that nucleic acids will move 
through an agarose or polyacrylamide gel matrix towards the anode in an electric 
field. Migration of nucleic acids are governed by three properties: the molecular 
weight and charge, its three-dimensional shape, and the physical properties of the gel 
matrix
161
. A protein or peptide with an affinity for nucleic acids will either modulate 
the conformational structure of the RNA/DNA or substantially increase the 
molecular weight which can alter the mobility through the gel. Affinity of HNP1 for 




set out to assess the HNP1 binding affinity for three of the four nucleobases within 
RNA: adenine (A), cytosine (C) and uracil (U). This study involved the use of three 
25bp oligonucleotide sequences consisting of either A, C, or U, referred to as Poly A, 
Poly C and Poly U, respectively. These oligonucleotides were kindly donated by Dr 
Matthew Brook (Centre for Reproductive Health, Edinburgh University). 
 
5.2.3.1 Optimisation experiments 
Initial experiments began with optimising the migration of Poly A and C in two 
differing binding buffer conditions adapted from sources in literature. This was  in an 
attempt to obtain the most gradual of oligonucleotide ‘shifts’ in the gel with 
increasing HNP1 concentrations (detailed in Chapter 2, section 2.11). The migration 
in these two sets of buffers were electrophoresed in two differing percentages of non-
denaturing acrylamide gels (5% and 7% [60:1] acrylamide/bisacrylamide), again to 
obtain the most gradual shift of oligonucleotide for subtle changes in migration 
patterns with titrated HNP1 (Figure 5.10). Initial assessments of the differences were 
made by incubating fixed amounts of Poly A or Poly C (10pmol) with 75pmol HNP1 
(oligo:HNP1 ratio of 1:7.5) for 30min followed by electrophoresis. The migration of 
unbound oligonucleotide was visually compared to that of untreated controls, 
fluorescently detected by the Cy5 fluorophore label at the 5’ end of each 
oligonucleotide. 
 
By visual comparison, HNP1-bound Poly A and C within buffer ‘GT’ resulted in a 
streak of impeded oligonucleotide noticeable throughout the entire gel lane, as 
opposed a more favoured shift in the whole oligonucleotide band as seen in the 
majority of protein-nucleic acid interactions using EMSAs. This streak was less 
severe in buffer ‘SL’ in both 5% and 7% acrylamide gels (Figure 5.10A and B, 
respectively). This suggests that the reagents in buffer SL supported a more stable 
HNP1-oligonucleotide complex during migration, resulting in a more definitive shift 
compared to buffer GT. In both acrylamide gel percentages, no shift pattern of bands 
occurred within the gel. Results showed that oligonucleotides either migrated freely 
within the gel (visible at the migration front), migrated to variable degrees (visible as 




(visible as a complex situated within the loading wells). This lead to early 
suggestions that HNP1 formed a complex with Poly A and C that was too complex to 
migrate through the gel to form a shifted band. It was anticipated that the use of a 5% 
acrylamide gel would allow for a matrix pore size large enough to accommodate this 
complex. The difference in gel integrity was visibly noticeable between 5% and 7% 
gels without showing much difference in migrated oligonucleotide. As further 
reductions in acrylamide percentages would only compromise gel stability, it was 
decided to perform subsequent experiments using 7% acrylamide gels, abandoning 
the desired band shift concept. 
 
Further optimisation experiments compared the HNP1 binding association with Poly 
A and Poly C in buffer GT and SL containing 3mM magnesium chloride, included to 
simulate the physiological requirement of magnesium for optimal protein-RNA 
binding as a result of Mg
2+
-stabilised RNA conformations (Figure 5.11)
162,163
. HNP1 
was tested at ratios to oligonucleotide of 7.5 and 15 and the samples containing 
MgCl2 displayed fewer streaks of oligonucleotide compared to samples without 
MgCl2, suggesting an enhanced complex stability. As a result, EMSA binding 
buffers would include MgCl2. Assessment of migrated oligonucleotide comparisons 
between buffers showed that buffer SL displayed a more gradual decline in migrated 
(unbound) Poly A and C in the presence of HNP1, which was favoured in order to 
effectively compare differences in the stoichiometric binding ratios of HNP1 with  
Poly A, C and U. Evidence from optimisation experiments was beginning to suggest 
that buffer SL containing MgCl2 was the preferred incubation conditions for binding 
assessments. 
 
The final optimisation procedure was to compare the differences in HNP1 and W26A 
affinity for oligonucleotides using both binding buffer systems (Figure 5.12). In two 
repeat experiments (Figure 5.12A and B) using HNP1 and W26A at ratios of 7.5 and 
15 to Poly A and Poly C, a clear contrast was observed between the evident binding 
capability of HNP1 and lack thereof with W26A. Semi-quantification of free 
oligonucleotide was performed for Figure 5.12A, defined by the total band volume 




to the nil peptide control lane. Results confirmed the strong binding affinity of HNP1 
for both oligonucleotides, again with buffer SL displaying the more gradual binding 
affinity between the 7.5 and 15 ratios. In the case of W26A, unbound oligonucleotide 
migration was comparable to untreated controls with a slight streaking observed for 













Figure 5.10: Comparative migration of Poly A and Poly C in differing 
binding buffer conditions and acrylamide concentrations 
Electrophoretic migration of 10pmol Poly A and Poly C after incubation with 
75pmol HNP1 (ratio of 1:7.5) in either buffer ‘GT’ or ‘SL’ compared to Nil peptide 
control. A non-template control (NTC) with no oligonucleotide was included. 
Samples were electrophoresed in either a 5% (A) or 7% (B) [60:1] 















Figure 5.11: Comparative EMSA gels of differing binding buffer 
conditions and MgCl2 inclusion 
Electrophoretic migration after Poly A (i) and Poly C (ii) incubation with HNP1 
(pmol) in either buffer ‘GT’ or ‘SL’ with or without the addition of 3mM MgCl2 
added to the buffer. Migration of free oligonucleotide was compared to nil peptide 
control while a non-template control (NTC) was included. Results are of two 










Figure 5.12: Comparative EMSA gels of differing binding buffer 
conditions containing MgCl2 
(A) Electrophoretic migration after Poly A (i) and Poly C (ii) incubation with HNP1 
or W26A (pmol) in either buffer ‘GT’ or ‘SL’ containing 3mM MgCl2. Migration of 
free oligonucleotide was compared to nil peptide control while a non-template 
control (NTC) was included. Resulting gel images were compared and migration of 
free oligo was semi-quantitated using Quant1 TL software analysis.  
(B) Repeat experiment of (A) for visual comparison of electrophoretic migration of 





5.2.3.2 HNP1 binds non-selectively to oligonucleotides in EMSAs 
Following optimisation experiments, it was possible to employ a stoichiometric 
assessment of HNP1 binding Poly A, C and U, using equivalent molar ratios of HNP 
to oligonucleotide (Figure 5.13 – 15, respectively). It was also possible to determine 
if dimerization and hydrophobicity (altered in W26A) were critical to binding. In 
each experiment, the fixed amount of oligonucleotide (10pmol) was incubated with 
titrated molar equivalent ratios of HNP1 or W26A, using a two-fold serial dilution to 
result in a range of ratios: 28, 14, 7.5, 3.5, 1.25 and 0.875. In three repeats for each 
oligonucleotide, results showed a statistically significant decrease in the amount of 
unbound oligonucleotide with increasing ratios of HNP1 relative to W26A. In Poly A 
and C, significance is reached in HNP1-oligonucleotide ratio of 14:1 onwards. 
Interestingly, the amount of unbound Poly U compared to W26A is significantly 
attenuated at an HNP1-Poly U ratio of 7:1. This preliminary finding suggests a 
stronger interaction with the RNA nucleobase uracil, as half the amount of HNP1 is 
required to impede its migration compared to adenine and cytosine. By plotting a 
graph from the calculated fraction of unbound (migrated) oligonucleotide, the 
increased affinity of HNP1 for Poly U could be visualised to that of Poly A and C, 
which appear similar (Figure 5.16). Thus the hypothesis was concluded that HNP1 is 
able to bind to oligonucleotides sequences in a manner that suggests independence of 
sequence specificity, given that all nucleobases bound within a small stoichiometric 
range. An early indication suggests an increased binding affinity for uracil; however 
this increased affinity remains to be demonstrated in more complex binding systems 
in order to remain a valid observation (covered in the discussion). 
 
What was clearly evident was the tendency of HNP1 to transition from having 
minimal association with oligonucleotide to forming complexes unable to apparently 
transition into the gel matrix within a very tight stoichiometric range. This is in 
contrast to conventional protein-RNA binding interactions which show a more 
sigmoidal binding pattern over several magnitudes of protein concentration
161
. This 
could be attributed to the role of dimerization to form complex oligomers once bound 
to oligonucleotides, which will be addressed in the discussion section. What was also 




U migration. This was in agreement with the inhibitory concentrations observed for 
TNF-α production as well as in vitro translation of reporter mRNAs, and begins to 








Figure 5.13: EMSA of Poly A following incubation with titrated HNP1 or 
W26A 
Migration of Poly A (10 picomole) after incubation with increasing picomole ratios 
of HNP1 or W26A, resolved by non-denaturing electrophoresis. (A – C) EMSA gel 
images of Poly A compared to nil peptide control sample with NTC control included. 
(D) Semi-quantitation of unbound Poly A from n=3 experiments with error bars 











Figure 5.14: EMSA of Poly C following incubation with titrated HNP1 or 
W26A 
Migration of Poly C (10pmol) after incubation with increasing pmol ratios of HNP1 
or W26A, resolved by non-denaturing electrophoresis. (A – C) EMSA gel images of 
Poly C compared to nil peptide control sample with NTC control included. (D) Semi-
quantitation of unbound Poly C from n=3 experiments with error bars representing 











Figure 5.15: EMSA of Poly U following incubation with titrated HNP1 or 
W26A 
Migration of Poly U (10pmol) after incubation with increasing pmol ratios of  HNP1 
or W26A resolved by non-denaturing electrophoresis. (A – C) EMSA gel images of 
Poly U compared to nil peptide control sample with NTC control included. (D) 
Semi-quantitation of unbound Poly U from n=3 experiments with error bars 












Figure 5.16: Stoichiometric interactions of HNP1 with Poly A, C, and U 
Fractions of bound Poly A, C and U (y-axis) were calculated from quantitated 













The main rationale behind the experiments in this chapter was to begin investigating 
the molecular mechanisms behind the inhibitory observations of HNP1 on protein 
synthesis in HMDMs. This was in light of the fact that no apparent cellular stress 
event involved in translation regulation could account for the inhibition of protein 
synthesis observed. Studying the mechanistic actions of HNP1 in an in vitro 
translation system allowed for a more detailed understanding of the fundamental 
inhibitory mechanism. This system was useful as translation of reporter mRNAs with 
two very different modes of translation initiation could be assessed. 
 
Using this system, it was evidently clear that HNP1 unambiguously inhibited cap-
dependent translation and to a lesser extent cap-independent (IRES-mediated) 
translation. This suggests HNP1 was able to block the activity of fundamental 
translation components in some way which resulted in a loss of translation capability. 
Inhibition of cap-independent translation was an unexpected result, as protein 
expression of this translated mRNA is often relied upon as an internal reference 
control to normalise against experimental variations. Provided with this evidence of 
cap-independent translation inhibition, emerging suggestions are that HNP1 might 
impede the most fundamental of mRNA-ribosome associations required for 
translation initiation. This inhibitory action may be further hindered in cap-dependent 
translation initiation by the complexity of eIF4E binding to m7G and subsequent 
initiation factor recruitment which is required for assembly of the pre-translation 
initiation complex. This was suggested by the even greater reduction in luciferase 
protein compared to untreated controls. Going forward from this, the implication of 
HNP1-affected translation initiation could be elucidated; An in vitro translation 
experiment could be performed identical to the IC50 experiment comparing the 
inhibitory rates of translation inhibition between a cap-dependent and cap-
independent reporter mRNA. This would require two identical reporter mRNAs, 
differing only in the addition of an m7G cap or non-physiological cap analogue. If 
the rate of translation inhibition is similar in the two reporters with titrated HNP1, 
this would imply that translation inhibition is likely to be due to other mechanisms 




this would provide evidence that the HNP1 inhibitory mechanism includes the 
impediment of translation initiation, contributing to the underlying inhibitory 
mechanism.  
 
What is untested at this stage is if HNP1 affects translation at multiple stages, 
inhibiting not only initiation, but polypeptide chain elongation or termination. It was 
anticipated that analysis of polysome distribution could provide an answer to this 
question. For example a build-up of 43S/60S ribosome complex and lack of 
polysomes could imply inhibition at the point of translation initiation, while an 
accumulation of dense polysomes in latter fractions could imply stalled ribosomes 
unable to dissociate from mRNAs. Unfortunately after multiple optimisation 
attempts, a result from a single experiment showed no difference in polysome 
distribution with HNP1 treatment compared to controls at 4hrs. Without repeating 
the experiment in Figure 5.9, it is difficult to interpret the observation of decreased 
translation-inactive RNA material in HNP1-treated cells. The fact that a difference 
was observed provides justification into the continuation of these experiments, 
encompassing multiple time points over 24hrs to map the differences in ribosome 
distribution with HNP1. In addition to the analysis of polysome distribution, qPCR 
of a gene of interest such as the single attempt at quantitating TNF-α mRNA could 
provide further information into how HNP1 affects translation of such a key 
inflammatory mRNA. 
 
The results from the EMSA experiments began to define the mechanistic actions of 
HNP1 from a biochemical perspective. EMSA assays have long been used as an 
analytical tool that serves as valuable control model in defining the binding 
interactions for any biological system. These introductory EMSA experiments set out 
to address if there was any sequence selectivity in HNP1 binding, assessed by 
comparing the stoichiometric interactions between the nucleobases that make up 
three quarters of RNA (adenine, cytosine and uracil). Through fixed amounts of an 
oligonucleotide sequence and titrating in molar-equivalent amounts of HNP1, these 
preliminary studies showed a sequence-independent binding affinity for Poly A, C 




principle, there is the propensity for HNP1 to bind to all RNA once inside a cell, 
whereas W26A would most likely not. This strongly suggests the importance of 
HNP1 hydrophobicity and dimerization potential to interact with RNA. What was 
noticed in these direct titration experiments (i.e. in non-competitive binding 
interactions) is that there was a significantly increased binding affinity for uridine in 
this system. This affinity was observed at a HNP1:Poly U ratio of approximately 
3.5:1 compared with Poly A and C (approximately 7:1). Interpretation of this 
observation would infer that there may be an affiliation for uridine within RNA. 
However this increased affinity should be scrutinised further in order to confirm this 
observation. By assessing the HNP1-oligoncleotide binding in a competitive binding 
experiment, competitor RNA (unlabelled) could be titrated in with the labelled Poly 
U-HNP1 complex, and the efficiency of the competitor RNA to disrupt the complex 
can be determined by native gel electrophoresis. Plotting the fraction of bound 
(labelled) oligonucleotide could assess if the stronger interaction for uridine still 
remained valid compared with results performed with Poly A and Poly C. 
 
Conventionally, analysis of protein-mediated ‘shifts’ of RNA within native gels 
make it theoretically possible to determine the protein-to-RNA stoichiometry by 
virtue of the degree of shift within the gel
161
. This implies that one is able to assess 
whether proteins bind to RNA in a homodimer (2:1) complex, or 3:1, or 4:1 etc. 
While HNP1 binding with oligonucleotide was observed at a peptide:oligo ratio of 
3.5:1 in Poly U, the apparent accumulation of labelled oligonucleotide at the top of 
the loading well as opposed to a conventional shift pattern suggests that a large, 
multimeric complex formation is the general binding characteristic of HNP1. Using 
examples as defined by Ryder et al. (2008)
161
, protein-RNA binding interactions are 
normally gradual spanning over at least two orders of magnitude (100 fold) between 
the binding minimum (unbound RNA) and maximum (completely bound RNA). 
From this rule-of-thumb, it is evident that the binding property of HNP1 was quite 
unusual and very rapid once binding was initiated. This was apparent in Figure 5.16 
as the fraction of completely unbound Poly U became almost completely bound to 




Collectively these results support the newly established hypothesis that the inhibitory 
actions HNP1 could be attributed to a structurally complex binding with RNA-
containing components involved in protein synthesis, such as ribosomal RNA or 
mRNA. It is suggestive in these initial EMSA experiments that, if an RNA binding 
event is indeed implicated in the inhibitory mechanistic action of HNP1, the 
magnitude and rapid complexity of binding would surely be detrimental to cellular 









6 α-defensin interactions with ribosomes  
 
 Introduction 6.1
Electrophoretic mobility shift assays in Chapter 5 demonstrated the strong 
association of HNP1 for oligonucleotide sequences of adenine, cytosine and uracil. 
In conjunction with the inhibitory observations on de novo protein synthesis in 
HMDMs and within in vitro translation systems, the hypothesis was formulated that 
the HNP1 inhibitory mechanism on translation could be mediated by binding to, and 
interference with, nucleic acids within translation machinery. This hypothesis could 
infer that upon entry into cells, HNP1 could migrate to areas of active translation and 
bind to rRNA, preventing ribosome complex formation with mRNAs. The 
hypothesis could also include the potential to bind to mRNA itself, possibly 
impeding shuttling to the ribosomes and attachment to eukaryotic initiation factors 
and 43S pre-initiation complexes. In addition, binding activity may well impede 
tRNA delivery of amino acids to ribosomes. The implications of this hypothesis are 
potentially considerable to the cell’s translation capabilities and could establish a 
new therapeutic target for inflammation regulation. If binding under physiological 
conditions replicates the binding affinity observed in representative analytical 
methods such as EMSAs, the potential effects on cell function could be far-reaching. 
 
Thus, the final set of results in this thesis expands on the binding interactions of 
HNP1 with nucleic acids. It would seem reasonable to suggest that ribosomes could 
be one of the main targets of HNP1 within a cell given the size, abundance and RNA 
composition. Eukaryotic ribosomes are very large macromolecules situated within 




units per cell and a molar mass of about 
4.3 million Daltons, of which ~60% is attributed to rRNA content
164,165
. As briefly 
touched on in the previous chapter, ribosomes are comprised of two subunits: The 
large 60S subunit which consists of three rRNA molecules (28S, 5.8S, and 5S) 
together with 46 proteins, while the 40S subunit includes one 18S rRNA chain and 





Thus with this background knowledge into ribosomes together with the newly 
discovered properties of HNP1, the focus of research going forward was to determine 
whether ribosomes were a potential target for HNP1 binding. Since the EMSA data 
using oligonucleotides provided good evidence for RNA binding, it was extended 
using total HMDM RNA to assess whether 28S and 18S rRNA shifts could be 
observed. Furthermore, immunofluorescence experiments were performed 
identifying the location of HNP1 within HMDMs in relation to ribosomes. If this 
emerging data agreed with the growing body of evidence provided in previous 
chapters, it could further substantiate the hypothesis that HNP1-mediated translation 







6.2.1 HNP1 causes an electrophoretic shift in HMDM rRNA 
Building on the EMSA results from Chapter 5, the binding affinity of HNP1 for 
nucleic acids was tested on total RNA extracted from HMDMs. This method was 
derived from assays described in two previous publications, which linked the binding 
of antimicrobial peptides to nucleic acids as the proposed target for bacterial 
killing
124,155
. The methodology involved incubating 1μg of RNA with titrated 
amounts of HNP1, LHNP1 and W26A added into binding buffer ‘GT’, adapted from 
Park et al. (1998)
124
. Details on the method are described in Chapter 2, section 2.11. 
After 1hr incubation, samples were electrophoresed by non-denaturing gel 
electrophoresis. The visible shifting effects between HNP1 and LHNP1 on 28S and 
18S rRNA were compared from the resulting gel image obtained (Figure 6.1i). The 
influence on 18S rRNA migration was observed by its impaired migration (or shift) 
relative to the untreated control migration front with each increasing HNP1, 
represented by the horizontal dashed line across the gel image. This visually apparent 
shift suggested that minimal HNP1 in ratio with RNA was required in order to 
induce a shift, beginning at an HNP1:RNA ratio of 0.2:1 (200ng:1μg). It was also 
suggested that the shift steadily increased with added ratios of HNP1. In contrast, no 
distinct shift in migrated 18S rRNA was noticeable in LHNP1 treated samples. In 
addition to a shift, HNP1 treatment also resulted in a gradual reduction on the band 
intensity of 18S rRNA from a peptide/RNA ratio of 0.1 onwards, culminating in an 
approximate 25% loss of unbound, migrated 18S rRNA at a ratio of 1:1, confirmed 
by semi-quantitative band analysis (Figure 6.1ii). In contrast, the band intensity of 
unbound, migrated 18S rRNA with LHNP1 treatment remained above 90% 
compared to untreated controls. This affinity of HNP1 for RNA was comparable to 
two antimicrobial peptides known to bind RNA tightly; both bovine neutrophil-
derived Indolicidin
155
 and Buforin II, a derived form of Buforin I obtained from 
stomachs of Asian toads
124
, also elicited a shift at peptide/RNA 0.2. In contrast 
Magainin 2, a membrane-active antimicrobial peptide obtained from frog skin 







While the shift on 18S rRNA was clearly evident, effects of HNP1 on 28S rRNA 
were more subtle. Shifts in 28S rRNA migration were visibly apparent compared to 
untreated controls with minor changes to semi-quantitated band intensities (Figure 
6.1-iii). In comparison, LHNP1 had no effect on 28S rRNA in both the migration of 
and band intensities quantitated. The reason for the reduced shift of 28S rRNA could 
be explained by the fact that 28S rRNA is almost three times the length of 18S rRNA 
(5025nt and 1869nt, respectively)
166,167
. Thus the impact of the added weight of 
bound HNP1 is suggested to be almost negligible when assessing the migration of 
28S rRNA given its size.  
 
In light of this, a slight modification was made to these experiments in an attempt to 
create a more substantial shift in 28S and 18S rRNA with bound HNP1. In this 
process, peptide/RNA incubations were followed by a further 30min incubation with 
1ng/μL monoclonal mouse anti-HNP1-3 antibody prior to electrophoresis (termed a 
supershift EMSA). The proposed idea was that the migration of rRNA, which was 
bound to HNP1, would be further retarded with HNP1 subsequently linked to an 
immunoglobulin G with an approximate monomeric weight of 150kDa. Initial 
experiments using the supershift EMSA were performed for HMDM RNA with 
titrated HNP1 and LHNP1 (Figure 6.2A). Although antibody addition did not lead to 
increased band shifts, it did result in greater reductions of unbound 18S rRNA at the 
migration front compared to the untreated sample (which also contained antibody). 
This was suggested by semi-quantitation of the unbound 18S rRNA, which showed 
an approximate 70% reduction at a peptide/RNA ratio of 1:1 (Figure 6.2A-ii). 
Migration of 18S rRNA in the presence of LHNP1 closely resembled that of the 
untreated control sample although band semi-quantitation did show a moderate 
reduction with increasing LHNP1 amounts, albeit over half as inhibitory compared to 
HNP1. 
A peculiarity occurred in the 28S rRNA band expression with HNP1 treatment in the 
form of uneven band distribution across the width of the lane. This made it difficult 
to accurately ascertain the true migration difference in this experiment. It also meant 
that 28S rRNA band semi-quantitation was skewed somewhat with HNP1 treatment, 




controls (Figure 6.2A-iii). In a validation experiment of the anti-HNP1-3 affinity to 
both HNP1 and LHNP1, Western blot analysis confirmed specificity for the wild 
type peptide but not LHNP1 (Figure 6.2B). This created a bias in shift with HNP1 
over LHNP1, meaning that comparisons between the two in a supershift assay could 
not be made.  
 
Supershift assays were then employed to compare the inhibitory effects of HNP1 
with structurally similar W26A, confirmed by NMR spectroscopy
58
, and since shift 
comparisons between the two peptide forms were performed using oligonucleotide 
sequences (Figure 6.3). The use of W26A in these supershift assays was validated 
since mouse anti-HNP1-3 antibody was able to detect the mutant form as confirmed 
by Western blotting (Figure 6.2.3C). In two independent RNA shift experiments 
comparing HNP1 and W26A at ratios 0.2 and 0.4, gel images showed clear shifts in 
28S rRNA with HNP1 not observed with W26A (Figure 6.3A). Combined semi-
quantitative analysis of the migrated 28S rRNA bands from both runs showed 
contrasting results as to whether HNP1 decreased the amount of unbound RNA 
(Figure 6.3B-i). Despite this, both experiments did suggest positive HNP1 binding to 
28S rRNA as was evident by a visual shift in migration, an effect which was not 
observed in W26A-treated 28S rRNA.  
Comparing the effects on 18S rRNA, HNP1 caused shifts in migrated bands as well 
as an approximate 50% decrease in the amount of unbound RNA at a ratio of 0.4 
(Figure 6.3B-ii). This was in contrast to W26A which showed no visible shift with a 
slight reduction in unbound rRNA compared to untreated controls. 
 
One final assessment of HNP1 binding interactions with RNA using EMSAs 
addressed the effects on mRNA. Using mRNA previously utilized during in vitro 
translation assays, Luc-A0 and CSFV-Gal mRNA were individually incubated with 
HNP1 or W26A at peptide/RNA ratios of 0.2 and 0.4 in a supershift EMSA (Figure 
6.4). At both ratios tested HNP1 was clearly able to shift both forms of mRNA, 
indicating strong binding interactions that were not observed with W26A. On the 
basis of this finding, it showed that HNP1 was able to bind to all RNA forms tested 




(Chapter 5), it added further evidence that supported the hypothesis of HNP1 binding 
to RNA as a mechanism of translation inhibition. Currently untested was the binding 
potential of HNP1 in a cellular environment, on ribonucleoproteins (RNPs) such as 





Overall the EMSA results in this Chapter present a less rigorous assessment of HNP1 
binding interactions to rRNA compared to that of Chapter 5, but still show a superior 
binding potential over both LHNP1 and W26A. These experiments formed the 
preliminary assays which helped establish the hypothesis of HNP1 interactions with 
RNA-containing translation machinery. In order to further this hypothesis, it was 
important to find supportive evidence in cell-based assays, starting off by identifying 










Figure 6.1: Electrophoretic Mobility Shift Assay (EMSA) of HMDM RNA 
in the presence of HNP1 and LHNP1 
Non-denaturing agarose gel electrophoresis of migrated HMDM RNA (1μg) with 
increasing HNP1 or LHNP1 ratios (in μg) between 0.1 and 1. 
(i) Gel images of migrated RNA with peptide ratios between 0.1 and 1. Horizontal 
dotted lines (yellow) represent the migration front of 28S and 18S rRNA of nil 
peptide control for shift comparisons with peptide inclusion. Mean grey values of 
migrated 18S (ii) and 28S (iii) rRNA bands normalised to nil peptide control (white 








Figure 6.2: The migration of HMDM RNA following HNP1 and LHNP1 
incubation in a supershift EMSA 
(A) The electrophoretic migration of HMDM RNA following incubation with titrated 
HNP1 or LHNP1. Monoclonal mouse anti-HNP1-3 antibody was added to all 
samples 30min prior to electrophoresis in 1% non-denaturing agarose (i). Semi-
quantitation of migrated 18S (ii) and 28S (iii) rRNA relative to nil peptide control 
sample (n=1). Horizontal dotted lines (red) represent the migration front of 28S and 
18S rRNA of nil peptide control for shift comparisons with peptide inclusion. (B) 
Antibody detection of HNP1 as well as HNP1-3 within 20μg of necrotic neutrophil 
protein (‘NN’) by Western blotting. The antibody used was unable to detect the 









Figure 6.3: The migration of HMDM RNA following HNP1 and W26A 
incubation in a supershift EMSA 
(A) Two independent EMSA experiments (i and ii) of HMDM RNA migration 
following incubation with titrated HNP1 or W26A. Monoclonal anti-HNP1-3 
antibody was added to samples 30min prior to 1% non-denaturing agarose gel 
electrophoresis. Horizontal dotted lines (yellow) represent the migration front of 28S 
rRNA of nil peptide control for shift comparisons with peptide inclusion. (B) Semi-
quantitation of migrated 28S (i) and 18S rRNA (ii) relative to nil peptide control 
sample with error bars representing the mean ± SD of band volumes (n=2). (C) 










Figure 6.4: Supershift EMSA of mRNA with HNP1 and W26A treatment 
Electrophoretic migration of 1µg Luc-Ao (A) and CSFV-Gal (B) mRNA incubated 
with titrated μg amounts of HNP1 and W26A. Monoclonal anti-HNP1-3 antibody 
was added to all samples 30min prior to electrophoresis in 1% non-denaturing 





6.2.2 HNP1 association with ribosome proteins 
With binding assays demonstrating the affinity of HNP1 to bind to RNA, the 
research progressed to provide supporting evidence of this effect in HMDMs in vitro. 
The most insightful assay to take the research forward was determined to be the 
localisation of HNP1 relative to ribosomes using immunocytochemistry by confocal 
microscopy. Using the monoclonal mouse anti-HNP1-3 antibody used for Western 
blotting in the previous section, HMDMs were stained for HNP1 after 4hr and 24hr 
treatments following incubation with either 12.5μg/mL or 25μg/mL HNP1 or W26A. 
Simultaneously, ribosomal protein S20 (rps20), which forms part of the 40S subunit, 
was detected using rabbit polyclonal anti-rps20 antibody. Details on the methodology 
are listed in Chapter 2, section 2.8. Using highly cross adsorbed Alexa Fluor 
secondary antibodies against mouse (HNP1) and rabbit (rps20), images of staining 
were obtained for HMDMs at 4hrs (Figure 6.5) and 24hrs (Figure 6.6) following 
treatment. 
 
Rps20 staining was characteristically condensed around the perinuclear region, 
forming a ‘halo’-like pattern around the DAPI-stained nucleus for reference and 
indicative of ribosomes associated with endoplasmic reticulum (rough ER). Results 
at 4hrs show that HNP1 was abundantly present within cells. Typically, HNP1 
displayed a characteristic condensed accumulation in and around the perinuclear 
region. F-actin filament staining of the whole the cell using Phalloidin confirmed this 
condensed HNP1 accumulation around the perinuclear region (Figure 6.6B). 
Supposed co-localisation of HNP1 and rps20 was indicated by the green HNP1 
staining and red rps20 staining merging to form yellow in the images. There existed 
patterns of minimal yellow staining, forming a halo-like association surrounding the 
nucleus (indicated by purple arrows). This staining could suggest that there may be 
evidence of HNP1 accumulation within regions of active translation. However, the 
patterns of overlap are minimal in comparison to the overall expression of HNP1 
relative to rps20, and remains uncertain at present as to whether this is genuine co-
localisation or areas of random signal overlap. There was weak evidence of areas of 
condensed, yellow staining (indicated by yellow arrows). It is currently uncertain if 




6.5A (third row). In this example there is an indication of a HNP1/rps20 association 
that is found on the periphery of the perinuclear region. This might well be an early 
indication of possible HNP1/rps20 aggregate formation caused by HNP1/rRNA 
binding. It is unclear at present as to the reason for this apparent dissociation away 
from the immediate perinuclear region, but initial interpretation is that perhaps these 
complexes were destined for cell-mediated clearance in an attempt to rid the cell of 
defective ribosomes bound by HNP1. The data, however, remains unconvincing and 
would require substantial further investigations to confirm or deny the preliminary 
findings. 
 
Further observations for HNP1/rps20 co-localisation were performed at 24hrs 
incubation with HNP1 (Figure 6.6). Weak HNP1/rps20 associations were indicated 
by yellow arrows away from the immediate perinuclear region. Purple arrows 
indicated that there still existed areas of HNP1 surrounding the perinuclear region, 
which was also observed for cells treated with W26A. While W26A staining showed 
the peptide’s capability to accumulate similar to that of HNP1, no evidence of 
condensed W26A/rps20 accumulation away from the perinuclear region existed at 
24hrs.  
 
Furthermore, an attempt was made to obtain quantitative analysis on the degree of 
co-localisation of HNP1/rps20 compared to that of W26A. Normally in 
immunofluorescence where co-localisation exists, it is possible to statistically assess 
the linearity or correlation between the two stains by quantitating the amount of 
overlapping pixels relative to pixels where no overlap exists. This method of 
analysis, known as the Pearson’s correlation coefficient, calculates correlation 
relationships ranging from a high degree of correlation (value of around 1) to having 
low or no correlation (value around 0), as detailed in Chapter 2, section 2.8.1.2. 
Using image analysis software (ImageJ), the Pearson’s correlation was performed in 
ten random field samples for both HNP1 and W26A treated HMDMs at 4hrs and 
24hrs (Figure 6.7). Analysis using this method found low correlation values between 
HNP1 as well as W26A staining relative to rps20, with no statistical significant 




correlation between HNP1 and W26A relative to rps20, visually evidential using 
observations of the staining patterns. Thus, if there were areas of subtle co-
localisation (if any), this quantitative method of analysis would be too insensitive to 
detect subtle peptide/rps20 association. This is due to the widespread peptide 
dispersion throughout the cell. 
 
Concerning the hypothesis of HNP1 binding to nucleic acids, EMSA results from 
Chapter 5 demonstrated that HNP1 bound to oligonucleotides consisting of uracil 
sequences as well as the DNA-containing adenine and cytosine oligonucleotides. 
This would imply that it is hypothetically possible for HNP1 to bind to DNA within 
cells. In all images of HNP1 staining within HMDMs, no evidence suggested that 
HNP1 accumulated within the nucleus and bound to DNA. In fact in the majority of 
images, HNP1 staining was minimal in the areas of DAPI-stained nuclei. Studies 
measuring the sizes of nuclear pore complex (NPC) were shown to be 
phylogenetically conserved at ~45Å (4.5nm)
169
, and demonstrated that 
macromolecules under 40kDa are able to passively diffuse into the nucleus
170
. Thus 
diffusion of the ~5kDa HNP though the NPC within HMDMs was theoretically 
plausible if unhindered by interactions with other organelles. In addition, the Triton 
X-100 detergent used in this assay to permeabilize cellular membranes was 
previously shown to permit the diffusion of anti-DNA immunoglobulins (IgG) 
binding to DNA in HeLa cells
171
, suggesting that it was possible to immunostain for 
HNP1 if it were present in the nucleus. In light of this information, this could 
indicate that HNP1 migrates no further than the endoplasmic reticulum surrounding 
the nucleus, and as result is more likely to interfere with translation machinery 
containing RNA and less likely to bind to DNA and prevent transcription. This is 
supported by the evidence in Chapter 3 that initial gene upregulation of TNF-α 
mRNA appears unaffected, even in HMDMs pretreated with α-defensins 1hr and 
24hrs prior to stimulation. 
 
The confocal data gave a weak initial suggestion of HNP1/rps20 aggregate formation 
in HMDMs, particularly after 24hrs treatment. This result suggested an indication 




restrictions on the remaining research period, considerations turned to performing 
validation experiments in order to provide greater evidence of a confirmed binding 
event. Two approaches were taken to address this question: immunoprecipitation of 
the complex and secondly sucrose density ultracentrifugation to isolate ribosomes in 
an attempt to detect HNP1 by Western Blotting. Both assays were unable to 














Figure 6.5 (continued) 
(A) Confocal microscopy images of HMDMs immunostained for DAPI, HNP1-3 and 
rps20 (in columns). Results are of HMDMs treated with 12.5µg/mL HNP1 for 4hrs 
along with untreated cells (n=3). Treatments are labelled left of the images in rows.  
Yellow and purple arrows indicate areas of suggested co-localisation with yellow 
arrows indicating suggested areas of aggregate formation. Controls were included 
for: HNP1-3 staining in untreated cells, non-specific fluorescence of both secondary 
antibodies in cells not stained with primary antibodies, and non-specific 
autofluorescence in unstained cells (with DAPI). 
 
(B) In the dual-antibody incubation system employed, an added validation control 
was included in HNP1-treated HMDMs for both secondary antibodies to control for 
specific binding to primary antibody targets (n=1). (i) Cells incubated with 
monoclonal mouse anti-HNP1-3 primary antibody followed by incubation with goat 
anti-rabbit Alexa Fluor 647 secondary antibody. (ii) Cells incubated with polyclonal 
rabbit anti-rps20 primary antibody followed by incubation with goat anti-mouse 















Figure 6.6 (continued) 
(A) Confocal microscopy images of HMDMs immunostained for DAPI, HNP1-3 and 
rps20. Results are of HMDMs treated with 25µg/mL HNP1 or W26A for 24hrs 
alongside untreated controls (n=2). Yellow and purple arrows indicate areas of 
suggested co-localisation with yellow indicating possible areas of aggregates 
formation. 
(B) F-actin staining in HMDMs using rhodamine phalloidin alongside HNP1-3 and 















Figure 6.7: Quantitative image analysis of HNP1 and rps20 in HMDMs 
Pearson correlation coefficient calculated from confocal microscopy images of 
HNP1 or W26A co-localisation to rsp20 in HMDMs treated with 12.5µg/mL peptide. 
Correlation was calculated from images obtained from 4hr and 24hr treatments. 
Results are of the mean ± SD from a single experiment, with a student’s t-test 











6.2.3 Assessing the fate of HNP1-associated ribosomes 
Although weakly identified to date, the decision was to pursue with the suggestion of 
HNP1/ribosomes associations within the cytoplasm. These complexes tended to be 
located on periphery of the immediate condensed regions of ribosome expression, 
suggesting complexes that were possibly being removed from the immediate rps20-
rich area. The fate of these complexes was questioned and whether they were either 
being degraded within the cell or even possibly destined for extrusion. By 
determining a possible loss of functioning ribosomes, this could be contributing to 
the decrease in translation rates due to less numbers of functioning ribosomes 
available. The possibility of a degradation of the rps20-containing complex was 
addressed, examining the most common form of macromolecule degradation within a 
cell, autophagy. 
 
6.2.3.1 Autophagy-mediated ribosome clearance was undetermined in 
HNP1 treated HMDMs 
As introduced in Chapter 1, expression of microtubule-associated protein light chain 
3, homolog B (LC3B) is one of the most common parameters measured for 
autophagy induction in mammalian cells. LC3B induction is routinely qualitatively 
assessed by immunofluorescence, characterised by distinct puncta within the 
cytoplasm. Alternatively LC3B-I to –II conversion is analysed by Western blotting, 
with autophagy induction characterised by the increased expression of the ~14kDa 
LC3B-II relative to the ~16kDa LC3B-I
172
. It is thought that although PE-conjugated 
LC3B-II is heavier, it migrates faster during SDS-PAGE due to its extreme 
hydrophobicity. Both forms of assays characterising LC3B expression were 
attempted in HNP1 treated HMDMs. 
 
Immunofluorescent analysis of LC3B 
Confocal microscopy assays attempted to detect the expression of LC3B relative to 
suggested HNP1 and rps20 complexes over a 72hr period. However, erroneous 
selection and application of mouse anti-LC3B antibody meant it was not possible to 
co-represent this expression with that of HNP1 (alongside rps20), since HNP1 
primary antibody was also derived from mice. Of the immunofluorescence results 




minimal existence of co-localisation between the two stains (Figure 6.8). It is worth 
mentioning at this point that all HMDMs were treated with bafilomycin A1 (Baf) 
4hrs prior to fixation and immunofluorescence staining. This compound was 
included to prevent the completion of the autophagic flux pathway, specifically at the 
point of autophagosome fusion with lysosomes. This was required to accumulate 
autophagosomes in order to make visual comparisons between expressions in test 
treatments compared to basal level expression seen in untreated cells. Yellow arrows 
within the images showed the suggestion of LC3B-rps20 associations in HNP1 
treated cells, but without the ability to assess the relative expression of HNP1, this 
observation could be attributed to normal ribosome turnover (termed ribophagy). In 
addition, using the second row as an overall representation the experimental results, 
the occurrence of LC3B-rsp20 proximity in a single cell of five in total suggested 
that this was an uncommon phenomenon. W26A treated HMDMs were compared 
which showed no signs of LC3B-rps20 accumulation. 
 
As a positive control for autophagy induction, control cells were treated with 
rapamycin, an inhibitor of the protein kinase mTOR (mammalian target of 
rapamycin) and mTORC1-mediated pathway which blocks autophagy whilst also 
mediating protein synthesis and cell metabolism amongst other responses
173
. Positive 
results saw rapamycin with bafilomycin-treated HMDMs display distinctive puncta 
associated with autophagy induction, which was not seen in either HNP1 or W26A 
treated cells. In order to gain more conclusive results, completion of these 
experiments would need to be repeated with validated antibodies used at various time 
intervals over 72hrs in order to confidently address whether suggested HNP1/rps20 













Confocal microscopy images of HMDMs immunostained for ribosomal protein S20 
(red), LC3B (green) and DAPI (blue). 
Results are of HMDMs treated with 12.5µg/mL HNP1, W26A or 25µg/mL 
rapamycin (Rap) in the presence of 50nM bafilomycin A1 (Baf). Yellow arrows 






LC3B-I and –II expression by Western blotting  
Analysis of LC3B conversion by Western blotting is considered a more stringent 
assay to measure autophagy. As a result of the unsuccessful attempts using 
immunocytochemistry, analysis of autophagy induction in HMDMs was further 
tested by Western blotting. 
 
Most cell culture experiments to date were performed in culture media without serum 
to avoid the neutralisation of HNP1. Conscious of the fact that serum starvation is 
known to contribute to autophagy induction; it was decided to keep HMDM serum 
starvation to a minimum while still allowing for HNP1 to exert its inhibitory effect. 
To circumvent this dilemma, a single validation experiment was performed where 
R848-stimulated HMDMs were incubated with HNP1 for 2hrs prior to the addition 
of donor serum (Figure 6.9). After 18hrs incubation, TNF-α ELISA was performed 
on the supernatants which confirmed that 2hrs was an adequate incubation period in 
order for HNP1 to establish its inhibitory actions. Subsequent treatments in 
autophagy-related experiments were set up in this manner.  
 
Experiments were set up to treat HMDMs with 12.5μg/mL HNP1 and W26A for 4hr 
and 24hr incubations alongside untreated controls, as well as rapamycin (Rap) 
treatment as a positive control for autophagy induction. Each experiment contained 
two sets of treatments: one set for the addition of bafilomycin 4hrs prior to cell lysis 
and another set without bafilomycin addition. According to Mizushima and 
Yoshimori (2007)
172
, a positive indication for increased autophagy degradation is 
measured by the LC3B-I to –II conversion within each sample, indicated by an 
increased LC3B-II expression relative to LC3B-I. In addition, increased LC3B-II 
protein band expression in bafilomycin-treated cells should be more pronounced 
relative to LC3B-II expression in bafilomycin-untreated equivalent samples. This is 
considered to be a robust distinction between positive autophagy degradation over a 
mere treatment-induced accumulation of autophagosomes due to a defect in 
autophagic flux completion. 
Using this assessment criterion, the induction of autophagy was firstly assessed at 




separation of the two LC3B forms made it difficult to confidently interpret the 
autophagy expression profiles. Judging by the partial LC3B-II band expression in 
untreated cells without bafilomycin, already there was an indication of converted 
LC3B-II expression relative to LC3B-I. Both HNP1 and W26A treated with 
bafilomycin showed an increase in L3CB-II expression relative to their bafilomycin-
untreated equivalents. This was in addition to showing larger LC3B-II expression 
over LC3B-I. This meant that both HNP1 and W26A were indicating early signs of 
autophagy degradation. This expression appeared similar to that of rapamycin (with 
bafilomycin) treated control samples as well as serum starved N2A cell lysates, 
which were included by the LC3B antibody supplier as a positive control for 
autophagy induction. β-Actin loading controls remained similar during all 
treatments, thus validating the differences in LC3B expression observed. 
Of the three repeat experiments, Figure 6.10B was possibly the clearest result, albeit 
with limited information regarding the rapamycin-bafilomycin positive induction of 
autophagy. Results showed that LC3B-II expression was profoundly expressed in 
untreated, HNP1 and W26A samples treated with bafilomycin relative to their 
bafilomycin-untreated controls. Since untreated controls indicated autophagy 
degradation, this suggested that HMDMs were at the time undergoing autophagy 
under these given experimental conditions. Speculation was that the 2hr serum 
starvation might have induced this induction which was still ongoing at the time of 
treatments, thus obscuring the effect of HNP1 (if any) relative to W26A. The third 
repeat experiment in Figure 6.10C confirmed this trend, with LC3B-II notably 
increased in all treatments containing bafilomycin relative to treatments without 
bafilomycin. Assessment of autophagy at 4hrs was possibly too soon following the 
period of serum starvation. 
 
At 24hrs and in two repeat experiments, the substantial expression of LC3B-II in all 
treatments regardless of bafilomycin addition supported the evidence that HMDMs 
prepared in this manner were inadequate for the studies on hypothesised HNP1-
induced autophagy (Figure 6.11). In these cells, it could not be assessed if the actions 
of HNP1 caused ribosome degradation via the autophagy pathway. Going forward, 




with minimal baseline levels of autophagy and where the inhibitory actions of HNP1 
on translation have been validated.  
One final assessment was performed on these samples to qualitatively analyse if 
there was a noticeable change in the expression of ribosomes by Western blotting for 
rps20 at 4hrs, 24hrs and 48hrs (Figure 6.12). Results from two repeats showed no 
apparent decrease in rps20 expression with HNP1 compared to untreated and W26A 
control samples. There was also no difference in rps20 expression compared to 
bafilomycin-treated HNP1 samples, where autophagic flux (and hence ribosome 
degradation) was supposedly prevented.  
 
This apparent lack of ribosome clearance was confirmed in semi-quantitative 
fluorescent analysis of rps20 by confocal microscopy (Figure 6.13). The images 
obtained from confocal microscopy, which were used previously to measure the 
degree of Pearson correlation between HNP1 and rps20 (section 6.2.2, above), were 
used to quantitate the expression of rps20 in HNP1, W26A and untreated cells after 
24hrs incubation. Ten random field images were taken of each treatment with no 
adjustments made to the settings of the microscope between slides. Areas of rps20 
were defined within cells and the integrated pixel density was determined and 
corrected for the background intensity of the image (termed the Corrected Total Cell 
Fluorescence, detailed in Chapter 2, section 2.8.1.1) as previously published
121
. No 
statistical difference existed for the fluorescence of rps20 in HNP1 treated HMDMs 
after 24hrs compared to W26A and untreated controls.  
 
Thus in using two standard laboratory techniques available, no evidence could show 
a decrease in the amount of ribosomes over 24hrs with HNP1 treatment. Currently it 
remains unclear what the fate is of the possible HNP1/rps20 complexes and is a point 










Figure 6.9: TNF-α ELISA of HNP1 treated HMDMs with serum addition 
Quantitated TNF-α at 18hrs following R848-stimulated HMDMs alone or with 
12.5µg/mL HNP1. White bars depict samples where 10% (final volume) donor 
serum was added to culture after 2hrs following treatment, while black bars represent 
samples that were serum-starved throughout the 18hr incubation period. Treatments 












Figure 6.10: LC3B expression in HNP1-treated HMDMs at 4hrs 
Western blot results for LC3B-I and –II expression in HMDMs treated with 
12.5µg/mL HNP1, W26A or 20µg/mL rapamycin (Rap) alone or with 50nM 
bafilomycin A1 (Baf). Untreated controls were included as a negative control while 
serum-starved N2A cell line lysates were included as a positive induction of 
autophagy. Samples from first repeat (A) were electrophoresed by 12% SDS-PAGE 
while second and third repeat (B and C) were resolved by 15% SDS-PAGE (all 
home-made). β-actin detection was included as a sample loading control. Experiment 









Figure 6.11: LC3B expression in HNP1-treated HMDMs at 24hrs 
Western blot results for LC3B-I and –II expression in HMDMs treated with 
12.5µg/mL HNP1, W26A or 20µg/mL rapamycin (Rap) alone or with 50nM 
bafilomycin A1 (Baf). Untreated controls were included as a negative control while 
serum-starved N2A cell line lysates were included as a positive control for 
autophagy induction. Electrophoresis was performed by 15% SDS-PAGE using 
home-made gels from two independent experiments (A and B). β-actin detection was 







Figure 6.12: Rps20 expression in HNP1-treated HMDMs over 48hrs 
Western blot results for ribosomal protein S20 in HMDMs treated with 12.5µg/mL 
HNP1, W26A or 20µg/mL rapamycin (Rap) alone or with 50nM bafilomycin A1 
(Baf). Untreated controls were included as a negative control. Electrophoresis was 
performed by 15% SDS-PAGE using home-made gels from two independent 
experiments (A and B). β-actin detection was included as a sample loading control. 









Figure 6.13: Quantitative image analysis of rps20 in HMDMs 
Rsp20 corrected total cell fluorescence (CTCF) in HNP1 and W26A treated HMDMs 
at 24hrs compared to untreated controls, as described in Chapter 2 (2.8.1.1). Results 
are the mean ± SEM from 10 images per treatment from a single experiment. 












6.2.3.2 Evidence that ribosomes in HNP1 treated HMDMs may exist as 
heavy complexes in pelleted fractions  
The last set of data attempting to determine the fate of ribosomes in HNP1-treated 
HMDMs was based again on the weakly identified rps20 aggregate formation within 
confocal microscopy images. These aggregates tended to be unusually large in size, 
using the stained nucleus as a reference organelle. It was questioned that these 
aggregates were large enough to be pelleted out along with other large organelles 
conventionally removed by bench-top centrifugation prior to subsequent applications 
such as for Western blotting or polysome analysis. General protocols describe 
performing centrifugation below speeds of 15 000 × g following cell lysis in order to 
pellet nuclei, cellular membranes, mitochondria, lysosomes and peroxisomes. This is 
normally performed to minimize complications with sample loading and migration 
during electrophoresis, for example. Since these suggested rps20-containing 
aggregates were approximately a quarter the size of DAPI-stained nuclei, it was 
wondered if these aggregates would pellet out using bench-top centrifugation speeds 
and if it was possible to quantitate this. 
 
Using an adaptation of the method as performed for polysome analysis; HMDMs 
were treated for 6hrs with 25μg/mL HNP1 and compared to untreated samples. Cells 
were then incubated with 150μg/mL cycloheximide for 30min prior to lysis in the 
same polysome lysis buffer used before, which acts to stabilise translating complexes 
including preventing polysome run-off. Samples were then centrifuged for 10 000 × 
g for 10min after which supernatant and pellets were separated followed by RNA 
extraction. Samples were then resolved by non-denaturing gel electrophoresis and 
stained for RNA (Figure 6.14). Although only performed once, semi-quantitative 
analysis of both 28S and 18S rRNA (quantitated area highlighted in blue and red 
bars, respectively) revealed an increase in the amount of rRNA material in the 
pelleted fractions relative to rRNA in supernatants in HNP1-treated HMDMs. 
Comparisons in the percentage difference between HNP1-treated and untreated 
HMDMs showed a +8.4% increase in quantitated 28S rRNA and +16.2% increase in 
quantitated 18S rRNA with HNP1 treatment. It is appreciated that this was a single 
observation, which requires repeating in order to make a more convincing argument. 




somewhat of a positive indication for the overall hypothesis which can be addressed 
in future using more rigorous testing methods. 
 
A slight modification was made to this experiment, this time treating HMDMs with 
12.5μg/mL HNP1 or W26A alongside untreated controls for 2hrs and 24hrs prior to 
incubation with cycloheximide and subsequent cell lysis. A two-tier centrifugation 
process was performed; firstly centrifuging lysates at 700 × g (10min) to pellet and 
collect the heaviest cellular organelles e.g. nuclei (labelled ‘pellet A’), followed by 
remaining supernatant centrifugation at 15 000 × g (5min) to pellet medium-sized 
cellular organelles e.g. mitochondria and lysosomes (‘pellet B’). Supernatants 
(‘supe’) were removed from Pellet B and all three fractions underwent RNA 
extraction and subsequent non-denaturing gel electrophoresis (Figure 6.15). 
Semi-quantitation of the 28S and 18S rRNA bands at 2hrs revealed no difference in 
the rRNA expression in HNP1 treated HMDMs compared to W26A and untreated 
cells (Figure 6.15A). Expression of rRNA confirmed that most rRNA (hence 
ribosomes) was still retained within the supernatants (‘supe’), with relative rRNA 
expression reduced by ~70% in ‘pellet B’ fractions, and by ~85% in ‘pellet A’.  
The change in this trend occurred in HNP1-treated HMDMs at 24hrs (Figure 6.15B). 
These fractions showed that there was an apparent reversal in the semi-quantitated 
amount of both 28S and 18S in the heavier ‘pellet A’ compared to ‘pellet B’. Again 
appreciating the limitations of this experiment; it at least agreed with the trend 
observed in the previous result which suggests that rRNA, possibly implying 
ribosomes, form heavy aggregates in the presence of HNP1, which are fractionated 
out using low-speed centrifugation. This was an early indication of this phenomenon 
which does require thorough testing since it could be useful in building towards the 
overall hypothesis. If future experiments could confirm these preliminary findings, it 
could modify the hypothesis to suggest that: through the mechanism of binding with 
rRNA within ribosomes and possibly resulting in aggregate formation, HNP1 
reduces global translation in inflammatory macrophages, contributing towards the 










Figure 6.14: rRNA semi-quantitation of HNP1-treated HMDMs 
Results of 28S and 18S rRNA band semi-quantitation for experiment performed as if 
for polysome analysis, where HMDMs were treated for 6hrs with either 25µg/mL 
HNP1 or left untreated prior to cycloheximide treatment and lysis. Samples were 
centrifuged (10 000 × g, 10min) followed by the separation of supernatant and pellet 
fractions after which RNA extraction was performed (n=1). 
(A) Extracted RNA from fractions were electrophoresed in a non-denaturing agarose 
gel. 
(B) Band semi-quantitation of rRNA from pelleted fractions normalised to rRNA 








Figure 6.15: HMDM rRNA semi-quantitation of lysate fractions 
separated by centrifugation 
Results of 28S and 18S rRNA band semi-quantitation for experiment performed as if 
for polysome analysis, where HMDMs were treated with 12.5µg/mL HNP1 or 
W26A alongside untreated control for 2hrs (A) or 24hrs (B, overleaf). RNA was 
extracted from collected fractions following cell lysate centrifugation at 700 × g, 
10min (‘Pellet A’) and after 15 000 × g, 5min (‘Pellet B’). rRNA in pelleted fractions 






Figure 6.15 (continued) 
(B) 28S and 18S rRNA band semi-quantitation of HMDMs treated with 12.5µg/mL 







Evidence has been presented in this thesis which proposes a binding interaction 
between HNP1 and nucleic acids. Not only was this binding effect evident in short 
oligonucleotide sequences, but also on larger RNA complexes such as 28S and 18S 
rRNA, and also mRNA. Since all forms of RNA material tested so far have displayed 
an electrophoretic shift with HNP1 treatment, it implies that sequence selectivity is 
not required to facilitate HNP1 binding. While the wild-type peptide has repeatedly 
confirmed this binding interaction, mutant forms thereof (W26A and LHNP1) have 
demonstrated a much diminished binding affinity towards RNA.  
 
Just how the binding interactions initiate and develop remains unknown and would 
require more advanced methods of computational biology and bioinformatics to 
decipher. Given the cationicity of HNP1 in the form of four arginine amino acids, it 
could be suggested that early electrostatic interactions initiate this attraction for 
RNA. However, this relatively weak force is most likely insufficient to sustain 
interaction since arginine amino acids are conserved in the mutant peptide forms. In 
support of this, Zou et al. (2007)
174
 showed a deleterious effect on HNP1’s ability to 
kill Staphylococcus aureus and E.coli by merely substituting arginine amino acids 
for similarly positively charged lysines. Furthermore, having a positive net charge 
does not directly infer good RNA binding. This is demonstrated by comparing the 
net charge of HNP1 (+3) to Buforin II (+6) which binds RNA tightly versus 
Magainin 2 which does not (+4)
124
. It is interesting to note that nucleic acid binding 
peptides do not share structural homology either. α-Defensins fall under the β-sheet 
peptide category, while Buforin II is characterised by α-helices. A DNA binding 
peptide Indolicidin, which has similar binding affinities to that of α-defensins and 
Buforin II, fall under the category as having extended peptide structures dominated 
by a proline and tryptophan amino acids
175
. This is possibly where the 
amphipathicity of a peptide is critical for association with nucleic acids.  
There is evidence in Indolicidin interactions with DNA that suggest that the 
proximity of polarised nucleic acids brings about conformational changes to 
tryptophan amino acids
155
. It suggests that the altered polarity around non-polar 




peptide/nucleic acid interactions. This is further supported by data within this thesis 
that HNP1 lacking its tryptophan amino acid (W26A) showed a severely diminished 
RNA binding potential. Furthermore, all three nucleic acid-binding peptides contain 
arginine amino acids while Magainin 2 does not. Since arginine has previously been 
shown to be important in mediating HIV-Tat protein binding to RNA
176
, these 
collective publications suggests that altered tryptophan conformation brought about 
by polar RNA might increase the capacity for arginine residues to mediate RNA 
binding. This evidence provides preliminary insight into HNP1 interactions with 
RNA and could be further addressed using similar methods to those employed for 
Indolicidin-DNA binding interactions.  
 
Based on the evidence presented to date, it is conceivable to suggest a binding 
mechanism in which strands of RNA in this system are laced with HNP1 peptides. 
This could possibly have led to an increased molecular weight which impeded 
electrophoretic migration suggested in both 28S and 18S rRNA. Also, it could 
account for the strong inhibition of migrated oligonucleotides, suggested by the 
accumulation of complexes at the top of the loading well apparently too large to 
transition into the gel. Not only could free monomers be contributing to the 
expanding complex, but also by RNA-bound HNP1 perhaps forming links with 
HNP1 bound to neighbouring RNA strands.  
 
It is this biochemical binding property which formed the basis for the hypothesis of 
binding with ribosomes, contributing to the inhibition of translation. The keyword in 
the preceding statement is contributing, as it is appreciated (but as yet untested) that 
translation could also be inhibited by HNP1 binding to mRNA, or even tRNA-
containing amino acids. Binding interactions would clearly need to be examined on a 
more detailed level in all of these RNA-containing components under physiological 
conditions in order to support this property of HNP1. Confocal microscopic data 
provided as-yet unconvincing suggestions of HNP1 interaction with ribosomes. 
Evidence at 4hrs suggested that HNP1 tended to concentrate in areas of translation 
activity, signified by the presence of rps20 within the perinuclear region where the 




centralises around the endoplasmic reticulum. HNP1 has a well described affinity for 
membranes. Since the endoplasmic reticulum is an intracellular membranous 
structure; the ER could serve as a ‘docking station’, which could account for the high 
peptide concentration observed. It is in this area of concentrated ribosomes and 
HNP1 where hypothetical associations between the two could be allowed to interact. 
The weakly apparent HNP1/rps20 accumulations formed at 24hrs are however 
similar to the aggregates located at the top of the wells in the EMSA experiments, 
but this remains to be determined. If this hypothesis of ribosome binding is supported 
by further data, it is clear that this phenomenon could impair large amounts of 
ribosomes, decreasing the amount of free ribosomes available for translation. 
Already preliminary data has suggested an increase in the amount of sedimented 
rRNA with HNP1 at low centrifugation speeds. This result does support evidence of 
aggregated ribosomes, but more reliable experiments could be used in future to 
confirm this finding. An example of a more robust co-localisation techniques that 
could be utilized include FRET (Fluorescence Resonance Energy Transfer)
177
. In this 
method, interactions between two suspected protein partners are labelled with 
fluorescent molecules (donor and acceptor fluorophores). FRET can be quantitated 
within live cells in vivo by stimulating the acceptor fluorophore at an appropriate 
excitation wavelength. The emitted fluorescence intensities are measured at the 
wavelengths corresponding to the emission peaks of the donor compared to that of 
the acceptor. When the donor and acceptor fluorophores are within close proximity- 
due to the interaction of the two proteins (1-10nm) - emission spectra of the acceptor 
is predominantly observed, which is due to the intermolecular energy transfer 
(FRET) from the donor to the acceptor. 
 
What the fate is of these suggested HNP1/rps20 structures is currently unknown. 
They did appear to be located on the outer periphery of the perinuclear region. Future 
experiments could assess whether these accumulations are cleared by 72hrs; for this 
would tie in with the published data that showed that TNF-α production was regained 
in stimulated HMDMs after 72hrs following HNP1 treatment
87
. Experiments were 
conducted to determine if autophagy was induced in order to clear these proposed 




HMDMs used meant it was not possible to answer this question at present. This valid 
question does require further testing, possibly in alternative cell types which do not 
display pre-existing elevated levels of LC3B-II expression. Interestingly, LC3B 
expression by Western blotting indicated that the HMDMs prepared for 
experimentation were naturally undergoing autophagy. This was evident even in 
HMDMs that were serum-starved for 2hrs to facilitate the effects of HNP1. This 
implied that the inhibitory effects of α-defensin were functionally independent of the 
activated autophagic pathways within the cell. This finding has possible implications 
in vivo, especially in nutrient-depleted cells that are undergoing autophagy. Not only 
then are concentrated areas of neutrophil death at sites of tissue injury impervious to 
the presence of macromolecules within serum which could bind α-defensins (e.g. 
albumin)
50
, but α-defensins are able to mediate their inhibitory functions on these 
nutrient-starved cells. 
 
Interestingly, autophagy is implicated in the clearance of polyubiquitinated protein 
aggregates which accumulate either in situations of routine protein clearance or 
under circumstances of stress, aging, and disease owing to damaged or misfolded 
proteins. This form of macroautophagy, known as aggrephagy, might well be a 
mechanism employed by the HMDMs and ubiquitin tagging of these HNP1/rps20 




Lastly, it was surprising to find no evidence of decreased rsp20 by either quantitative 
confocal image analysis or reduced rps20 protein expression by Western blotting. If 
there is future evidence supporting HNP1/ribosome aggregate formation, it would 
suggest that this did not lead to the clearance of HNP1-bound ribosomes to the extent 
that ribosome numbers were noticeably reduced within the given timeframe of 
HNP1-mediated inhibition (i.e. within 24hrs). Given that de novo protein synthesis 
(Chapter 4) resulted in an attenuation of intracellular proteins within 24hrs, it is 
currently unknown if ribosome biogenesis was affected and, if it was, at what point 








7 Conclusions and future work 
The work described in this thesis set out to extend the current understanding of the 
inhibitory actions of α-defensins on pro-inflammatory macrophages. Previously 
published data showed for the first time that α-defensins are released from dying 
human neutrophils and inhibit the secretion of cytokines from inflammatory 
macrophages
87
. The inhibitory mechanism by which cytokines were attenuated 
remained largely unknown and this thesis provides the first definitive insight into 
how this inhibition is achieved. The focus areas of research within the cell and the 
techniques used are summarised in Figure 7.1. 
 
 
Figure 7.1: Summary of the intracellular research conducted that was 
potentially affected by α-defensins 
The figure presents an overview of the main areas of cell biology that were 




the cellular recognition of PAMPs and DAMPs by PRR receptors (1) that activate 
signalling pathways and transcription factors (2), subsequent mRNA expression of 
inflammatory factors (e.g. TNF-α) (3), protein synthesis (4), protein folding and 
translocation (5) and finally cytokine secretion (6). Areas of research interest along 
the cellular pathway are indicated by green ticks where appropriate, along with the 
technique performed and the anti-inflammatory agent used (HNP1 or NN). 
 
 
The inhibitory effect of membrane-free necrotic human neutrophil supernatants (NN) 
on secreted cytokines TNF-α, IL-6, IL-8 and IL-10 recapitulated the observations 
made in Miles et al. (2009) using TLR7/8 stimulated HMDMs (Chapter 3). Since the 
inhibitory effects of α-defensins were observed in HMDMs stimulated with either a 
TLR7/8 agonist or CD40L and IFN-γ, it so far suggests an inhibitory mechanism that 
is independent of the pattern recognition receptor (PRR) activated, subsequent signal 
transduction and transcription factor activation. α-Defensins were also shown to 
inhibit LPS and SAC activation of HMDMs, but this is more likely attributed to the 
known lectin-like properties of α-defensins which has been shown to block binding 
of LPS to LPS binding protein (LBP) required for CD14 receptor activation
50,179
. 
TNF-α and IL-10 mRNA expression in α-defensin treated HMDMs supported the 
evidence that signalling pathways remained unaffected, since initial upregulation of 
gene transcription of both cytokines were similar in magnitude to agonist-stimulated 
alone control cells. Beyond initial expression IL-10 mRNA was unaffected in two 
experiments using both NN and HNP1 while secreted protein was noticeably 
attenuated within 24hrs of treatment. For TNF-α mRNA expression, minor variations 
in expression between HMDM donors tested with α-defensins could not account for 
the consistent inhibition of secreted TNF-α observed. The same could be said for the 
mRNA decay rates of TNF-α in the two experiments performed. Arguments that 
another inhibitory factor was driving cytokine attenuation were more convincing. 
Notably, the unaffected mRNA levels of IL-10 while secreted IL-10 was notably 
reduced, together with the inhibition of de novo secreted proteins regardless of 




inhibitory mechanism within the cell was the major contributing factor as opposed to 




S-methionine during protein synthesis in HNP1-treated HMDMs 
was the first experiment linking the inhibitory mechanism of HNP1 to effects on 
translation (Chapter 4). This inhibitory effect, independent of cell stimulation, 
demonstrated that both secreted and intracellular protein synthesis was affected with 
the former showing a greater degree of inhibition within 24hrs. It is unclear at 
present as to how secreted proteins would be further inhibited over intracellular 
proteins and requires further testing. Confocal images of HNP1 localisation within 
HMDMs suggested concentrated areas where ribosomes were situated, which is in 
close proximity to the endoplasmic reticulum. It may be that the inhibitory action of 
HNP1 includes preventing ribosome attachment to the ER, thus reducing the number 
of polypeptides being assembled within the ER lumen destined for secretion. Based 
on ER stress data, the hypothesis was ruled out suggesting that HNP1 within cells 
caused a regulatory shutdown of translation due to misfolded proteins brought on by 
an imbalance of cytoplasmic calcium. Although HNP1 greatly impacted calcium 
mobilisation within the cell within 24hrs, this imbalance did not result in an ER 
stress event, with no apparent activation of the Unfolded Protein Response (UPR) 
pathway. Since the ER stress data implied no impairment at the stage of protein 
folding, it did lead to the thought that the mechanism was possibly occurring prior to 
this stage in translation, and is further supported in literature showing no halt in 




The most powerful and unambiguous evidence presented within this thesis was the 
inhibitory impact of HNP1 on in vitro translation (Chapter 5). In a pure translation 
system, this assay was able to show the significant inhibition of both cap-dependent 
and cap-independent (IRES-mediated) mRNA translation. With this information, it 
became more evident that the inhibitory actions were mediated by a direct 
impairment of the translation machinery. Since the comparatively simpler form of 
cap-independent mRNA translation was also affected (but to a lesser extent), it raises 




assembly with ribosomes. This mechanical interference with mRNA-ribosome 
assembly may be further hindered in cap-dependent translation, given the added 
complexity of the requirement for initiation factor recruitment to form the translation 
initiation complex. This could explain the differences in percentages of inhibition 
between cap-dependent and cap-independent reduction observed. This proposed 
model of mechanistic interaction would require extensive investigation, but it is also 
appreciated that this result does not give any insight into the effects of HNP1 on 
polypeptide chain elongation and chain termination. With that said, the process of 
initiation is by far the most complex stage in translation. It is the stage where 
absolute fidelity of message to be translated is required. It thus serves as pivotal point 
in translation regulation and also acts as the rate-limiting step. It is difficult not to 
concede that, if there was a point where HNP1 would likely impact the process of 
translation, it would be within the intricacies of initiation. The technique of polysome 
analysis was employed in HNP1-treated HMDMs in an attempt to uncover such 
details of translation inhibition. It was anticipated that polysome analysis could 
provide this detailed level of information into the impact effect of HNP1 on 
translating ribosomes. Polysome analysis was able to offer limited insight using 
HMDMs with a decrease in translation-inactive RNA material observed in a single 
observation. Since this assay became fully optimised at the latter stages of the 
research period, further experiments on polysome distribution are worthwhile 
continuing and may provide key answers into the mechanisms involved.  
 
The hypothesis of HNP1 binding to RNA was formulated on the basis that published 
literature provided evidence of antimicrobial peptide binding to RNA/DNA. 
Exploring this concept using HNP1 binding to HMDM RNA in EMSAs showed an 
affinity similar to that of Buforin II and Indolicidin. Both these antimicrobial 
peptides are known to bind nucleic acids tightly, which is implicated in their 
mechanistic killing of bacteria independent of membrane permeabilisation leading to 
cell death. These cationic peptides share no similarities in charge or structure, but all 
possess arginine residues. Since arginine residues are implicated in mediating the 
binding with nucleic acids
176
, this provides the first clue along with the observation 




to polarised nucleic acids, seen with Indolicidin
155
. Since evidence within this thesis 
showed RNA binding with W26A (lacking tryptophan) was lacking, it would be 
interesting to determine if the presence of RNA alters tryptophan conformation 
within HNP1, thus exposing arginine amino acids to mediate RNA binding.  
 
More extensive studies using EMSAs revealed that HNP1 binding was not dependent 
on sequence specificity as it non-selectively bound with similar affinity to 
oligonucleotide sequences of adenine, cytosine and uracil. It remains to be shown if 
the apparent increased affinity of HNP1 for uracil would be demonstrated in a 
competitive binding environment. What is apparent is that the mechanism of binding 
to these oligonucleotides was complex to the point that these complexes remained 
within the loading wells, evidently too large to migrate into acrylamide gels. These 
observations provided the first evidence in the literature for suggested HNP1-RNA 
aggregation, potentially mediated by the property of HNP1 dimerization. 
 
Together with evidence of retarded migration of HMDM 28S and 18S rRNA 
retardation with HNP1 during EMSAs, a hypothesis was formulated that the 
inhibitory mechanism of HNP1 is mediated through direct association with RNA-
containing components involved in translation. So far, evidence suggests that it could 
potentially not only bind to rRNA within ribosomes but also mRNA, although 
binding to the latter remains to be tested within cells (Chapter 6). 
Immunofluorescence within HMDMs was able to indicate the concentrated 
localisation of HNP1 around the perinuclear region, which are the sites of active 
ribosome activity as indicated by rps20 protein that forms part of the 40S ribosomal 
subunit. This further supported the hypothesis of RNA binding interactions given the 
densely populated localisation of both rps20 and HNP1. Within 4hrs of HNP1 
treatment, confocal microscopy suggested few yet so far unconvincing areas of 
HNP1-rps20 accumulation. By 24hrs confocal images began to show emerging 
evidence of possible HNP1-rps20 accumulation, but it remains unclear as to whether 
this is true co-localisation or areas of fluorescent signal overlap. With further 
supporting evidence, it is thought that these suggested complexes could contain 




Although extrusion of these suggested complexes was not addressed, degradation by 
autophagy was performed with limited success in obtaining a clear indication of this 
process. It remains a valid proposition should the formation of an HNP1-ribosome 
complex be tangible and could be a study to address in future.  
 
An interesting link was made in three key assays performed regarding the 
concentration range of HNP1 and the inhibitory potential. Where titration of HNP1 
was performed, a trend was observed in the minimum HNP1 concentration threshold, 
below which inhibitory activity was noticeably limited. Using EMSAs, it was 
observed that migration of the uridine oligonucleotide became impeded at a 
peptide/RNA ratio of 3.5:1. This was also the concentration at which HNP1 was 
calculated to be 11.3μg/mL. Assessment of the half maximal inhibitory concentration 
(IC50) of HNP1 on cap-dependent translation determined the mean IC50 value to be 
~8.62 ± 3.0μg/mL (n=3). These threshold concentrations were compared to the 
minimum inhibitory concentration affecting TNF-α production in HMDMs. HNP1 at 
12.5μg/mL achieved a trend towards TNF-α inhibition, below which TNF-α 
remained largely unaffected (Chapter 3, section 3.2.2). Thus it brings into question if 
these minimum inhibitory ranges observed in three independent assays are more than 
simply coincidental. It perhaps identified a correlation between the binding to RNA, 
which can account for the inhibition observed in in vitro translation systems as well 
as in de novo protein synthesis in HMDMs, which showed attenuation at 12.5μg/mL 
HNP1. This link may ultimately account for the inhibitory effects of HNP1 observed 
on secreted TNF-α in HMDMs - the action which defines the ultimate purpose of this 
thesis. If this link in concentration can be pinpointed to RNA-binding identified in 
cell-based systems, it proposes an intriguing immunomodulatory role for α-defensins 
at this concentration range.  
 
In the discussion section of Chapter 4 (section 4.3), I introduced an observation made 
on the activity of α-defensins depending on the peptide concentration, which is 
concluded from observations within this thesis as well from previous literature. I 
refer to it as the ‘three tiers of α-defensin modulation’ which proposes that the 




dying neutrophils, depending on the severity of inflammation. This suggests that 
early inflammation brings with it an appropriate number of infiltrating neutrophils 
which assume their conventional antimicrobial, phagocytic and immunoregulatory 
functions. Should the number of invading microbes and severity of inflammation 
overwhelm the capabilities of the leukocytes presently within the tissue, in death, 
neutrophils elicit a rescue response, which includes the release of α-defensins. Since 
lower concentrations of α-defensin have been shown to be pro-inflammatory and 
chemotactic for monocytes and dendritic cells
130,131
 the function of α-defensin at 
lower concentrations, roughly below 1μg/mL, appears to be that of a chemokine and 
cell activator, supporting further leukocyte infiltration and inflammation.  
In states of exacerbated inflammation (e.g. rheumatoid arthritis), the death of 
elevated neutrophil numbers is likely to bring with it the release of an intermediate 
concentration of α-defensins, as previously determined in the synovial fluid of twelve 
rheumatoid arthritis patients where the average HNP1-3 concentration was 
12.4μg/mL
87
. It would appear that the peptide adopts a function of an inflammation 
suppressor by entering macrophages (and possibly other leukocytes) and preventing 
translation of inflammatory mediators, thus limiting their tissue destruction potential. 
The effect at this concentration was first proposed in Miles et al. (2009)
87
 and is now 
supported by new evidence within this thesis.  
Higher concentrations of α-defensin, above 40μg/mL, have been shown to possess 
cytotoxic effects on cells in vitro. These include lung epithelial cells (A549)
180
, 




, as well as eight lymphoma 
cell lines tested by Lichtenstein et al. (1986)
132
. Indeed elevated concentrations of 
HNP1-3 have been reported in the serum of patients with sepsis and bacterial 
meningitis (up to 170μg/mL)
182
, and in the sputum of cystic fibrosis patients (300-
1600μg/mL)
183
. Thus it may be that in cases of severe inflammation the purpose of 
released α-defensins caused by extensive neutrophil death is in the containment of 
opportunistic infections at all costs to the detriment local host tissue. This collateral 
tissue damage by α-defensins may be considered a necessary trade-off as a last resort 





The impact of the primary discoveries within this thesis offers an extrapolation to the 
current knowledge regarding the role of α-defensins in an inflammatory 
environment. Using the chronic inflammatory disorder of rheumatoid arthritis as a 
tangible platform, this research suggests an added factor in the complexity of this 
debilitating disease. It is widely acknowledged that cytokines and chemokines 
secreted by synoviocytes are key contributors to disease progression and 
exacerbation
113,184
. Indeed overexpression of cytokines is present within rheumatoid 
synovium
107
, with TNF-α key in inflammation regulation and a contributor to 
synovial pannus formation and bone and cartilage erosion
114
. Indeed, biological 
inhibitors of TNF-α in combination with Methotrexate have been a first-approach 
anti-inflammatory therapeutic strategy against rheumatoid arthritis disease 
progression
185
. In addition, secreted IL-1β potently amplifies and sustains neutrophil 
recruitment and inflammation
184
. Thus it would appear that α-defensins released 
from tissue areas of large-scale neutrophil death might serve to ameliorate an over 
heightened cycle of synoviocyte activation, cytokine and chemokine secretion, 
leukocyte infiltration, and joint destruction. By potentially blocking protein synthesis 
within synoviocytes, internalized α-defensins may well contribute to the 
immunosuppressive factors limiting a chronic inflammatory event, which is certain 
to result in irreparable cartilage damage if uncontrolled. 
 
Future work 
The central hypothesis proposed in this thesis suggested that the underlying 
mechanistic inhibitory property of α-defensins, which accounts for the anti-
inflammatory effect on HMDMs, is mediated during translation by binding to RNA. 
This may include binding to rRNA within ribosomes but could also include binding 
to other RNA forms, such as mRNA. Data from immunofluorescence analysis has 
unconvincingly (to date) proposed an interaction between HNP and ribosomes within 
HMDMs. Thus in order to further the hypothesis, future work would need to show 
definitive evidence of HNP-ribosome binding, and if possible HNP binding to the 
rRNA portions of ribosomes. Attempts to provide further evidence of this were 
attempted using immunoprecipitation assays as well as immunoblotting for HNP1 in 




C). Although these experiments were unsuccessful, similar approaches could be 
employed to confirm this binding effect (e.g. FRET). If this were proven, it could 
present a novel approach to targeting inflammation regulation. 
 
Importantly, the inhibitory effects of α-defensins were briefly demonstrated on 
HMDMs obtained from clinically diagnosed rheumatoid arthritis patients as well as 
primary B cells (Chapter 3). Not only does this work support a future therapeutic role 
for α-defensins in the treatment of this chronic inflammatory disease but could be 
expanded upon to assess the inhibitory effect on a multitude of cells involved in the 
inflammatory cascade. Notably, it would be interesting to determine if dying 
neutrophils prevent activated neutrophils from releasing pro-inflammatory mediators, 
forming a negative feedback system.  
 
Ultimately the immunomodulatory actions of α-defensins, or synthesised mimetics 
thereof, could go on to be trialled in the treatment of diseases relating to 
inflammation in vivo. Prior mention has been made that delivery of these serum-
sensitive peptides would need to be addressed. Future work could include the 
bioengineering of inactive forms of the encapsulated peptide, perhaps utilizing 
current delivery systems such as liposomes. Upon liposome ingestion by phagocytes, 
the active form of α-defensin would be released to inhibit the activated cell by 
mechanisms suggested within this thesis. It is thought that this could efficaciously 
alleviate localised inflammation, bringing with it a chance for accelerated tissue 








Optimization assays of buffy coat-derived HMDM stimulants 
Continuation of the inhibitory actions of NN on buffy coat HMDMs was performed 
using the agonist CD40L and IFN-γ. HMDMs were treated with titrated NN from a 
single donor together with 3μg/mL CD40L and 5ng/mL IFN- γ (CI) in two 
independent experiments. Observations did show a partial reduction in TNF-α with 
increasing NN percentages, although maximal stimulation remained low in CI 
stimulated cells after 18hrs incubation (Figure A.1A). CI was unable to stimulate 
HMDMs in Figure A.1B as quantitated TNF-α was similar to untreated negative 
control values.  
 
Attempts were made to optimise CI stimulation in buffy coat HMDMs starting with 
increasing the concentration of human IFN-γ in culture with 3μg/mL CD40L (Figure 
A.2A). IFN-γ concentrations ranging from 5, 10, 20 or 50ng/mL did not enhance 
TNF-α values compared to controls where no IFN-γ was added. The addition of 
100ng/mL IFN-γ doubled the amount of quantitated TNF-α to 100pg/mL, but 
remained low compared to previously published amounts using HMDMs obtained 
from fresh blood donations (>500pg/mL). Further experiments were conducted to 
test if the current batch of IFN-γ had expired. The original IFN-γ batch (labelled 
‘IFN-γ batch1’) was compared to a second batch of human IFN-γ (‘IFN-γ batch2’) 
donated by Dr David Kluth (Centre for Inflammation Research, Edinburgh 
University). Using HMDMs from a single buffy coat donor, titrated IFN-γ 
concentrations from either batch were unable to effectively stimulate HMDMs in 
combination with 3μg/mL CD40L to published TNF-α levels (Figure A.2B). 
 
An experiment was performed with increased CD40L concentration (5 and 10μg/mL) 
in an attempt to stimulate buffy coat HMDMs. As a comparison, the same stimulant 
was added to mature THP-1 cells as a potential alternative human macrophage 
source (Figure A.3A and B). Both cell types demonstrated low levels of produced 





Experiments were conducted to test alternative agonists for buffy coat HMDMs and 
THP-1 activation. Staphylococcus aureus Cowan Strain (SAC), the 
amidazoquinoline compound R848 and Peptidoglycan (PGN) were effective at 
stimulating HMDMs at stipulated concentrations (Figure A.4A), with secreted TNF-α 
values >3000pg/mL. Stimulation with 5μM CpG ODN 2006 was not able to induce 
TNF-α production. In THP-1 cells SAC and PGN stimulation effectively resulted in 
increased TNF-α production while LPS (1ng/mL), R848 (5μg/mL) and CpG ODN 
2006 (5μM) showed no effect (Figure A.4B). 
 
The effect of titrated NN was re-introduced into experiments and the inhibitory 
properties of NN were strongly demonstrated in buffy coat HMDMs stimulated with 
5μg/mL R848, with TNF-α values close to near basal control levels (Figure A.5A). 
Although NN concentrations increasingly inhibited TNF-α in THP-1s stimulated 
with R848, TNF-α levels remained relatively low (Figure A.5B). The same 
experiment was applied to 0.1% SAC stimulated cells and the inhibitory effect of 
titrated NN increased with concentration in HMDMs (Figure A.5C). The inhibitory 
effect was also demonstrated with THP-1s, reducing the amount of TNF-α from 
approximately 7000pg/mL in SAC-stimulated alone controls to 4000pg/mL with 













Figure A 1: Secreted TNF-α in CI stimulated buffy coat HMDMs treated 
with NN  
ELISA results obtained from 18hrs incubation in two HMDM donors (A and B) 
stimulated with 3μg/mL CD40L and 5ng/mL IFN-γ alone or together with NN 
obtained from a single donor. Error bars are of the mean ±SD from treatments 










Figure A 2: CD40L stimulation of buffy coat HMDMs with titrated IFN-γ 
Quantitated secreted TNF-α after overnight incubation of HMDMs stimulated with 
3μg/mL CD40L and increasing amounts (ng/mL) of human IFN-γ alongside 
unstimulated negative controls (Nil). Error bars represented the mean ±SD from one 
experiment (A) and repeated using two batches of human IFN-γ (B). All treatments 













Figure A 3: CD40L optimisation for stimulation of buffy coat HMDMs 
and THP-1 cells 
TNF-α ELISA quantitation of buffy coat HMDMs (A) and monocytic THP-1 cells 
(B) stimulated with two concentrations of CD40L with 100ng/mL IFN-γ at 18hrs 
incubation (alongside untreated control). Results represent the mean ±SD of single 












Figure A 4: Response of buffy coat HMDMs and THP-1 cells to a range 
of TLR agonists 
TNF-α values quantified from ELISAs obtained after 18hrs incubation for buffy coat 
HMDMs (A) and THP-1s (B) from a single experiment. Error bars represent the 













Figure A 5: NN effect on buffy coat HMDMs and THP-1 cells stimulated 
with R848 or SAC 
TNF-α quantitation of HMDMs (A) and THP-1 cells (B) stimulated with 5μg/mL 
R848 in the presence of titrated necrotic neutrophils. Stimulation using 0.1% 
Staphylococcus aureus Cowan strain (SAC) was performed in HMDMs (C) and 
THP-1 cells (D). Error bars represent the mean ±SD of single experiments at 18hrs 











Figure B 1: HNP1 effect on secreted and intracellular HMDM protein 
synthesis (Run2) 
A repeat experiment of Figure 4.3 (A) Gelcode Blue stained gels showing total 
secreted (i) and intracellular (ii) proteins. Radiolabelled protein images of de novo 
secreted (iii) and intracellular (iv) protein synthesis, with green boxes indicating 
areas of reduced or absent proteins. (B) TNF-α ELISAs of secreted proteins at 4hrs 
(i) and 18hrs (ii) with error bars of the mean ±SD of triplicate repeats. Experiment 









Figure B 2: HNP1 effect on secreted and intracellular HMDM protein 
synthesis (Run3) 
Repeat experiment of Figure 4.3. (A) Gelcode Blue stained gels showing total 
secreted (i) and intracellular (ii) proteins at 18hrs incubation. Radiolabelled protein 
images of de novo secreted (iii) and intracellular (iv) protein synthesis, with green 
boxes indicating areas of reduced or absent proteins. (B) TNF-α ELISAs of secreted 
proteins at 18hrs with error bars of the mean ±SD of triplicate repeats. Experiment 











Figure B 3: Calcium mobilisation in HNP treated HMDMs (with external 
Ca2+ ions) 
(B and C) Two repeat experiments of Figure 4.6. Calcium flux was induced using 
1μM Platelet-Activating Factor (PAF) on buffy coat HMDMs treated overnight with 
HNP in Ca
2+
-containing HBSS buffer. Cytoplasmic calcium was measured in real-













Figure B 4: Calcium mobilisation in HNP treated HMDMs (without 
external Ca2+ ions) 
Calcium flux was induced using 1μM Platelet-Activating Factor (PAF) on buffy coat 
HMDMs treated overnight with HNP in HBSS buffer free of Ca
2+ 
ions. Cytoplasmic 
calcium was measured in real-time and total amounts were calculated using the area 












Figure B 5: Gene expression of ER stress markers BiP, spliced XBP-1 
and CHOP with α-defensins (Run2) 
Repeat of Figure 4.14 with BiP (A), spliced XBP-1 (B) and (C) CHOP mRNA 
expression normalised to basal levels in untreated cells. Buffy coat HMDMs were 
stimulated with R848 alone or in co-culture with 25% NN, 12.5µg/mL HNP1, 
LHNP1, or 1uM thapsigargin. (D) Secreted TNF-α quantified by ELISA at 24hrs. 
Error bars represent the mean ± SD of samples performed in triplicate. Results co-
performed in conjunction with the Professor Pieter Hiemstra research lab (Leiden 










Figure B 6: Gene expression of ER stress markers BiP, spliced XBP-1 
and CHOP with α-defensins (Run3) 
A repeat of Figure 4.14: qPCR quantitation over 24hrs of ER stress markers BiP (A), 
spliced XBP-1 (B) and (C) CHOP normalised to basal levels in untreated cells. Buffy 
coat HMDMs were stimulated with 2.5µg/mL R848 either alone or in co-culture with 
25% NN or 100nM thapsigargin as a positive control. (D) Quantitated secreted TNF-
α by ELISA at 24hrs. Values obtained are from triplicate repeats for all samples with 
mean ± SD for error bars. Results co-performed in conjunction with the Professor 





Chemically-induced calcium manipulations in α-defensin treated 
HMDMs 
 
Bryostatin-1 does not rescue TNF-α secretion in defensin-treated HMDMs 
Around the same period in the research, the inhibition of calcium mobilisation with 
HNP was linked to the ongoing debate as to whether TNF-α mRNA stability was 
accountable for the inhibition of the secreted cytokine. It was postulated that there 
perhaps was a link between irregular calcium levels in HNP-treated HMDMs and the 
rapid decline in TNF-α mRNA (Chapter 3, section 3.2.3). The family of kinase 
enzymes known as Protein Kinase C (PKC) form part of the AGC kinase group, one 
of eight super-kinase families within the cell
186
. PKC enzymes are important 
mediators of the immune signalling response which direct cell growth, differentiation 
and gene expression. One PKC mediated signalling pathway is the Mitogen 
Activated Pathway (MAPK) which regulates cytokine gene expression. The 
conventional PKC isoforms (PKCα and β) require calcium alongside cell membrane-
bound Diacylglycerol (DAG) for full enzymatic activity. This isoform has previously 
been implicated in mRNA stability by regulating the shuttling of the stimulus-
dependant mRNA stabilizing factor HuR from the nucleus to the cytoplasm
187
. HuR 
forms part of the embryonic lethal abnormal vision (ELAV) protein family which act 




The hypothesis was that decreased calcium mobilisation through the actions of α-
defensins may result in incomplete cPKC activation. This could imply a decrease in 
TNF-α mRNA stability, possibly mediated by limited or no HuR shuttling into the 
cytoplasm. To establish if PKC activation could reverse TNF-α mRNA stability and 
restore secreted cytokine in α-defensin treated HMDMs, the macrolactone 
Bryostatin-1 was used to artificially activate PKC. 
 
For this buffy coat HMDMs were pretreated with bryostatin-1 at 5nM (Figure B 7) 
and 10nM (Figure B 8) for 30min. Cells were then stimulated with R848 alone or 
together with 12.5μg/mL HNP1, LHNP1, or 25% NN for 24hrs and TNF-α ELISA 





Secreted TNF-α in stimulated HMDMs with HNP1 treatment remained attenuated in 
bryostatin-1 pretreated HMDMs at both time points, with inhibition similar to that 
observed in cells that were not pretreated with bryostatin-1. Stimulated cells with 
25% NN showed partial TNF-α inhibition at 4hrs which became largely inhibited at 
24hrs incubation, again being similar to controls that were not pretreated with 
bryostatin-1. Linearised HNP1 (LHNP1) again had no effect on TNF-α secretion. 
Levels of TNF-α secreted were approximately doubled with Bryostatin-1 pre-
treatment compared to their untreated alternatives, suggesting a priming of the 
PKC/MAPK pathway prior to the inhibitory actions of α-defensins ensued.  
 
This result suggests that although PKC activation is linked to enhanced TNF-α 
production, this activation alone is not sufficient to rescue the effects of α-defensins. 
It was discovered in retrospect that α-defensins inhibit PKC activity by direct 
binding
152,189,190
. This direct binding effect could neutralise PKC activation by 
Bryostatin-1. Thus future PKC activity studies in macrophages would look to address 
how α-defensin-mediated PKC inhibition might affect downstream signal 







Figure B 7: The anti-inflammatory effect of α-defensin on HMDMs 
pretreated with 5nM Bryostatin 1 
Secreted TNF-α of buffy coat HMDMs stimulated with 2.5μg/mL R848 alone or in 
the presence of 12.5μg/mL HNP1, LHNP1 or 25% NN and quantitated by ELISA at 
4hrs (A) and 24hrs (B) alongside unstimulated controls. Results represent the mean ± 





Figure B 8: The anti-inflammatory effect of α-defensin on HMDMs 
pretreated with 10nM Bryostatin 1 
Secreted TNF-α of buffy coat HMDMs stimulated with 2.5μg/mL R848 alone or in 
the presence of 25μg/mL HNP1, LHNP1 or 25% NN and quantitated by ELISA at 
4hrs (A) and 24hrs (B) alongside unstimulated controls. Results represent the mean ± 






Artificial calcium replacement enhances inhibitory effect of α-defensins 
Up to this point, two clear patterns were beginning to emerge on the cell biology of 
α-defensin treated macrophages; proteins synthesis was being inhibited and cells 
were displaying irregular calcium mobilisation regulation. These two symptoms were 
suggestive of the most common diagnosis, endoplasmic reticulum stress. The 
emerging hypothesis was that, through irregular intracellular calcium homeostasis, 
the optimal functioning of the ultra-sensitive endoplasmic reticulum was impaired 
resulting in the possible accumulation of unfolded or misfolded proteins. If ER stress 
was implicated, it would explain the reduction in translation as the cell undergoes a 
rescue response termed the Unfolded Protein Response (UPR) pathway. In an 
attempt to reverse this process, calcium was artificially introduced into these α-
defensin treated HMDMs by way of a calcium ionophore (the name of which 
remains undisclosed due to potential patent application violations). 
 
Figure B 9 shows the first attempt at rescuing the inhibitory effect of 25% NN in 
R848 stimulated buffy coat HMDMs with ionophore at 10μM. The results were in 
direct contrast to what was anticipated; the ionophore synergistically inhibited 
secreted TNF-α, IL-6 and IL-8 with NN after 18hrs incubation and on its own the 
inhibitory effects were similar to NN (albeit different in mechanism).  
The effect of the ionophore was also tried at a concentration of 20μM. As an added 
control for the effects of calcium-mediated inhibition, culture media chelated of 
calcium with 1mM EGTA was used (Figure B 10). The inhibitory effects of NN, 
calcium ionophore, and the synergistic effects of the two were confirmed in two 
HMDMs donors after 24hrs incubation stimulated with R848. The inhibitory effects 
of the ionophore were, however, partially prevented in calcium-depleted culture 
media. The inability to completely restore pro-inflammatory potential in these cells 
was possibly due to incomplete calcium chelation (i.e. higher EGTA concentrations 
were required) or due to the influx of other cations which this ionophore is known to 
transport to a lesser extent (magnesium). The delicate balance of calcium 
homeostasis was further highlighted as EGTA on its own had a mild inhibitory effect 
on stimulated HMDMs. This is possibly attributed to the efflux of calcium from 





Since it was observed that basal levels of calcium were higher after 24hrs in HNP 
treated HMDMs compared to controls (Figure 4.6), it was thought that this elevated 
calcium concentration might be the catalyst to the downstream effects of calcium 
homeostasis and protein synthesis. In an attempt to prevent this increase in calcium 
brought on by α-defensin treatment, R848 stimulated HMDMs were treated with 
12.5μg/mL HNP1 or LHNP1 in culture media depleted of calcium (using 1mM 
EGTA) and compared to HMDMs in conventional culture media over 24hrs (Figure 
B 11). Results show that calcium depletion had no reverse effect on the inhibitory 
actions of α-defensins, with only a mild recovery of secreted TNF-α in ionophore-









Figure B 9: Treatment of NN-treated HMDMs with a calcium ionophore 
(Run1) 
Quantitated secreted TNF-α (A), IL-6 (B) and IL-8 (C) at 18hrs of R848-stimulated 
buffy coat HMDMs in co-culture with NN (25%), 10µM calcium ionophore 
(ionophore), or in combination. Untreated and NN controls were included. Results 









Figure B 10: Treatment of NN-treated HMDMs with a calcium ionophore 
(Run2) 
Secreted TNF-α at 24hrs of buffy coat HMDM from two donors (A and B) 
stimulated with R848 in the presence of either 25% NN, 20µM calcium ionophore 
(ionophore), or in combination. EGTA (1mM) was added to stimulated cells treated 
with ionophore as a control. Negative controls included EGTA alone samples and 









Figure B 11: EGTA addition in HNP1 treated HMDMs 
TNF-α values quantitated by ELISA after 24hrs incubation of 2.5μg/mL R848 
stimulated buffy coat HMDMs with 12.5μg/mL HNP1, LHNP1 or 10μM calcium 
ionophore (ionophore) in IMDM media with or without 1mM EGTA. Untreated 
controls for both media conditions were included. Error bars represent the mean ± 












The activation of L-type calcium channels does not rescue NN inhibitory effect 
Since calcium influx was stunted in α-defensin-treated HMDMs upon plate-
activating factor, it was thought that α-defensins might have impaired the opening of 
outer membrane dihydropyridine-sensitive calcium channels, also known as termed 
L-type calcium channels. It was postulated that, if impaired calcium channels are 
linked to the inhibitory effects of α-defensins on secreted TNF-α, could the 
chemically-induced opening of this channel restore HMDM function. This study was 
likened to the blocking of the L-type calcium channel in peripheral blood-derived 
human dendritic cells by exogenous human immunodeficiency virus, type 1 Tat 
protein
191
. By the addition of dihydropyridine calcium channel agonist, Bay K8644 
(100nM), inhibition of IL-12 and apoptotic body engulfment was reversed in these 
dendritic cells. 
 
In the first of these experiments, HMDMs were R848 stimulated and simultaneously 
treated with 25% NN either alone or with 1μM Bay K8644 for 24hrs (Figure B 12A). 
As an added control, external calcium concentration was increased with the addition 
of 1mM CaCl2. Results from a single experiment showed no reversal in the 
inhibitory actions of NN on secreted TNF-α. To pre-empt the potential inhibition of 
L-type calcium channels by α-defensins, the next experiment allowed for the 
pretreatment of HMDMs with Bay K8644 4hrs prior to stimulation and 25% NN 
addition (Figure B 12B). There remained no reversal of the inhibitory actions of NN 
when compared to control cells that did not receive Bay K8644 pretreatment. In 
these limited experiments, no implication could be made on the connection between 
α-defensins and impaired calcium channel function. Although the positive effect of 
Bay K8644 was observed in other leukocytes obtained from human peripheral 
blood
191
, no validation experiments were performed to confirm their activity on 
HMDMs. The use of Fura-2/AM within Bay K8644 treated cells could have been 











Figure B 12: The effect of calcium channel agonist Bay K8644 in NN-
treated HMDMs 
Secreted TNF-α quantified by buffy coat ELISA after 24hrs.(A) R848 stimulated 
HMDMs co-cultured with 25% NN, 1µM Bay K8644 or both. 1mM CaCl2 was 
added in a separate test sample. (B) HMDMs pre-incubated with Bay K8644 (30min) 
prior to stimulation in co-culture with 25% NN alone or 1mM CaCl2. Results 











Techniques addressing molecular interactions failed to confirm 
HNP1/rps20 binding 
The confocal data gave a suggestion of HNP1/rps20 aggregate formation in 
HMDMs, particularly after 24hrs treatment. As evidential as this data was, it did not 
conclusively prove HNP1 binding to ribosomes. With limited time restrictions on the 
remaining research period, considerations turned to performing downstream 
molecular techniques in order to provide greater evidence of a binding event. Two 
approaches were taken to address this question.  
Firstly, it was decided to utilize the system that provided the strongest results of 
HNP1-mediate translation inhibition, specifically the in vitro translation assay. Using 
25μg/mL HNP1 and W26A treated rabbit reticulocytes as before, the protocol was 
modified to separate out and detect ribosomes using sucrose density 
ultracentrifugation as performed for polysome analysis. Following manual 
fractionation of centrifuged sucrose gradients, RNA extraction (by TRIzol method) 
and subsequent agarose electrophoresis meant it was possible to identify the rRNA-
containing fractions (Figure C 1A). The residual organic phase from the TRIzol 
extraction process corresponding to the rRNA-containing fractions were pooled in 
order to perform protein precipitation and subsequent SDS-PAGE and Western 
blotting to positively identify the presence of HNP1 (Figure C 1B). Details on the 
methodology can be found in Chapter, section 2.15. 
Resulting Western blots were unable to detect the presence of HNP1 or W26A in 
both rRNA-containing fractions (F6-10) and fractions which did not contain rRNA 
(F1-5). As a positive control for the detection of both HNP1 and W26A by Western 
blotting, amounts of pure peptide corresponding to the starting amount added to 
reticulocyte mixtures were added alongside test samples for electrophoresis (Figure 
C 1C). Monoclonal mouse anti-HNP1-3 antibody confirmed the positive immuno-
detection of both peptide forms. Antibody sensitivity for both HNP1 and W26A was 
performed using titrated amounts of pure peptides, which displayed sensitivity down 





Since neither fractions pooled were able to detect any peptide, this assay was not able 
to provide any further positive identification of HNP1 association with ribosomes. 
The most likely cause could be attributed to the unrefined protein precipitation 
method described for purifying proteins from TRIzol extraction, possibly losing 
peptide during the extraction process. Alternative methods considered included 
protein purification by dialysis. Factoring in the starting microgram amounts of 
peptide, this method would have been too cumbersome to effectively process and 
identify HNP1/W26A. 
 
The second method attempted to prove HNP1-ribosome binding was by 
immunoprecipitation (IP). In this experiment (which was attempted twice without 
success) the rabbit reticulocyte system was again utilized to perform an in vitro 
translation as previously performed in Chapter 5 (section 5.2.1). After 90min 
incubation with 25μg/mL HNP1, W26A or vehicle control samples (performed in 
duplicate for each samples), rabbit reticulocyte mixtures were incubated in IP 
reaction buffer (detailed methodology described in Chapter 2, section 2.10.6). For 
duplicate samples, mixtures either contained 500ng anti-HNP1-3 antibody or an 
IgG1,κ isotype control antibody which were incubated for 2hrs prior to the addition of 
Protein G sepharose beads and subsequent overnight incubation. Following Protein G 
bead washing and purification by centrifugation, boiled bead samples were 
electrophoresed alongside eluents from the first washing stage, of which a portion of 
the volume was protein precipitated corresponding to ~0.5μL of pure rabbit 
reticulocyte lysate. The inclusion of the eluent was to ideally to determine the 
fraction of rps20 ‘pulled-down’ by HNP1 bound to Protein G beads relative to 
residual the amount of rsp20 remaining in the lysate. 
 
SDS-PAGE and Western blotting for rps20 (~13kDa) was unable to detect ribosomes 
in the purified bead fractions (Figure C 2A-i). The secondary antibody detected non-
specific bands on the blot, which was unusual considering that a Cleanblot reagent 
was used designed specifically for IP assays to detect native primary antibody 
conformations (i.e. the primary antibody to rps20 immunoblotted for) as opposed to 




preceding validation assay using Cleanblot which successfully detected titrated 
amounts of pure reticulocyte lysate following immunoblotting using anti-rps20 
primary antibody (Figure C 2B). It is possible that the polyclonal anti-rps20 primary 
antibody could have non-specifically bound to the high amounts of IgG used in the 
pull-down stage and this would require further optimisation. Eluted volumes from 
the bead washing step, equivalent to 0.5μL of pure rabbit reticulocyte were unable to 
be detected (Figure C 2A-ii). In addition, both blots contained a positive control 
sample of 0.5μL pure reticulocyte lysate included for Western blotting which failed 
to be completely detected. This indicated an overall error with the experiment which 







Figure C 1: Detection of HNP1 in sucrose density gradient 
centrifugation assay 
Collected fractions post sucrose density ultracentrifugation of rabbit reticulocyte 
lysates treated with 25μg/mL HNP1 or W26A and processed using TRIzol 
extraction.  
(A) RNA agarose electrophoresis of collected fractions. Increasing sucrose density 
resulted in the presence of 28S- and 18S rRNA (fractions 6-10).  
(B) By-product volumes from RNA extraction process containing proteins were 
processed by pooling volumes from rRNA-containing fractions (F6-10) and fractions 
without (F1-5). Proteins were precipitated, electrophoresed (12% SDS-PAGE) and 
immunoblotted using anti-HNP1-3 antibody. Original assay amounts of peptides 
were included as controls positive detection of peptides (1.25µg).  









Figure C 2: Rps20 expression by western blotting following 
immunoprecipitation 
(A) Western blot results for ribosomal protein S20 expression in rabbit retic lysates 
treated with 25µg/mL HNP1 or W26A as per in vitro translation protocol. Following 
immunoprecipitation bead-depleted fractions were electrophoresed by 12% SDS-
PAGE (i). Supernatant volumes separated from bead fractions were also 
electrophoresed, with volumes loaded equivalent to 0.5µL of pure rabbit reticulocyte 
lysate (ii). A positive control lane was added for the detection of rps20 in RRL, with 
0.5µL of pure rabbit reticulocyte lysate added (RRL).  
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